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Abstract 
 
Background: Necrotizing enterocolitis (NEC) is an inflammatory bowel disease affecting premature 
infants. The disease can progress rapidly and is associated with high mortality. Early diagnosis can be 
difficult as the early manifestations of NEC can be very similar to sepsis. There is currently no pre-
symptomatic screening method available. The aim of the work reported in this thesis was to identify 
microbial signatures in the gastrointestinal microbiota preceding NEC diagnosis in premature infants. 
Methods: Longitudinal (≥ daily) faecal samples and daily clinical data from throughout their neonatal 
intensive care unit stay were collected from 369 premature infants born at <32 weeks gestation over a 
two-year period. The faecal microbiota of 12 infants with definite/severe NEC, 8 with suspected NEC, 
and 44 control infants was characterised using next-generation sequencing of 16S ribosomal RNA 
gene regions. Clinical characteristics and operational taxonomical units (OTUs) that discriminated 
cases from controls were identified using logistic regression. Bacteria isolated from stored faecal 
samples underwent selective culture, and the resulting isolates were identified using Matrix-Assisted 
Laser Desorption Ionization Time-of-Flight. Isolates identified as Clostridium perfringens were 
additionally typed and screened for the presence of toxin genes. 
Results: Faecal samples collected from four NEC infants just prior to diagnosis were found to contain 
a higher abundance of a clostridial OTU compared to matched control samples. Culture investigation 
identified this OTU as Clostridium perfringens. No two Clostridium perfringens isolates were found 
to be identical, as determined by fluorescent amplified fragment length polymorphism. Infants with 
NEC who did not have an over-abundance of the clostridial OTU (n=7) prior to diagnosis had a faecal 
microbiota dominated by a Klebsiella OTU.  Only one infant did not have an abundance of either the 
clostridial OTU or the Klebsiella OTU. The use of prolonged continuous positive airway pressure 
therapy with supplemental oxygen (CPAP oxygen) was also found to be associated with NEC risk. 
Conclusions: Two OTUs (Clostridium and Klebsiella) were identified at high levels in faecal samples 
collected from infants prior to NEC diagnosis. A screening tool incorporating these biomarkers with 
the duration of CPAP oxygen use may aid the clinician in making an early diagnosis of NEC. 
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Chapter 1 General Introduction 
 
1.1 Necrotizing Enterocolitis – Background 
 
First described in 1888 by Paltauf and formally named necrotizing enterocolitis (NEC) in 1952 by 
Schmid and Quaiser, NEC is a devastating disease that has continued to baffle neonatologists for 
more than a century and a half.1,2 NEC is a neonatal inflammatory bowel disease which culminates in 
widespread necrosis of the gut tissue, in turn associated with a high mortality rate – approximately 
30%, and up to 40% in the smallest, most premature babies affected.3,4 Infants who survive are at 
significant risk of developing not only local gastrointestinal (GI) complications but may also suffer 
from non-GI related disability such as neurodevelopmental delay.5  
 
NEC is overwhelmingly a disease affecting premature infants.  Approximately 93% of those affected 
are born at less than 37 weeks gestation. The incidence of NEC is of the order of 7% in infants born 
between 500g and 1500g, with those that are born most prematurely at highest risk – 15% in babies 
born at 24 weeks compared to 8% in babies born at 28 weeks.6 In the past few decades there have 
been great advances in the medical care of babies born prematurely. Prior to this premature infants 
would die within the first few days/weeks due to lung disease - a consequence of the lack of 
production of endogenous surfactant leading to an inability to keep the lungs inflated. The 
introduction of exogenous surfactant in the 1970’s has resulted in more and more premature infants 
surviving beyond the first few weeks of life. Consequently with this has come a matched increase in 
the prevalence of NEC,7 which is now the most common neonatal surgical condition, with estimated 
costs of USD$186,200 per infant who requires surgical care.8 NEC prolongs an infant’s stay in the 
neonatal intensive care (NICU) by approximately 22 days, and this increases to 60 days if surgery is 
needed.8 One of the cruelties of the disease is its timing, for there is an inverse relationship between 
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the gestation a baby is born at and the onset of disease, such that those who are born most prematurely 
develop the condition later, sometimes weeks after they are born, when parents and medical staff have 
become confident that the infant has a good chance of survival and discharge from NICU. 
 
There is very limited, non-specific treatment for NEC at present and this has not changed much since 
the disease was originally described. This is predominantly due to our poor understanding of its 
aetiology. What has become clear is that our view of NEC as a single entity is flawed. Gordon et al.9 
recently proposed that NEC should be considered as a final outcome of disparate pathways, with 
different ‘subsets’ (see Figure 1). NEC affecting term infants is considered to be a separate group, 
generally occurring in infants with co-existing congenital cardiac defects leading to secondary gut 
ischaemia. The fact that NEC is a clinicopathological endpoint that can be reached by many routes 




Figure 1: Different pathways leading to NEC. NEC in premature infants is a distinct entity from 
NEC that occurs in term infants. After Gordon et al.9 
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1.2 Histological features of NEC 
 
NEC is an inflammatory bowel disease characterised by haemorrhagic necrosis on histology. The 
most commonly affected site is the ileum, although it can occur within any part of the small or large 
intestine. At the start of NEC, there is ulceration, oedema, and haemorrhage in the mucosal layer, 
cumulating in full-thickness necrosis and perforation. High levels of inflammatory mediators such as 
IL-6 and TNF-alpha have been found in NEC tissue samples or faeces from NEC infants. These 
cytokines lead to immune cell recruitment to the site of damage.10  
 
1.3 Clinical features of NEC 
 
Infants with NEC show both systemic signs - such as temperature instability, apnoeas, bradycardia, 
hypotension - and localised abdominal signs: for example increased gastric aspirates, abdominal 
distension and tenderness. The systemic signs are similar to those seen in sepsis, making the initial 
diagnosis of NEC challenging: the more so, as infants with sepsis often have an associated ileus, 
leading to abdominal distension. It is not uncommon for an infant with NEC to rapidly deteriorate, 
requiring surgery or dying within 24 hours of diagnosis. Recurrence of NEC occasionally does occur. 
 
1.3.1 Bell’s modified staging 
 
The most commonly used approach to define the severity of NEC is application of Bell’s modified 
staging criteria.11 Bell Stage 1 is suspected NEC, Bell Stage 2 is definite NEC, and Bell Stage 3 is 
advanced/severe NEC. There are three criteria used to categorise the infant: systemic, abdominal and 
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Table 1: Modified Bell’s criteria taken from Kliegman et al.11 
Stage Systemic Criteria Abdominal Criteria Radiographic Criteria 







occult blood in stool 
Normal or intestinal 
dilatation, mild ileus 
Stage 1b = suspected 
NEC 
Same as above Grossly bloody stool As above 
Stage 2a = definite 
NEC; mildly ill 
Same as above Same as Stage 1 plus 





Stage 2b = definite 
NEC; moderately ill 








cellulitis, right lower 
quadrant mass 
Same as above plus 
possible portal venous 
gas 
Stage 3a = advanced 
NEC; severely ill, 
intact bowel 







Same as above, with 
marked tenderness and 
abdominal distension 
Same as above plus 
ascites 
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Stage 3b = advanced 
NEC; severely ill, 
perforated bowel 
Same as Stage 3a Same as Stage 3a Pneumoperitoneum 
 (DIC – disseminated intravascular coagulation) 
 
It is important to note that ‘Bell’s Stage 1’ is a heterogeneous group of presentations and underlying 
conditions. For this reason, NEC studies generally only consider infants with Bell Stage 2 and 3. 
Bell’s staging must be applied with care, for there are other abdominal pathologies that are compatible 
with Bell’s Stage 3 (e.g. spontaneous intestinal perforation), although they have a very different 




The treatment of NEC is empirical with the mainstay of management being supportive care, cessation 
of enteral feeds, and administration of multiple antibiotics. In the worst case scenario, when 
perforation of the gut wall occurs, surgery is required to resect the necrotic bowel – although this is 
only possible if the infant is stable enough for surgery to be undertaken. Surgery is required in 30% - 
40% of cases of NEC.13 The management of NEC has not changed in the past 150 years, and remains 
non-specific and supportive in nature.  
 
Cessation of enteral feeds has serious implications.  For example, delaying feeds for three days has 
been shown to cause gut atrophy in an animal model.14 Furthermore, if an infant is taken off enteral 
feeds for a prolonged period, then they invariably require parenteral nutrition. For each day an infant 
has an intravenous catheter in situ and is given parenteral nutrition, the risk of bloodstream infection 
increases.15  
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1.3.3 Mortality and morbidity 
 
The mortality of NEC overall is 30%, but rises to 40% in its most severe form.3 Infants that survive 
can be left with devastating long term problems, especially those that have had surgery. These may be 
gut related,16,17 such as short bowel syndrome, recurrence of strictures, growth failure due to poor 
absorption and nutrition, or non-gut related, such as poor neurodevelopment outcomes.18 Both white 
and grey matter abnormalities on magnetic resonance imaging (MRI conducted on NEC survivors at 
term-equivalent age) have been found at higher rates than premature infants who have not had NEC or 
sepsis. At two years of age, infants who had NEC have also been found to have delayed cognitive and 
motor development compared to controls.19 
 
1.4 Risk factors and protective factors for NEC 
 
The aetiology of NEC is considered to be multi-factorial, with a triad of an immature gut, stress of 
enteral feeds and aberrant bacterial colonisation conspiring to confer the highest risk of developing 
the disease.20 Premature neonates are particularly vulnerable to NEC due to the convergence of a 
number of risk factors2, 8 illustrated in Figure 2. NEC represents the end of a journey which begins 
with premature birth: an immature GI tract unadapted for the microbe-induced stress encountered 
immediately in extra-uterine life, early exposure to enteral feeds, and compromised by underlying 
problems of inadequate tissue perfusion and host defence mechanisms. An immature immune system 
with low levels of protective maternal antibodies coupled with an immature gut with decreased levels 
of secretory immunoglobulin A (sIgA) and protective mucus, increase the risk of bacterial 
translocation. 
 
Risk factors can be divided into prenatal, intra-partum and postnatal factors. Postnatal risk factors will 
be the focus here. 
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Breast milk appears to be protective against NEC, and feeding with expressed breast milk (delivered 
via a naso/oro-gastric tube as the sucking reflex is not developed in infants born under ~ 32 weeks 
gestation) has been reported to reduce the risk of NEC by six to ten fold.21 Other than the secretory 
IgA transferred to the infant, substances in breast milk such as epidermal growth factor are thought to 
play a role in preventing NEC.8 Additionally, oligosaccharides and glycoproteins present in milk have 
been shown to prevent bacterial adhesion of pathogens to host cells, as well as block the action of 
bacterial toxins.22,23 More recently, it has been speculated that bacteria found in maternal milk such as 
bifidobacteria and lactobacilli may also be important in seeding the pre-term gut with ‘healthy’ 
colonisers. Breast milk is also a natural ‘pre-biotic’ (a non-digestible substance defined as providing a 
beneficial physiological effect for the host by selectively stimulating the favourable growth or activity 
of a limited number of indigenous bacteria).24  
 
Unfortunately, it is not always possible for a mother to provide expressed breast milk. In this scenario 
donor breast milk is given preferentially over formula milk where possible, as use of formula milk is 
associated with a high risk of NEC.25 In a hierarchy of NEC risk, feeding a premature infant with 
formula milk confers the greatest risk, followed by donor breast milk, with maternal breast milk 
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associated with the smallest risk.26 The reason why donor breast milk is not as protective as maternal 
breast milk may be due to steps taken to prevent infection via pasteurisation. This process is known to 
reduce the bioactivity of human milk.27 In a study comparing outcomes of premature infants given 
raw human milk versus donor banked milk, the rate of NEC was found to be lower in the group given 
raw human milk, although this was not statistically significant.28  Maternal breast milk is also 
‘personalised’ for the recipient in comparison to donor breast milk and its composition has been 
shown to vary,  for example from mothers who have had a baby prematurely compared to mothers 
who have had a baby at term.29  
 
Enteral feeds have been shown to be significant in ‘priming the gut’, aiding gut development and 
reducing the incidence of NEC. The optimal amount to be given, however, and rate of volume 
advancement are topics of controversy. In general, trophic feeds, defined as ‘a small volume of 
balanced enteral nutrition insufficient for the patient’s nutritional needs but producing some positive 
gastrointestinal or systemic benefit’,30 are commenced shortly after birth once the infant is stable and 
this is then increased as per local unit policy. A Cochrane review, published in 2014, found no 
evidence for slow increments (15ml/kg per day to 20ml/kg per day), compared to fast advancement 
(30ml/kg per day to 35ml/kg per day), of feeds being protective for NEC in premature infants born 
under 32 weeks gestation.31 A clinician faced with a premature infant will want to encourage delivery 
of enteral feeds, but must also ensure that the baby receives optimal nutrition for growth which 
inevitably will be in the form of parenteral nutrition (nutrients delivered intravenously) for the first 
few days/weeks. The time taken for an infant to be fully established on enteral feeds is of critical 




While antibiotics are used in the management of NEC, prolonged empirical antibiotic therapy at the 
beginning of life is associated with a two-fold increase in incidence of NEC.33 It is thought that this 
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may be due to the interference in normal gut colonisation (see Section 1.5).34 The selection of 
antibiotic regime may be of critical importance. In a retrospective study of 714 infants, investigating 
the effects of changing antibiotic regime in two Neonatal Intensive Care Units (NICUs), investigators 
found that the change in regime from ampicillin and gentamicin to piperacillin-tazobactam led to a 
reduction in NEC cases.35 
 
1.4.3 Histamine H2 receptor antagonists  
Histamine H2 receptor antagonists have been widely used for the treatment of gastro-oesophageal 
reflux in infants. An association has been recognised between their use and increased risk of NEC.36 It 
has been hypothesised that this is due to the reduction in gastric acid allowing pathogenic bacteria to 
multiply in the gastrointestinal (GI) tract: H2 receptor antagonists have been shown to alter the GI 




Probiotics are defined by the World Health Organisation (WHO) as ‘Live microorganisms which 
when administered in adequate amounts confer a health benefit on the host’. The most commonly 
used agents are lactic acid bacteria (LAB) such as bifidobacteria and lactobacilli.   
 
There has been enthusiastic promotion in some quarters of the use of probiotics in an attempt to 
prevent NEC. There have been several large meta-analyses yielding different results. The first 
landmark meta-analysis by Deshpande et al.38 in 2010 indicated that there was benefit in 
supplementing premature infants’ feeds with probiotics. Dissenting from this position, Mihatsch et al. 
published a meta-analysis stating that there was no overall benefit and that in the smallest infants, 
where NEC risk is greatest, the data is lacking.39 One reason for the mixed conclusions may be the 
heterogeneous studies included in these meta-analyses, with varying organisms used (multiple or 
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single organisms), varied doses, duration of treatment, start of treatment, use of breast milk and 
different exclusion criteria. 
 
1.5 The role of bacteria in NEC 
 
Bacteria have been firmly implicated in the pathogenesis of NEC. NEC has never been described in 
germ free environments such as in utero40 or in germ free animal models.41 Furthermore, evidence 
supporting an infectious aetiology (at least in part) stems from well documented outbreaks.42 The use 
of antibiotics to prevent progression of NEC, the fact that empirical antibiotic use is associated with 
an increased risk of NEC in later premature neonatal life, and that antibiotic choice can affect the 
incidence of NEC,35 also suggest that bacteria may play a role. Furthermore, Toll-like receptor 4 (TLR 
4) - a receptor in the innate immune system whose ligand is lipopolysaccharide (a component of 
Gram-negative bacteria) - plays a key role in the pathogenesis of NEC (see Section 1.8). 
 
Despite the strong arguments implicating bacteria in the pathogenesis of NEC, no single organism has 
been consistently found.42 Opinion has swung towards abnormal colonisation of the GI tract playing a 
central role in the pathogenesis of NEC through the development of an unfavourable balance between 
commensal and pathogenic bacteria.4,42 Plausibly, a primary failure or a delay in the acquisition of 
normal commensals leads to an aberrant population structure which may become dominated by 
pathogenic bacteria which are particularly prevalent in the hospital setting. Such organisms arriving in 
a sparsely populated GI tract may have the dangerous opportunity for rapid growth, generating tissue-
damaging toxins. 
 
Alternatively, a normal intestinal microbiota (all organisms in a given environment) may be 
established initially but the equilibrium subsequently disrupted for example by antibiotic use resulting 
in the symbiotic relationship between commensal bacteria and the gut being perturbed.34 Proliferation 
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of previously minor components of the microbiota in these vulnerable neonates may therefore be an 
important step in the multifactorial pathogenesis of NEC. 
 
The trajectory of development of the GI microbiota and how aberrant patterns may be related to 
disease is an area of topical interest. Recent studies of the premature GI microbiota have established 
that there are clear differences from the situation in term infants, with delayed colonisation patterns 
and decreased number of organisms present.43-45 These findings likely reflect a plethora of reasons 
such as high antibiotic use in both the mothers and babies, the inability of premature infants to breast 
feed and the relatively ‘sterile’ NICU environment - babies housed in incubators with limited skin-to-
skin contact with parents and carers.  
  
It is clear that both the host and the bacteria in the gastrointestinal tract contribute the pathogenesis of 
NEC. In my study I have chosen to focus on the bacteria with the goal of understanding the 
contribution that they make to the development of NEC. 
 
1.6 Studying the gastrointestinal microbiota 
 
Attempts to characterise the gastrointestinal microbiota have traditionally been based on culture 
methods. Culture methods however may miss over 80% of faecal bacteria if the incorrect medium or 
conditions are used.46 Non-culture methods based on characterization of the bacterial 16S ribosomal 
RNA (rRNA) gene have therefore been exploited to improve on this.47,48  
 
The 16S rRNA gene, a component of the 30S small subunit ribosome, is essential for cell function and 
consequently is present in all bacteria and archaea. The gene comprises nine conserved (C) domains 
and nine hypervariable (V) regions (Figure 3). The variable regions can be used for identification of 
the organism. Universal primers can be designed which bind to the conserved regions allowing 
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amplification and sequencing. Liu et al.49 have shown that it is not necessary to sequence the entire 
gene for phylogeny studies. 
 
 
Figure 3: Schematic diagram of the 16S rRNA gene (adapted from Petrosino et al.47). 
 
Until recently, 16S rRNA gene characterization was generally achieved by Sanger sequencing. As this 
method requires a homogeneous template, it is necessary first to produce clone libraries if a mixed 
population of organisms is to be characterised. This is not only highly labour intensive and expensive, 
but the extent to which the results reflect the composition of the original sample depends critically 
both on there being a lack of cloning bias (which is unlikely to be the case), and the selection of a 
sufficiently large number (hundreds) of clones for sequencing.   
 
Other approaches have used techniques such as denaturing gel gradient electrophoresis (DGGE) and 
temperature gel gradient electrophoresis (TGGE) to differentiate organisms either by identification 
through the incorporation of a ‘ladder’ with known organisms, or through sequencing of excised 
bands.  
 
Most recently, with the advent of next generation sequencing, the highly parallel sequencing approach 
circumvents these problems as it allows millions of 16S rRNA amplicons generated directly from a 
clinical sample to be sequenced simultaneously. Large-scale projects are now feasible due to the 
declining cost of next generation sequencing50 in combination with the option of sequencing multiple 
samples on a single sequencing run (‘multiplexing’). With the appropriate laboratory set-up, next 
generation sequencing is relatively quick to carry out and has the advantage of enabling detection of 
organisms present in at low abundance (the level of which is dependent on the sequencing depth 
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determined by the operator), allowing a more complete picture to be obtained of the microbial 
community in a sample.51  
 
While the use of next generation sequencing to characterise the 16S rRNA gene is becoming more 
widespread, careful consideration must be paid to the potential biases/limitations associated with this 
approach. These relate specifically to the next generation sequencing platform used – e.g. 454 
sequencing is prone to homopolymer errors,52 and the requirement to sequence relatively short regions 
of the 16S rRNA gene which can lead to limited taxonomic resolution.53 Furthermore, primer 
selection (see Chapter 4) and the regions of 16S rRNA gene chosen to be sequenced can impact on 
the final identification of the organism. Expertise is also required for the bioinformatics analysis to 
ensure that appropriate pre-processing of the data is carried out (e.g. incorporation of a denoising and 
chimera removal algorithm), and for downstream analysis to ensure accurate taxonomic assignment.54  
 
1.7 The microbiota and NEC 
 
The earliest studies examining the faecal bacteria in NEC infants were essentially pathogen hunts. 
Organisms such as Clostridium perfringens, Klebsiella oxytoca and Enterobacter sakazakii have been 
isolated from clinical samples collected from NEC infants.55,56 It quickly became apparent however 
that this approach would miss organisms that are not considered to be pathogenic and less selective 
media or non-culture based methods were then used.57-60  
 
In 2010, when the study reported in this thesis was first conceived, only four groups had reported 
using non-culture techniques to study NEC,57-60 and only one of the four had employed the technique 
of next generation sequencing.60 Results of the first NEC microbiota study based on non-culture 
methods, published in 1996 by Millar et al.57, showed no differences in the composition of the faecal 
microbial community between cases and controls.  Importantly however, these samples were only 
collected at the time of diagnosis.  De la Cochetiere et al.58 collected weekly faecal samples from 
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premature infants from birth, until NEC diagnosis, for three infants together with nine controls. Using 
TGGE and sequencing de la Cochetiere et al.58 detected Clostridium perfringens in NEC patients in 
the first two weeks of life but not in controls. Wang et al.59 used a combination of terminal restriction 
fragment length polymorphism analysis, cloning and sequencing of 16S rRNA gene fragments to 
analyse faecal samples from premature infants at the time of NEC diagnosis and found an abundance 
of Gammaproteobacteria. In contrast to this, Mshvildadze et al.60 found higher numbers of 
Enterococcus in infants with NEC or systemic inflammatory response syndrome compared to 
controls, and three out of the four NEC cases studied had Citrobacter species that were not present in 
controls. 
 
These studies were helpful in demonstrating the application of molecular based methods to the study 
of the microbiota in relation to NEC, but there were fundamental problems with study design, 
including small patient groups, inappropriate selection of controls, lack of longitudinal samples and 
lack of adequate clinical information. In addition DNA extraction and processing was not particularly 
stringently controlled (see Chapter 3). Of note, in two studies faecal samples were only collected 
around the time of NEC onset, so the microbiota detected may have been distorted due to the effects 
of antibiotic treatment. To address the hypothesis that elements in the GI microbiota trigger the 
inflammatory process leading to NEC, it is not enough to study samples collected at the time of 
diagnosis. Analysis of samples from previous weeks is of central importance. 
 
1.8 Microbiota and host interaction 
 
How might the microbiota lead to the clinical phenotype of NEC? The host clearly plays an important 
role in the development of NEC and recent research has identified TLR 4 as a key receptor at the 
interface between the microbiota and the host.    
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1.8.1 TLR 4 and innate immunity 
 
The role of TLRs in innate immunity is well established. They are expressed on immune cells such as 
macrophages, dendritic cells, neutrophils and lymphocytes. TLR ligands are known as Pathogen 
Associated Molecular Patterns (PAMPS), and the specific ligand for TLR 4 is lipopolysaccharide 
(LPS) which is a major component of the outer membrane of Gram-negative bacteria.61 Binding of 
LPS to TLR 4 leads to the activation of an inflammatory cascade with activation of the NF-κB 
pathway.61  
 
1.8.2 TLR 4 and gut development 
 
A completely distinct and central role of TLR 4 in foetal gut development has recently been 
elucidated. TLR 4 is expressed on foetal gut tissues such as intestinal epithelial and endothelial cells 
and intestinal fibroblasts.62 It plays a fundamental role in regulating apoptosis, proliferation and 
migration of enterocytes, differentiation of goblet cells and regulation of microcirculatory perfusion.62  
 
Gribar et. al.63 have demonstrated that the expression of TLR 4 in the murine gut increases with 
gestational age in utero, before dropping rapidly as term approaches.  Mice born prematurely have 
much higher levels of TLR 4 in the gut than those born at term.63  
 
1.8.3 The role of TLR 4 in the pathophysiology of NEC 
 
In the context of a premature infant with high levels of TLR 4 expressed in the gut, colonisation with 
Gram-negative bacteria will lead to over-activation of TLR 4. Not only does this lead to triggering of 
a pro-inflammatory response, but additionally it leads to intestinal stem cell apoptosis, poor 
differentiation and decreased migration of intestinal epithelial cells to the site of injury (due to 
increased adhesion of the enterocytes to the matrix).  This cumulates in gut damage coupled with poor 
gut healing.64  
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Evidence supporting the key role of TLR 4 in NEC can be found from a well-established murine 
model of NEC; TLR 4 mutant mice do not develop NEC and TLR 4 knockout mice show preservation 
of the small intestinal mucosa against NEC induction.64  As mentioned above, the TLR 4 receptor is 
expressed on both intestinal epithelial and endothelial cells. TLR 4 expression on each of these cell 
types is equally important. NEC severity has been found to be significantly reduced in mice either 
lacking TLR 4 selectively from the intestinal epithelium64 or the vascular endothelium.65 NEC in 
humans is associated with increased TLR 4 in the intestine compared to controls at similar gestations 
and there are high levels of TLR 4 expression in gut tissue collected from infants with NEC compared 
to spontaneous intestinal perforation.66,67  It is interesting that this heightened TLR 4 response appears 
to be particular to the immature infant. The rapid TLR 4 signalling seen after stimulation with LPS in 
foetal intestinal epithelial cells is not present in adult intestinal epithelial cells.68  
 
1.9 The Neonatal Microbiota Study (NeoM) 
 
The key aim of the NeoM study presented in this thesis has been to characterise the progression of the 
gastrointestinal microbiota in premature infants in order to identify microbial signatures anticipating 
NEC. All infants born at <32 weeks gestation (high risk of developing NEC) within the Imperial 
College NHS neonatal intensive care unit (NICU) were recruited and longitudinal faecal samples 
collected from birth until discharge/death. To ensure that confounders affecting the microbiota were 
accounted for such as antibiotic use and feeding regimes, detailed daily clinical data for all infants 
recruited into the study was collected.  
 
A non-culture approach was used to capture as much of the microbiota as possible and 16S rRNA 
gene characterisation using the 454 platform was chosen since at the time of the study the sequencing 
read length matched the desired amplicon size. 
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1.10 Hypotheses 
 
Identifiable differences exist in the microbial composition of the premature neonatal faecal microbiota 
in infants just prior to NEC diagnosis compared to matched controls. 
 
There are changes in the premature neonatal faecal microbiota which are discernible prior to the onset 
of symptoms in infants who go on to develop NEC. 
 
There exist different microbial signatures in the faecal microbiota associated with NEC which is a 




To characterize the faecal microbiota from birth until discharge/death in healthy premature infants and 
up to the point of NEC diagnosis in infants who develop the disease. 
 
To identify sequential changes in the faecal microbiota preceding NEC in affected infants. 
 
To identify clinical parameters that differ between healthy premature infants and those who develop 
NEC. 
 
To distinguish NEC ‘subsets’ on the basis of both microbial composition and/or clinical 
characteristics. 
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Chapter 2 Materials and Methods 
 
In this chapter the materials and methods used for the main study are described. Validation work 
leading up to the final selection and implication of these protocols is detailed in Chapters 3 and 4. 
 
2.1 Study cohort 
2.1.1 Inclusion and exclusion criteria 
 
Infants born at less than 32 completed weeks of gestation admitted to the Imperial College Healthcare 
NHS Trust neonatal intensive care unit (NICU) (a two-site NICU, at St. Mary’s Hospital and Queen 
Charlotte’s and Chelsea Hospital) between January 2011 and December 2012 were deemed eligible 
for inclusion in the study unless considered to be in extremis in the first days of life. 
 
2.1.2 Study site 
 
The NICU is a tertiary centre with ~700 admissions per annum. Both hospitals have identical feeding, 
antibiotic and antifungal protocols, and staff members rotate between the sites. Probiotics and H2 
receptor antagonists are not used within the NICU. 
 
2.1.3 Ethics declaration 
 
The study ‘Defining the Intestinal Microbiota in Premature Infants’ (NeoM – The Neonatal 
Microbiota study) (ClinicalTrials.gov Identifier NCT01102738) was approved by West London 
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Research Ethics Committee Two, United Kingdom (Reference number: 10/H0711/39). Parents gave 
written informed consent for their infant to participate in the study. 
 
2.1.4 Funding  
 
This thesis is independent research arising from a Doctoral Research Fellowship (NIHR-DRF-2011-
04-128) funded by the National Institute for Health Research. The views expressed in this thesis are 
my own and not necessarily those of the NHS, the National Institute for Health Research or the 
Department of Health. Additional resources were funded by the Winnicott Foundation.  
 
2.1.5 Cohort size 
 
Three hundred and sixty infants born at less than 32 completed weeks of gestation were anticipated to 
be admitted to the NICU over the two year period based on previous admission data.  Five to ten 
percent were predicted to develop NEC.  
 
2.1.6 Data collection and database design 
 
Detailed admission data including baseline demographics, antenatal history, details surrounding the 
labour and delivery (e.g. use of maternal antibiotics, presence of prolonged ruptured membranes, 
chorioamnionitis, APGAR (Appearance, Pulse, Grimace, Activity, Respiration) scores and delivery 
method) as well as detailed daily clinical information was collected from the patients’ records. Daily 
clinical information included respiratory and cardiovascular status/support, feeding regime, 
medications, blood results, microbiology and radiology results, as well as abdominal examination 
findings. The data collection proformas can be found in Appendix 1. 
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An online relational database (https://cisbic.bioinformatics.ic.ac.uk/neonatal/index.html) was created 
specifically for the study.  This allowed pseudononymised clinical data, samples details including 
archiving location and sequencing data to be entered. 
 
2.1.7 NEC case definition and control selection 
 
A NEC case was defined using the Vermont Oxford Network criteria and staged according to Bell’s 
modified staging criteria.69 The diagnosis was made by the attending neonatal consultant and 
confirmed by an independent neonatologist. Three control infants (no NEC or bloodstream infection 
(BSI) diagnosis during admission) were selected for each NEC Bell Stage 2/3 case, and one control 
infant was selected for each NEC Bell Stage 1 case, based on postnatal age. Where possible, control 
infants were subsequently matched by mode of delivery, admission hospital and antibiotic use. Infants 
with suspected NEC (Bell Stage 1) were similarly paired to a single control infant. As a separate sub-
study, each NEC (Bell Stage 1, 2 and 3) infant was independently matched to a contemporaneous 
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2.2 Materials 
 
The materials used for the study and validation work (Chapters 3 and 4) are listed in Table 2, 
solutions shown in Table 3 and equipment in Table 4.  
 
Table 2: Details of materials used for the study. 
Item Supplier 
Agencourt AMPure XP system Beckman Coulter, High Wycombe, United Kingdom 
Anaerogen Anaerobic sachet Thermo Scientific, Paisley, United Kingdom 
Betaine Sigma, Dorset, United Kingdom 
Bovine serum albumin (BSA) Sigma, Dorset, United Kingdom 
Brain heart infusion (BHI) Sigma, Dorset, United Kingdom 
Cetyl Trimethylammonium Bromide (CTAB) Sigma, Dorset, United Kingdom 
Chloroform Sigma, Dorset, United Kingdom 
CHROMagar Orientation BD, Oxford, United Kingdom 
Chrome gelatine coated 18-well slides Thermo Scientific, Paisley, United Kingdom 
Citifluor AF1  Citifluor Ltd, London, United Kingdom 
Cooked Meat media broth Oxoid, Hampshire, United Kingdom 
Dimethyl Sulfoxide (DMSO) Sigma, Dorset, United Kingdom 
DNA ladder (1kb) Life Technologies, Paisley, United Kingdom 
DNA Zap Ambion, Paisley, United Kingdom 
dNTP mix Roche, Mannheim, Germany 
E-gel size select gels Life Technologies, Paisley, United Kingdom 
Microcentrifuge tubes VWR, Lutterworth, United Kingdom 
100% Ethanol VWR, Lutterworth, United Kingdom 
Ethidium bromide Sigma, Dorset, United Kingdom 
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Ethylene Diamine Tetra-acetic Acid (EDTA) Sigma, Dorset, United Kingdom 
Fastidious Anaerobic Agar (FAA) Oxoid, Hampshire, United Kingdom 
FastStart 10x Buffer #2 Roche, Mannheim, Germany 
FastStart HiFi Polymerase Roche, Mannheim, Germany 
FISH probes Biolegio B.V., Nijmegen, the Netherlands 
FLOQswabs VWR, Lutterworth, United Kingdom 
Glycerol Sigma, Dorset, United Kingdom 
Glycoblue Ambion, Paisley, United Kingdom 
Lysing Matrix E Tube (LME) MP Biomedicals, Santa Ana, U.S.A. 
Lysing Matrix A Tube (LMA) MP Biomedicals, Santa Ana, U.S.A. 
Lysozyme Sigma, Dorset, United Kingdom 
Matrix Solution Bruker Daltonics, Coventry, United Kingdom 
Mo Bio Faecal Kit Mo Bio, California, U.S.A. 
Mo Bio PowerSoil Kit Mo Bio, California, U.S.A. 
Molecular biology grade water Sigma, Dorset, United Kingdom 
MP Bio Fast DNA SPIN Kit for Soil MP Biomedicals, Santa Ana, U.S.A. 
Phase lock tubes 5-Prime, VWR, Lutterworth, United Kingdom 
Phenol Sigma, Dorset, United Kingdom 
Phenol:chloroform:isoamyl alcohol Sigma, Dorset, United Kingdom 
Phosphate buffered saline (PBS) Sigma, Dorset, United Kingdom 
Polyethylene glycol (PEG) Sigma, Dorset, United Kingdom 
Primers Eurofins MWG Operon, Ebersberg, Germany 
Proteinase K Sigma, Dorset, United Kingdom 
QIAamp DNA mini kit QIAgen, Manchester, United Kingdom 
Quant-iT PicoGreen dsDNA Assay Kit Life Technologies, Paisley, United Kingdom 
RNAse A QIAgen, Manchester, United Kingdom 
SEWS-M (wash solution from the MP Bio MP Biomedicals, Santa Ana, U.S.A. 
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Fast DNA SPIN Kit for Soil) 
Sodium dodecyl sulphate Sigma, Dorset, United Kingdom 
Sodium phosphate buffer Sigma, Dorset, United Kingdom 
Sodium taurocholate hydrate Sigma, Dorset, United Kingdom 
Spatula VWR, Lutterworth, United Kingdom 
Sterile defibrinated sheep blood Scientific Laboratory Supplies, Yorkshire, United 
Kingdom 
Tris-hydrochloride Sigma, Dorset, United Kingdom 
 
Table 3: Details of solutions used for the study. 
Solution Constituents 
Lysis buffer 400mM Tris, 60mM EDTA, 150mM NaCl, 1% SDS 
Modified CTAB extraction buffer 1 part: 10% CTAB in 1M NaCl 
1 part: 0.5M phosphate buffer (pH 7.5-8) in 1M NaCl 
Polyethylene Glycol Sodium Chloride 
(PEG-NaCl) solution 
30% PEG 6000 in 1.6M NaCl 
Tris-EDTA 10mM Tris-HCl, 1 mM EDTA, pH 8.0 
Tris low-EDTA 10mM Tris-HCl, 0.1mM EDTA, pH 8.0 
 
Table 4: Details of equipment used for the study. 
Equipment Model Supplier 
454 sequencer 454 Life Sciences GS Junior 
Titanium machine 
454 Life Sciences GS FLX 
Titanium machine 
Roche, Mannheim, Germany 
Centrifuge Eppendorf 5415R Eppendorf, Stevenage, United 
Kingdom 
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Microplate reader FLUOstar Omega microplate 
reader  
BMG Labtech, Ortenberg, 
Germany 
Homogeniser FastPrep-24 instrument MP Biomedicals, Santa Ana, 
U.S.A. 
Laboratory oven Shake ‘n’ stack hybridization 
oven 






Bruker Microflex LT Bruker Daltonics, Coventry, 
United Kingdom 
Nanodrop machine ND-1000 spectrophotometer Thermo Scientific, Paisley, 
United Kingdom 
Polymerase Chain Reaction 
(PCR) machine  
BIO-RAD, DNAEngine BIO-RAD, Hertfordshire, 
United Kingdom 
Quadruple band filter set  Set 84000 Chroma Technology Corp., 
Brattleboro, U.S.A 
Qubit - Life Technologies, Paisley, 
United Kingdom 
Scan^R screening station - Olympus, Hamburg, Germany 
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2.3 Sample collection and processing 
 
Figure 4 shows the general schema of collection and processing of clinical samples through to 
identification of the microbial composition of the sample. 
 
 
Figure 4: Overall work flow from sample collection to identification of microbial composition.  
2.3.1 Sample collection 
2.3.1.1 Faecal sample collection  
Almost every faecal sample produced by each participant from the point of recruitment until 
discharge was collected by the nursing staff responsible for the infant.  Samples from each infant were 
labelled with the date and time of collection as well as the date and time the sample was placed into 
the local -20oC freezer. Samples were collected from the nappy using a sterile autoclaved spatula 
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placed into a DNAase-, RNAase-free, sterile 1.5ml Microcentrifuge tube, stored in a dedicated -20oC 
freezer located on each neonatal unit site within two hours of collection, before being moved, within 
five days, to -80oC prior to DNA extraction.  
 
2.3.1.2 Skin swabs  
Sterile FLOQswabs, which enable improved release of bacteria, were moistened with sterile 
molecular biology grade water and the groin of the infant swabbed as per routine clinical protocol as 
soon as feasibly possible. The swabs were then placed into the -20oC freezer before being moved, 
within five days, to -80oC prior to DNA extraction. 
 
2.3.1.3 Environmental swabs  
If an infant was cared for inside an incubator, then weekly incubator swabs were collected. A sterile 
FLOQswab was moistened with sterile molecular biology grade water and the rubber ring of the right 
port hole of the incubator swabbed three times. The swabs were then placed into the -20oC freezer 
before being moved, within five days, to -80oC prior to DNA extraction. 
 
2.3.1.4 Gut tissue samples  
A small piece of the diseased tissue (~200mg wet weight) from the washed, resected bowel was 
collected at the time of surgery. Samples from the site of disease as well as the healthy margin were 
collected when possible. Where available, luminal contents were collected, or a swab of the lumen 
taken. The samples were either placed at -80oC for storage or underwent DNA extraction within one 
hour of collection. 
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2.4 DNA Extraction 
2.4.1 DNA extraction from faecal samples 
 
Weekly DNA extractions, with one sample from that week from every baby, were performed in order 
to produce an archive of ‘fresh’ DNA. DNA was extracted from faecal samples (~200mg) using the 
MP Bio FastDNA SPIN Kit for Soil (see Section 3.1). Extractions were performed as per the 
manufacturer’s protocol. In brief, 978µl of sodium phosphate buffer and 122µl of MT buffer was 
added to the faecal sample in a lysing matrix E (LME) tube. Two homogenization steps were carried 
out for 40 seconds at speed setting 6.0 using the FastPrep-24 instrument with the samples placed on 
ice for 30 seconds between homogenizations. The samples were centrifuged at 14,000 g for 10 
minutes to pellet the debris and the supernatant transferred to a 2ml tube containing 250µl of protein 
precipitation solution. This was inverted 10 times and centrifuged at 14,000 g for 5 minutes to pellet 
the precipitate. The supernatant was added to a 15ml tube containing 1ml of re-suspended binding 
matrix solution and rotated for 2 minutes at room temperature to allow binding of the DNA to take 
place. The tube was subsequently placed in a rack for 3 minutes to allow the silica matrix to settle and 
1ml of the supernatant discarded. The rest of the matrix was transferred into a 2ml tube and 
centrifuged for 2 minutes at 14,000 g. The supernatant was removed and the binding matrix re-
suspended in 500µl of SEWS-M, transferred into the SPIN column, and centrifuged for a further 1 
minute at 14,000 g. A second dry spin was performed for 2 minutes and the catch tube then replaced 
with a clean tube and the SPIN filter air dried at room temperature for 5 minutes. The binding matrix 
was re-suspended in Tris-low EDTA, incubated for 5 minutes at 55oC in a laboratory oven and the 
DNA eluted by centrifuging at 14,000 g for 1 minute. DNA was transferred into a screw-cap tube and 




2.4.2 DNA extraction from swab samples  
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DNA was extracted from the swab heads using the MP Bio FastDNA SPIN Kit.  Extractions were 
performed as per the manufacturer’s protocol. In brief, 1ml of cell lysis solution was added to the 
swab head which was cut from the swab using scissors cleaned with 70% ethanol and DNA Zap 
solution in a lysing matrix A (LMA) tube. Two homogenization steps were carried out for 30 seconds 
at speed setting 6.0 using a FastPrep-24 instrument with the samples placed on ice for 30 seconds 
between homogenizations. The samples were centrifuged at 14,000 g for 10 minutes to pellet the 
debris and the supernatant transferred to a 2ml tube containing 600µl of binding matrix solution. This 
was then inverted 10 times and incubated with gentle agitation for 5 minutes at room temperature on a 
rotator to allow binding of the DNA. Next the tube was centrifuged at 14,000 g for 5 minutes to pellet 
the binding matrix and the supernatant discarded. The binding matrix was re-suspended in 500µl of 
SEWS-M, transferred into the SPIN column and centrifuged at 14,000 g for 1 minute. A second dry 
spin was performed for 1 minute after which the catch tube was replaced with a clean tube. The 
binding matrix was re-suspended in Tris-low EDTA, incubated at 55oC in a laboratory oven for 5 
minutes and the DNA eluted by centrifuging at 14,000 g for 1 minute. The DNA was transferred into 
a screw-cap tube and following quantification (see Section 2.5) stored at -80oC. 
 
2.4.3 DNA extraction from gut tissue 
 
Gut tissue specimens were washed three times in 30ml of sterile phosphate buffer solution prior to 
extraction. Fresh gut tissue specimens or intestinal luminal contents were extracted using the same 
protocol as for faecal samples (Section 2.4.1). Several samples were provided in formalin, or were 
post-mortem samples. Formalin can cause fragmentation of DNA and DNA-protein cross-linking 
which leads to difficulties in successful DNA extraction. A heating step to break DNA-protein cross 
linkage, as well as a proteinase K digestion step was incorporated as both of these methods have both 
been shown to increase DNA yield.70  
Gut tissue fixed in formalin or post mortem specimens were extracted using the following protocol. 
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A maximum of 500mg of tissue sample was placed into a LME tube, to which 122µl of MT buffer, 
13.3µl of lysozyme (75mg/ml), 50µl of 10% sodium dodecyl sulphate and 578µl of sodium phosphate 
buffer solution was added. The sample was homogenized twice for 40 seconds at speed 6.0 using a 
FastPrep instrument with the samples placed on ice between homogenisation steps. The samples were 
incubated with gentle agitation on a rotator for 10 minutes at 37oC. One hundred µl of Proteinase K 
(20mg/ml) was added and the samples incubated overnight at 55oC on a rotator. They were then 
homogenised for 40 seconds at speed 6.0 and incubated at 90oC for 1 hour in a laboratory oven.  Two 
further homogenizations using the same settings were performed with samples placed on ice between 
homogenization steps. The samples were then centrifuged for 10 minutes at 14,000 g to pellet the 
debris and the supernatant transferred to a 2ml tube containing 250µl of protein precipitation solution. 
Next the tube was inverted 10 times and centrifuged at 14,000 g for 5 minutes to pellet the precipitate. 
The supernatant was added to a 15ml tube containing 1ml of binding matrix solution (already re-
suspended) and rotated for 2 minutes at room temperature to allow binding of the DNA. The tube was 
placed in a rack at room temperature for 3 minutes to allow the silica matrix to settle after which 1ml 
of the supernatant was discarded. The rest of the matrix was transferred into a 2ml tube and 
centrifuged for 2 minutes at 14,000 g. The supernatant was removed and the binding matrix re-
suspended in 500µl of SEWS-M, transferred into the SPIN column, and centrifuged at 14,000 g for 1 
minute. A second dry spin was performed for 2 minutes after which the catch tube was replaced with 
a clean tube and the SPIN filter air dried at room temperature for 5 minutes. The binding matrix was 
re-suspended in Tris-low EDTA, incubated for 5 minutes at 55oC in a laboratory oven and the DNA 
eluted by centrifuging at 14,000 g for 1 minute. DNA was transferred into a screw-cap tube and stored 
at -80oC post quantification.  
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2.5 DNA quantification 
 
The concentration of DNA per µl within each extracted DNA sample was established using a 
Nanodrop machine. Concentrations (ng/µl), 260nm/280nm and 260nm/230nm ratios were recorded in 
the NeoM database. The 260nm/280nm and 260nm/230nm ratios are used to assess the purity of the 
DNA sample. A ‘pure’ DNA sample will have a 260nm/280nm ratio of 1.8, and 260nm/230nm ratio 
of between 2.0-2.2. Contaminants such as proteins, phenol and RNA in the sample will affect the 
ratios. Whilst the Nanodrop provides a quick and cost effect method of determining DNA 
concentrations, its accuracy is limited by contaminants affecting the absorbance measurements. The 
PicoGreen dsDNA (double stranded DNA) assay which is based on a fluorescent dye which binds to 
dsDNA is a more accurate method of measuring DNA concentration and this was used in specific 
steps of the protocol (Section 2.9). 
 
2.6 Sample selection criteria  
 
DNA extracted from at least one faecal sample per week from 53 healthy pre-term infants (without 
NEC or BSI) was processed and underwent 454 sequencing to characterise the normal GI microbiota. 
From each NEC infant weekly faecal samples from birth and eight faecal samples collected in the two 
weeks (where possible) prior to day of diagnosis D0 were also selected for sequencing (Figure 5). 
 
 
Figure 5: Sample selection strategy for NEC infants. 
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2.7 Amplification of the V3-V5 regions of the 16S rRNA gene 
 
The V3-V5 regions of the 16S rRNA gene were amplified using the forward primer 357F with 
adaptor B from 454 Life Sciences for pyrosequencing: 5’ 
CTATCCCCTGTGTGCCTTGGCAGTCTCAGCCTACGGGAGGCAGCAG 
3’, and the ‘bifidobacteria-optimised’ reverse primer 926Rb (see Chapter 4): 5’ 
CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNNNNNNNNCCGTCAATTYMTTTRAGT 
3’. The reverse primers included the 454 Life Sciences adaptor A and a 12 base-pair error-correcting 
Golay barcode (denoted by 12 ‘N’s) (details of barcodes provided in Appendix 2) allowing 
multiplexing of multiple samples in a single run.  
 
In order to reduce random mis-priming bias, PCR was carried out in quadruplicate for later pooling. 
No-template PCR negative controls were also included for contamination detection. Each 25µl 
reaction contained 1µl each of forward and reverse primers (10µM), 1µl of template DNA, 0.25µl of 
5 U/µl FastStart HiFi Polymerase, 0.5µl of dNTP mix (10mM each), 2.5µl of FastStart 10x Buffer #2, 
11.25µl of molecular biology grade water, 1µl of 20 g/mL BSA and 6.5µl of 5 M Betaine. To 
maintain sterility and minimise potential external contamination, all PCR reactions were assembled 
within a PCR hood. The internal surfaces of the hood and all equipment were cleaned with DNAZap 
and underwent UV irradiation prior to use. Thermal cycling consisted of initial denaturation at 94oC 
for 2 minutes followed by 35 cycles of denaturation at 94oC for 20 seconds, annealing at 50oC for 30 
seconds, and extension at 72oC for 5 minutes.  
 
2.8 Amplicon clean-up 
2.8.1 Ampure beads 
 
The replicate amplicons were pooled and cleaned using the Agencourt AMPure XP system.  Briefly, 
70µl of AMPure beads (ratio of 0.7:1 AMPure beads:amplicon) were added and mixed to the pooled 
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amplicons. After incubation for 10 minutes at room temperature (RT) the plate was placed on a 96 
well magnetic stand and left for 5 minutes at RT until the supernatant was clear.  The supernatant was 
then discarded and the beads washed with 100µl of 70% ethanol. Using the magnetic stand the beads 
were then pelleted and the supernatant removed. Another wash step was performed before the pellet 
of beads was left to air dry for 5 minutes after which it was re-suspended in 50µl of 1x Tris-EDTA. 
Finally, the beads were removed using the magnetic stand and the supernatant consisting of the 
purified amplicon was transferred into a clean 96-well plate. 
 
2.8.2 Size selection 
 
Amplicons of the correct size were selected using 2% E-Gel SizeSelect gels. Twenty six µl of 
molecular grade water was added to the bottom wells, and 5µl of marker added to the marker well. 
The gel was run for 16 minutes (program: SizeSelect 2%) and the wells refilled with molecular grade 
water. When a band of the correct size reached the well (visualised using the inbuilt blue-light 
transillumination device) this was aspirated and placed into a clean 96 well plate. 
 
2.9 Amplicon quantification and pooling 
 
Purified amplicons were quantified in duplicate using the Quant-iT PicoGreen dsDNA Assay Kit. 
Eight standards in duplicate were used. Ninety nine µl of 1x Tris-EDTA buffer, 1µl of each purified 
amplicon and 100µl of a 1:200 dilution of PicoGreen reagent was added to each well and mixed 
thoroughly. The FLUOstar Omega microplate reader was used to measure fluorescence and DNA 
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2.10 454 Sequencing 
 
Next-generation sequencing of amplicon pools was either performed in-house using a 454 Life 
Sciences GS Junior Titanium machine, or carried out by the Department of Biochemistry, University 
of Cambridge, using a 454 Life Sciences GS FLX Titanium machine following the Roche Amplicon 
Lib-L protocol. Both of the machines utilise the same sequencing chemistry. Figure 6 shows a 
summary of the main steps required for 454 sequencing. The main difference is the number of 
resulting sequencing reads, with the GS FLX machine having a much larger capacity (maximum 
~1,000,000  reads) compared to the GS Junior machine (maximum ~100,000 reads). Work carried out 
for validation purposes (Chapters 3 and 4) was performed mainly on the 454 GS Junior instrument 
(Roche), and samples from the main NeoM study were analysed using the 454 GS FLX instrument 
(Roche). 
 
Figure 6: Workflow for 454 sequencing. Adapted from the Roche GS Junior emPCR Amplification 
and Sequencing Method Manual (May 2010).71  
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2.11 Culture work 
 
An antecedent frozen sample collected as close as possible to the day of diagnosis of NEC (D0) from 
every case and their corresponding contemporaneous control was selected for culture for both 
Clostridium spp. and Enterobacteriaceae. 
 
2.11.1 Growth of Clostridia  
 
For isolation of Clostridium spp. an alcohol shock method was used to eliminate non-sporing 
organisms. Briefly, 50mg of freshly thawed faeces taken from -80oC were added to 1ml of 
Robertson’s Cooked Meat Media broth. Five hundred µl of 100% ethanol was added to 500µl of the 
broth and the mixture incubated for 30 minutes at room temperature. This was streaked out onto 
Fastidious Anaerobic Agar (FAA) with sodium taurocholate hydrate (46g of FAA added to 500ml of 
water and autoclaved at 121oC for 15 minutes, with 25ml of sterile defibrinated sheep blood and 0.5g 
of sodium taurocholate hydrate added) and incubated at 37oC for 48 hours in an anaerobic jar 
containing an Anaerogen anaerobic sachet. Purity plates were grown of each morphologically distinct 
colony and stocks were stored in fresh Robertson’s Cooked Meat Media broth at room temperature.  
 
2.11.2 Growth of Enterobacteriaceae  
 
Samples were inoculated on to CHROMagar Orientation and incubated at 37oC for 48 hours. Purity 
plates were grown of each morphologically distinct colony compatible with an Enterobacteriaceae 
identification (based on the description of the colony) and stocks were stored in 30% glycerol – 70% 
brain heart infusion and stored at -80oC. 
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2.12 Identification of organisms using Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) 
 
A single colony was transferred to a cleaned MALDI-TOF plate using a toothpick. A thin film of the 
organism was created directly over the target spot and air dried at room temperature for two minutes 
before 1µl of matrix solution was added to each spot. Duplicates of each morphologically distinct 
colony were spotted onto the plate.  All bacterial isolates were identified by MALDI-TOF using a 
Bruker Microflex LT by the Microbiology Department at Imperial College Healthcare NHS Trust. 
 
2.13 Clostridia Toxin Typing 
 
Isolates of C. perfringens were analysed at the Public Health England Foodborne Pathogens reference 
service and screened for the presence of alpha, beta, epsilon, iota, cpe and beta2 toxins by multiplexed 
PCR. 
 
2.14 Fluorescent Amplified Fragment Length Polymorphism (fAFLP) 
 
Fluorescent amplified fragment length polymorphism (fAFLP) typing was performed at the Public 




2.15.1 Operational taxonomic unit (OTU) identification 
 
The ‘Quantitative Insights Into Microbial Ecology’ (QIIME) v1·5·0 package was used for analysing 
the sequencing data.72 Shotgun processed data was first denoised using AmpliconNoise52 followed by 
  67  
chimera-removal with Perseus.52 Sequences were aligned using the SILVA rRNA database 
(SSU_REF108)73 for reference and clustered at 97% sequence identity into operational taxonomic 
units (OTUs) using the UCLUST algorithm.74 Representative sequences were selected and classified 
using the Ribosomal Database Project Classifier.75 Rarefaction was performed, removing 
heterogeneity of sequencing reads per sample. Sequences that were present only once in the dataset 
(singletons) and OTUs found in only one sample were removed after alpha diversity calculations were 
performed. 
 
2.16 Alpha diversity calculations 
 
Alpha diversity is a function of species richness (number of different species present) and evenness 
(relative abundance of each of the species presence) in a given environment/sample.76 In this study the 
Shannon-Weaver index was calculated for each sample prior to rarefaction and singleton removal. 
The Shannon-Weaver index (also known as Shannon entropy) varies such that a sample with minimal 
diversity (e.g. one dominant OTU present in the sample) will have a near zero value, and a very 
diverse sample (e.g. many OTUs with similar abundances) will have a high value.  
 
2.17 Beta diversity calculations 
 
Beta diversity is a measure of the difference in species composition between two 
environments/samples. The weighted UniFrac metric77 was used as a measure of beta diversity. This 
was chosen rather than the un-weighted UniFrac metric as it takes into account OTU abundance 
which was anticipated to be important for the analysis. Samples identical to one another will have a 
UniFrac metric of zero, and samples extremely dissimilar to one another will have a value close to 
one. Principal coordinate analysis (PCoA) was implemented using QIIME to visualise the resulting 
matrix of the UniFrac results. 
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2.18 Statistics 
 
The R statistical package (version 3.0.2) was used for statistical analysis. The Shapiro-Wilks test was 
used to assess normality of the data set in order to determine the appropriate statistical tests. Case and 
control patient characteristics were compared using Student’s t-tests, the Wilcoxon-Mann-Whitney 
test, or Chi-squared tests or Fisher’s exact test where appropriate. OTUs that were differentially 
abundant between NEC and control groups were identified using logistic regression performed using 
the generalised linear model and stepwise algorithm of the R statistical package (version 3·0·2).78 P 
values less than 0.05 were considered to be significant. A Bonferonni correction was applied in cases 
where multiple testing was required. Stacked bar charts depicting the microbial composition of faecal 
samples were created using the R statistical package. 
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Chapter 3 Validation Work – Part 1 
This chapter describes work carried out in order to determine the best methods to adopt for the main 
NeoM study, the final methods chosen being detailed in Chapter 2. In this chapter the issue of DNA 
extraction methods (Section 3.1), the effect of short and long term storage of faecal samples (Section 
3.2), the impact of variation of the weight of starting faecal material on the faecal microbiota (Section 
3.3), and finally, the ability of 454 pyrosequencing to faithfully represent the composition of bacterial 
mock mixtures (Section 3.4) are all addressed.  
 
3.1 Investigation of DNA extraction methods 
3.1.1 Introduction 
 
Selection of an appropriate DNA extraction method is crucially important as Gram-positive bacteria 
are difficult to lyse, and methods that do not completely lyse Gram-positive bacteria will lead to 
under-representation of these organisms.79 Notably, protocols which utilise bead-beating steps have 
been shown to produce DNA which is more representative of the sample constituents.80  
 
DNA used for downstream analysis such as next generation sequencing must be of high quality. 
Faecal samples contain PCR inhibitors such as bile salts, haemoglobin degradation products and 
complex polysaccharides,81 and the resulting extracted DNA must be free of such inhibitors before 
pyrosequencing is carried out. While standard laboratory phenol-chloroform based extraction methods 
are effective in achieving high-quality DNA, they are now being replaced with commercial kits that 
are much quicker to use, undergo rigorous quality control checks, and are optimised to remove PCR 
inhibitors from difficult-to-process samples such as faeces. The risk of residual phenol products 
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affecting downstream reactions is removed as the methodology is not based on a phenol-chloroform 
extraction method. DNA extraction kits developed to process soil samples for environmental studies 
have been found to be particularly successful, as like faecal samples, soil contains PCR inhibitors (e.g. 




To determine the best DNA extraction method for bacterial mixtures and faecal samples that: 
1) Gives the highest DNA concentration 
2) Faithfully represents a bacterial mock mixture comprising 50% Gram-positive and 50% 
Gram-negative organisms, as confirmed by 454 pyrosequencing 
 
3.1.3 Methods 
3.1.3.1 Bacterial mixtures  
Five x107 CFU each of frozen pre-quantified Neisseria lactamica (Gram-negative) and Streptococcus 
pneumoniae (Gram-positive) organisms were combined to make 50:50 mixtures.  The mixtures were 
then extracted using the methods detailed below (Section 3.1.3.3). 
 
3.1.3.2 Faecal samples  
A single faecal sample from a 16 day old baby born at 37 weeks was homogenized and then divided 
into six sub-samples (~100mg each). DNA from one sub-sample was extracted immediately (within 
one hour of sample collection) using the ‘C’ protocol below. The remaining five sub-samples were 
stored at -80oC within one hour of collection. DNA from each of the five sub-samples was then 
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extracted four days later using a different DNA extraction method as outlined below. DNA from the 
three highest yielding methods subsequently underwent pyrosequencing. 
 
3.1.3.3 DNA extraction methods   
The three kits used within the comparison study were: MP Bio Fast DNA SPIN kit for Soil, Mo Bio 
PowerSoil kit and the Mo Bio Faecal kit. The manufacturers’ directions were followed with no 
modifications. All three kits include a bead-beating step. In addition two non-commercial laboratory 
protocols were used: 1.) Protocol ‘C’ based on methods described by DeAngelis et al.82, and 2.) 
Protocol ‘L’ (an in-house method developed by our group). 
 
‘Protocol C’:  Approximately 100mg of faeces was added to a Lysing Matrix E (LME) tube 
containing 50µl of 0.1M aluminium ammonium sulphate and 500µl of modified cetyl 
trimethylammonium bromide (CTAB) extraction buffer. Five hundred µl of 
phenol:chloroform:isoamyl alcohol (25:24:1) was added, the mixture vortexed and placed on ice. 
Samples then underwent bead-beating – speed setting 5.5 for 30 seconds on a FastPrep machine after 
which they were centrifuged for 5 minutes at 16,000 g. Supernatants were transferred to phase-lock 
gel tubes and the LME tubes kept on ice. An equal volume of chloroform was added to the phase-lock 
tubes and inverted to mix the solution prior to centrifugation at 12,000 g for 5 minutes. Five hundred 
µl of modified CTAB buffer was added to the LME tubes, bead-beating and centrifugation carried out 
as above and the supernatant added to a fresh phase-lock tube. Chloroform was added and the sample 
centrifuged as above. One µl of Glycoblue (15mg/ml) was added to a fresh microcentrifuge tube and 
the aqueous top layer from the phase-lock gel tubes added to the microcentrifuge tube. Two volumes 
of polyethylene glycol (PEG)-NaCl solution was added to each microcentrifuge tube and thoroughly 
mixed before incubating at room temperature for two hours. After centrifugation for 10 minutes at 
16,000 g, the PEG solution was removed and the resulting pellet washed in ~1ml of ice-cold 70% 
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ethanol before re-centrifuging for 5 minutes at 16,000 g. All the ethanol was removed and the pellet 
left to air-dry for 5 minutes before resuspending in 30µl of molecular grade water. DNA originating 
from the same sample were combined into one tube and stored at -80oC. 
 
Protocol ‘L’: Six hundred µl of TE was added to ~100mg of faeces and vortexed. Ten µl of lysozyme 
(75mg/ml) was added and the sample incubated for 10 minutes at 37oC. The entire mixture was 
transferred to a LME tube and bead beating carried out for 45 second pulses at speed setting 6.0 m/s 
on the FastPrep machine, followed by incubation at room temperature for 10 minutes. Two hundred 
µl of lysis buffer containing RNAse A and proteinase K (1ml lysis buffer, 12µl of RNAse A 
(10mg/ml), 30µl of Proteinase K (20mg/ml)) was added and bead beating repeated as above. The 
homogenised mixture was incubated at 56oC for 30 minutes and bead beating repeated. Phenol-
chloroform extraction was then carried out. The supernatant was added to an equal volume of phenol, 
vortexed to ensure an emulsion was formed, spun down for 5 minutes at 14,000 g and the procedure 
repeated three times after which the supernatant was removed and added to an equal volume of 
chloroform. Finally, the supernatant was removed and a 2x volume of 100% ethanol added before 
clean-up carried out using the QIAamp DNA mini kit. The lysate was added to the QIAamp spin 
column and centrifuged at 14,000 g for 1 minute. The spin column was transferred to a fresh 2ml tube 
and 500µl of Buffer AW1 added before another step of centrifugation and the column placed in 
another new 2ml tube. Five hundred µl of Buffer AW2 was added and two centrifugation steps carried 
out (1x dry spin) before eluting the DNA in 50µl of Buffer AE. 
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3.1.3.4 PCR amplification of the V3-V5 regions of the bacterial 16S rRNA gene.  
The V3-V5 regions of the bacterial 16S rRNA gene were amplified for each sample using primer sets 
from the Human Microbiome Project.83 The forward primer 
5’CTATCCCCTGTGTGCCTTGGCAGTCTCAGCCTACGGGAGGCAGCAG  3’ contained the 454 
Life Sciences primer B sequence and the broadly conserved bacterial primer 357F.  The reverse 
primer 5’ CCATCTCATCCCTGCGTGTCTCCGACTCAG-NNNNNNNNNNNN-
CCGTCAATTCMTTTRAGT 3’ (see Chapter 4) contained a unique 12 base-pair error-correcting 
Golay barcode (denoted with ‘N’ (details of barcodes provided in Appendix 2)) used to tag each 
amplicon, and the broad-range bacterial primer 926R.  
 
PCRs were performed as described in Section 2.7 except that they were carried out in triplicate 
instead of quadruplicate. The replicate amplicons were pooled and loaded onto a 1.5% agarose gel 
together with a 1kb DNA ladder and run for 45 minutes (100 volts) and visualized using ethidium 
bromide (10mg/mL). The pooled amplicons were cleaned using a QIAamp DNA mini kit according to 
the manufacturer’s instructions.  
 
3.1.3.5 Amplicon quantitation, pooling and 454 sequencing   
The cleaned amplicon DNA concentrations were measured using the Qubit based on the PicoGreen 
dsDNA assay. Cleaned amplicons were combined in equi-molar ratios into a single tube and diluted in 
Tris-EDTA such that the final pool contained 106 molecules. Five µl of this pool was added to the 
emulsion PCR reaction. Pyrosequencing was either carried out on a 454 Life Sciences GS Junior 
instrument (Roche) or a FLX instrument following the Roche Amplicon Lib-L protocol as described 
in Section 2.10. 
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3.1.3.6 Bioinformatic analysis  
The QIIME pipeline was used to separate the sequences into their original sample based on their 
unique 12 nucleotide barcode and bioinformatics analysis conducted as laid out in Sections 2.15, 2.16 
and 2.17.  
 
3.1.4 Results 
3.1.4.1 DNA yields from 50:50 bacteria mixtures and faecal sub-samples  
DNA yields from the 50:50 bacterial mixtures varied from less than 0.5ng (sic) (MoBio Faecal kit) to 
1.19µg. Yields up to 20.25µg were recovered from the faecal samples, as shown in Table 5. 
Surprisingly, the MoBio Faecal kit consistently performed extremely poorly despite being apparently 
optimised to extract DNA from faecal samples.  
 
3.1.4.2 PCR amplification  
DNA from the 50:50 bacterial mixtures and faecal sub-samples extracted using the MP Bio Fast DNA 
Soil kit, Protocol ‘C’ and Protocol ‘L’ (top three highest yields out of all the extraction methods) were 
taken forward for PCR amplification. Amplicons were successfully produced from all the DNA 
samples as confirmed by visualisation on an agarose gel using ethidium bromide. The amplicons were 
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Table 5: DNA yield from 50:50 mixtures and faecal sub-samples. 
Extraction Method 50:50 mixtures DNA 
yield (µg) 
Faecal sub-samples 
DNA yield (µg) 
MP Bio Fast DNA SPIN kit for Soil 1.19 13.60 
MoBio PowerSoil 0.33 0.21 
MoBio Faecal kit <0.0005 <0.0005 
Protocol ‘C’ 
(DNA extraction performed within one hour of 
sample collection) 
N/A 20.25 
Protocol ‘C’ 0.68 18.35 
Protocol ‘L’ 0.54 0.43 
 
With the exception of one sub-sample (which was extracted within one hour of sample collection) all 
faecal sub-samples were extracted four days after collection, during which time the sub-samples were 
stored at -80oC. 
 
3.1.4.3 Pyrosequencing data results  
The pyrosequencing run yielded 12,999 good quality sequencing reads after denoising and chimera 
removal was carried out. Eleven samples from the storage experiment (described in Section 3.2.3.1) 




3.1.4.4 Pyrosequencing results – 50:50 mixtures  
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Sequencing of the 50:50 bacterial mixtures of Neisseria lactamica and Streptococcus pneumoniae 
extracted using the MP Bio Fast DNA SPIN kit for Soil, Protocol ‘C’ and Protocol ‘L’ generated 1359 
sequences for analysis (rarefied to 453 reads per sample).  16S rRNA gene copy numbers (Neisseria 
lactamica = 5, Streptococcus pneumoniae = 4) were taken into account to calculate the proportions of 
reads ascribed to each organism in relation to the three different extraction methods. Although none of 
the three methods produced an exact 50:50 ratio, they all performed similarly (Figure 7). In terms of 
convenience, the MP Bio Fast DNA SPIN kit for Soil was found to be considerably quicker and 
substantially less labour intensive than either Protocol ‘C’ or Protocol ‘L’. 
 
Figure 7: Proportions of reads of 50:50 mixtures by extraction method.  
 
3.1.4.5 Pyrosequencing results – faecal samples  
Sequencing of the DNA extracted from the four faecal sub-samples using the MP Bio Fast DNA SPIN 
kit for Soil, Protocol ‘C’ and Protocol ‘L’ generated 1,812 high quality sequences (rarefied to 453 
reads per sample) which were used in the analysis. Two of these sub-samples were extracted using 
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days prior to extraction (details in Section 3.1.3.2).  A principal component analysis was performed 
using the weighted UniFrac metric and samples from the Storage experiment which is described in 
Section 3.2 is included for comparison. The samples pertaining to this section addressing different 
extraction methods are shown within the red circle in Figure 8. (Note that Figure 8 and Figure 10 are 
identical but are reproduced for clarity to emphasise two different experiments (Section 3.1 and 
Section 3.2).) These four faecal sub-samples form a distinct cluster in the principal component 




Impact of DNA extraction methods on 50:50 mixtures and faecal samples 
DNA yields varied up to four orders of magnitude depending on the DNA extraction method selected. 
In order to ensure adequate representation of all the bacteria present in the biological sample, maximal 
yield is preferable. While bead-beating is highly recommended to lyse Gram-positive bacteria79 and 
all three commercial kits tested incorporated a bead-beating step, the results revealed a substantial 
difference between the kits in their ability to extract DNA (Table 5).  This difference may be 
attributable to difference in bead sizes that each kit employs for the bead beating step.  Notably the kit 
with the largest sized beads (MoBio Faecal Kit) performed the poorest in terms of DNA yield. 
 
The three methods that produced the highest DNA yields, MP Bio Fast DNA SPIN kit for Soil, 
Protocol ‘C’ and Protocol ‘L’, gave similar results in the preservation of the 50:50 Gram-
positive:Gram-negative mixture (Figure 7).  The same three methods when applied to actual faecal 
samples also resulted in a similar microbial composition of the faecal samples (Figures 8 and 9).  
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Figure 8: Principal component analysis produced using the weighted UniFrac metric of DNA 
extracted from faecal samples using different methods. Results from two different experiments are 
displayed showing the effect of using different DNA extraction methods and different faecal storage 
conditions (see Section 3.2 below). DNA from sub-samples 1-4 (shown inside the red oval), were 
extracted using different DNA extraction methods and are indicated by circular symbols. The 
triangular and square symbols represent the composition of DNA extracted from sub-samples 4-15 
which relate to the ‘Storage Experiment’ as outlined and discussed in Section 3.2.  
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Figure 9: Microbial composition of faecal samples extracted by different methods. Figure created 
by Geraint Barton (Bioinformatics Support Service, Imperial College) and reproduced with 
permission. 
 
3.2 Investigation of short term versus long term storage of faecal samples  
3.2.1 Introduction 
 
At the time this study commenced there was limited information about the length of time that a faecal 
sample could be safely stored at room temperature prior to processing. Literature suggested that faecal 
samples could be kept at room temperature for up to 5 days if stored on Whatman FTA cards, dried 
over silica gel beads, or stored in RNAlater or a Paxgene tube, without the microbial community 
being significantly altered.84 Large scale clinical studies need to be realistically devised and 
consideration needs to be given to the impact of leaving samples at room temperature without any 
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treatment for a period of time. Long term storage of faecal samples at -80oC (over two months), has 
been considered to be problematic as it has been shown to potentially lead to lower detection rates of 




To assess the impact of short-term and long-term storage of faecal samples on the composition of the 
microbial community as determined by next generation sequencing. 
 
3.2.3 Methods 
3.2.3.1 Samples for storage experiment (Part 1)  
A single faecal sample was collected from a 15 day old baby born at 29 weeks and 4 days. The sample 
was divided into 10 sub-samples within one hour of collection. Samples were either stored directly at 
-80oC, or stored at -20oC for a period of time prior to storage at -80oC, or stored at room temperature 
for varying lengths of time before being transferred to -20oC and then -80oC (Table 6) in order to 
replicate likely clinical scenarios. DNA was extracted from 100mg of each sub-sample using Protocol 
‘L’ (Section 3.1.3.3). The DNA samples then underwent PCR amplification and 454 sequencing 
(protocols as per Sections 3.1.3.4 and 3.1.3.5). 
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Table 6: Storage conditions of faecal sub-samples. 
 
Ten sub-samples were maintained under different storage conditions to replicate short term versus 
long term storage scenarios. Sub-samples were stored at different lengths of time at room-
temperature, -20oC and -80oC prior to DNA extraction.   
 
3.2.3.2 Samples for extended storage experiment (Part 2)  
In addition to the original storage experiment (Section 3.2.3.1) an experiment was set up including 
additional long-term time points as well as more infants, the latter allowing reproducibility of results 
to be assessed. A single faecal sample was collected from each of four premature infants and the 
demographics of the four infants are detailed in Table 7.  Each single faecal sample was divided into 
12 sub-samples within one hour of collection and stored as detailed in Table 8 for varying lengths of 
time prior to DNA extraction. DNA was then extracted from 100mg of each sub-sample using 
Protocol ‘L’ (Section 3.1.3.3). These samples then underwent 454 sequencing (protocols as per 
Sections 3.1.3.4 and 3.1.3.5). 
Table 7: Demographics of infants included in storage experiment Part 2. 
Baby ID Gestation (weeks + days) Postnatal age (days) on day of 
sample collection 
Mode of delivery 
Q49 23+4 31 Vaginal delivery 
Q53 29+4 28 C-section 
M29 28+1 76 C-section 
M42 29+2 15 C-section 
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3.2.4 Results 
3.2.4.1 Storage Experiment – Part 1  
DNA from the ten faecal sub-samples were successfully amplified and underwent 454 sequencing 
using the 454 GS Junior instrument. 4,530 high quality sequences remained post denoising, chimera 
removal and rarefaction (453 reads per sample). Beta diversity was calculated using the UniFrac 
metric and a PCoA generated (Figure 10). (Note that Figure 8 and Figure 10 are identical but are 
reproduced for clarity to emphasise two different experiments (Section 3.1 and Section 3.2).) The 
PCoA also displays the results of the beta diversity of the faecal samples collected from a different 
infant for the DNA extraction method experiment (Section 3.1) for comparison. The samples which 
relate to this storage experiment lie within the red oval. The PCoA demonstrates clustering of the 
faecal sub-samples by baby, i.e. the effect of different storage conditions and DNA extraction method 
is not as significant as inter-individual variation. Figure 11 shows the bacterial taxa identified in the 
faecal sub-samples, and the change in proportions depending on DNA storage conditions. Again, for 
comparison, a second faecal sample (sample number 15) was collected one week later from the same 
infant who produced the sample for the storage experiment – this sample is distinct on the PCoA 
(Figure 10) and has a very different microbial community (Figure 11) from the other samples. 
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Figure 10: Principal component analysis produced using the weighted UniFrac metric of DNA 
extracted from faecal sub-samples stored under different conditions. Results from two different 
experiments are displayed showing the effect of using different DNA extraction methods (see Section 
3.1 above) and different faecal storage conditions. DNA from sub-samples 1-4 were extracted using 
different DNA extraction methods and are indicated by circular symbols. The triangular symbols 
represent the composition of DNA extracted from sub-samples 4-14 (shown in the red oval) relate to 
this storage experiment. The storage conditions for each of the sub-samples are shown in Table 6. 
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The purple square represents the DNA extracted from a faecal sample collected from the same infant 
who provided sub-samples 5-14, but taken one week later.  
 
Figure 11: Microbial composition of faecal sub-samples stored under different conditions. 
Figure created by Geraint Barton (Bioinformatics Support Service, Imperial College) and reproduced 
with permission. 
 
3.2.4.2 Extended Storage Experiment – Part 2  
Forty-four faecal sub-samples (4 infants, 11 time-points) underwent DNA extraction and all were 
successfully amplified (confirmed by visualisation on an agarose gel using ethidium bromide). The 
amplicons were pooled and underwent 454 sequencing on a GS FLX machine together with other 
samples from another project. After denoising and chimera removal, sequencing reads for this 
experiment were rarefied to a depth of 421 reads per sample. Two samples (M42.11 and Q49.5) did 
not retain sufficient sequencing reads to be included in the final analysis. Figure 12 shows the 
microbial composition of the faecal samples with sufficient sequencing reads. In an attempt to assess 
quantitatively which samples deviated from the ‘gold standard’ of leaving the faecal sample at room 
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temperature for only 4 hours (sub-sample number 1), a matrix of the Weighted UniFrac metric was 
compiled for sub-samples from each infant. An arbitrary cut-off of 0.05 was designated to be an 
indicator of sub-samples being different from one another (Figure 13). The UniFrac metric exceeded 
this cut-off at the 72 hour, 1 week and 2 week time points in infant M29, the 48 hour, 72 hour and 1 
week time points in infant M42, the 2 week room temperature time point in infant Q49, and at the 48 
hour time point in infant Q53. These results indicate that samples should not be held at room 
temperature for longer than 24 hours.  
 
Considering long term storage of samples at -80oC, sub-samples were compared to the ‘gold standard’ 
sub-sample number one, as this was stored for two months at -80oC prior to extraction. In two of the 
five samples (infants M42 and Q53) a UniFrac metric of =/> 0.05 was calculated at the six month 
time point, and in one infant (Q53) the nine month time point had a raised (>0.05) UniFrac metric. All 
the samples at the one year and 18 month time points had a UniFrac metric <0.05. In general long 
term storage at -80oC does not appear to have significantly impacted on the structure of the microbial 
community.  
Table 8: Details of extended storage experiment. 
 Varying lengths of time at room temperature prior to 
short-term storage at -80oC 
Long-term storage at -80oC 
Label ID X.1 X.2 X.3 X.4 X.5 X.6 X.7 X.8 X.9 X.10 X.11 X.12 
Duration at room 
temperature prior 
to storage at -80oC 
4h 8h 24h 48h 72h 1w 2w 8h 8h 8h 8h 8h 
Duration at -80oC 
prior to DNA 
extraction 
2m 2m 2m 2m 2m ~2m 1.5m 6m 9m 12m 18m 24 m 
X = baby ID (Q49, Q53, M29 or M42), h = hours, w = weeks, m = months.  
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Figure 12: Stacked bar charts showing microbial composition of faecal sub-samples from each 
infant that have undergone varying storage conditions. The coloured bar above the sub-sample 
number indicates the sub-samples belonging to the two sub-experiments: impact of storage at room 
temperature for different lengths of time (blue bar), and impact of long term storage at -80oC for 
different lengths of time (red bar). Sub-samples 1-7 were kept at room temperature for different 
amounts of time prior to storage at -80oC for two months before DNA extraction was carried out. Sub-
samples 8-11 were kept at room temperature for four hours prior to storage at -80oC for a period of 6 
to 18 months before DNA extraction was performed (see Table 8 for further details). For sub-sample 
11 from infant M42, and sub-sample 5 from infant Q49 inadequate sequencing reads were generated 
to enable their inclusion in the analysis.  
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Figure 13: Matrices of the weighted UniFrac metric for the extended storage experiment 
samples for each infant. Short and long term storage conditions are indicated above the sub-sample 
label. Cells which have a weighted UniFrac metric of less than 0.05 are coloured in white (i.e. sub-
samples are very similar to one another), cells which have a metric >/=0.05 but <0.1 are coloured in 
light blue, and those that have a metric >/=0.1 are coloured in dark blue (i.e. sub-samples are 
extremely dissimilar). Samples M42.11 and Q49.5 had in sufficient sequencing data and therefore 




1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10
1 ### ### ### ### ### ### ### ### ### ### ### 1 ### ### ### ### ### ### ### ### ### ###
2 ### ### ### ### ### ### ### ### ### ### ### 2 ### ### ### ### ### ### ### ### ### ###
3 ### ### ### ### ### ### ### ### ### ### ### 3 ### ### ### ### ### ### ### ### ### ###
4 ### ### ### ### ### ### ### ### ### ### ### 4 ### ### ### ### ### ### ### ### ### ###
5 ### ### ### ### ### ### ### ### ### ### ### 5 ### ### ### ### ### ### ### ### ### ###
6 ### ### ### ### ### ### ### ### ### ### ### 6 ### ### ### ### ### ### ### ### ### ###
7 ### ### ### ### ### ### ### ### ### ### ### 7 ### ### ### ### ### ### ### ### ### ###
8 ### ### ### ### ### ### ### ### ### ### ### 8 ### ### ### ### ### ### ### ### ### ###
9 ### ### ### ### ### ### ### ### ### ### ### 9 ### ### ### ### ### ### ### ### ### ###10 ### ### ### ### ### ### ### ### ### ### ### 10 ### ### ### ### ### ### ### ### ### ###
11 ### ### ### ### ### ### ### ### ### ### ###
1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 6 7 8 9 10 11
1 0 0 0 0.1 0 0.1 0.1 0.1 0.1 0 0 1 ### ### ### ### ### ### ### ### ### ###
2 0 0 0 0 0 0.1 0.1 0 0.1 0 0 2 ### ### ### ### ### ### ### ### ### ###
3 0 0 0 0.1 0 0.1 0.1 0.1 0.1 0 0 3 ### ### ### ### ### ### ### ### ### ###
4 0.1 0 0.1 0 0.1 0.1 0.1 0 0 0 0 4 ### ### ### ### ### ### ### ### ### ###
5 0 0 0 0.1 0 0.1 0.1 0.1 0.1 0.1 0.1 6 ### ### ### ### ### ### ### ### ### ###
6 0.1 0.1 0.1 0.1 0.1 0 0 0.2 0.2 0.1 0.1 7 ### ### ### ### ### ### ### ### ### ###
7 0.1 0.1 0.1 0.1 0.1 0 0 0.2 0.2 0.1 0.1 8 ### ### ### ### ### ### ### ### ### ###
8 0.1 0 0.1 0 0.1 0.2 0.2 0 0 0 0 9 ### ### ### ### ### ### ### ### ### ###
9 0.1 0.1 0.1 0 0.1 0.2 0.2 0 0 0 0.1 10 ### ### ### ### ### ### ### ### ### ###10 0 0 0 0 0.1 0.1 0.1 0 0 0 0 11 ### ### ### ### ### ### ### ### ### ###





















Short Long Short Long
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3.2.5 Conclusion 
 
Samples stored under different conditions in general were found to cluster with other samples from 
the same infant as opposed to samples stored under the same conditions but from different infants. 
Using the weighted UniFrac metric, there does appear to be an impact on the microbial community if 
samples are left at room temperature for more than 24 hours. For the main study of this thesis samples 
were kept at room temperature for no longer than two hours to ensure that the microbial community 
would not be substantially affected. 
 
This investigation into storage time of faecal samples suggests that long term storage at -80oC for up 
to 18 months does not significantly impact on the microbial composition. It is important to note that 
these conclusions are based on faecal samples taken from premature neonates whose GI microbiota is 
considerably less complex compared to adults.  Consequently caution is required in extrapolation of 
findings to other populations.  
 
An acknowledged limitation of the storage study is that ideally multiple replicates of each sub-sample 
at each time point would have been analysed. Variation within the experiment could also have arisen 
from the process of making multiple aliquots from a single faecal sample as well as the DNA 
extractions as they were carried out at different times and are prone to user variability. Quantifying 
the ‘expected’ variation of each replicate would provide a baseline allowing the effect of storage alone 
on the microbiota to be determined. Unfortunately, due to the small amounts of faeces produced by 
these infants the number of aliquots that could be made was limited to those reported here. 
 
The bar charts of the microbial communities in Figure 12 illustrate that samples from infant Q49 and 
M29 are very similar to each other.  This is additionally supported by the fact that the UniFrac metric 
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has values of <0.05 when samples from these two infants are compared (data not shown).  This 
highlights the fact that while in general the inter-individual variation is greater than the variation 
caused by different storage conditions, it is dependent upon the microbial community present in the 
sample. This is particularly pertinent in the case of premature infants whose faecal microbiota is less 
complex with lower diversity than term infants or adults. Clearly the composition of the microbiota 
itself is also important.  Samples containing high levels of obligate anaerobes may conceivably be 
more affected by long periods of storage at room temperature, while facultative anaerobes may 
flourish. 
 
3.3 Validation of using different amounts of faeces for DNA extraction 
3.3.1 Introduction 
 
The amount of faeces produced by a premature infant can be very small and often variably absorbed 
by the nappy, a particular problem when the faecal material is liquid. In the main NeoM study 
attempts were made to ensure DNA extractions were conducted from a set wet weight of faecal 
material (~ 200mg) but this was not always feasible. In the cases where only a single sample was 
available to work with (e.g. only one sample produced on the day prior to NEC diagnosis), even if the 
weight was less than 200mg DNA extraction was attempted. Consequently it was important to 
establish whether the amount of faeces used for DNA extraction had any impact on the composition 
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3.3.2 Aim 
 
To assess the impact of varying the amount of faecal starting material for DNA extraction on the 




A single, large (1 – 1.5g) faecal sample was collected from each of four premature infants. Each 
sample was homogenised manually using a sterile pestle and divided equally by weight into five sub-
samples which were placed at -80oC within one hour of collection. DNA extractions were performed 
one week later using the MP Bio Fast DNA Spin Kit for Soil as outlined in Section 2.4.1. DNA 
extractions were performed on the following weights of faeces: 25mg, 50mg, 100mg, 200mg, and 
300mg (one sub-sample being used for each weight).  
 
Resulting DNA underwent quadruplicate PCRs, clean-up and pooling, and 454 sequencing using the 
454 GS FLX instrument as per Section 2.7, 2.8, 2.9 and 2.10. Amplicons from this experiment were 




DNA from 20 faecal sub-samples (4 infants, 5 different weights) were successfully amplified as 
confirmed by visualisation on an agarose gel with ethidium bromide and underwent 454 sequencing. 
After denoising and chimera removal, sequencing reads for this experiment were rarefied to a depth of 
1,200 per sample. There were insufficient sequencing data from the 25mg sub-sample from infant 
Q150 to be included in the analysis. Beta diversity using the weighted UniFrac metric was calculated 
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and a PCoA generated (Figure 14).   The PCoA revealed clustering of the faecal sub-samples by 
infant rather than by weight, although it should be noted that in the case of samples derived from 
infants Q133 and Q150, their 300mg weight samples did deviate slightly from their respective cluster.  
When the microbial composition is considered for each individual weight as shown in Figure 15, it is 
obvious that there is a significant difference in the composition of the 300mg faecal sub-sample 
compared to the rest of the other weights of the faecal sub-samples from the same infant, which would 
explain the deviation of these sub-samples on the PCoA. 
 
Figure 14: Weighted principal coordinate analysis showing clustering of sub-samples by infant. 
Different faecal weights (25mg, 50mg, 100mg, 200mg and 300mg) were used as starting material for 
DNA extraction. There is greater inter-individual variation than variation due to weight of starting 
material. Sub-samples are coloured by infant: M61 – red, M66 – green, Q133 – blue, Q150 – purple. 
Weight of faeces used for extraction are depicted using different shapes as shown in the key. There 
was insufficient sequencing data from the 25mg sub-sample from infant Q150 to be included in the 
analysis. 
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Figure 15: Stacked bar charts showing microbial composition of faecal sub-samples from each 
infant varying with different faecal weights used for DNA extraction. The sub-samples extracted 
with a weight of 300mg from infants Q133 and Q150 differ considerably from the rest of the sub-




Based on the results shown in Figure 14 and Figure 15, using data derived  from DNA extracted 
from faecal samples weighing less than 200mg should be valid as the microbial composition does not 
vary significantly in comparison to the 200mg reference sample.   
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3.4 Semi-quantification of 454 sequencing  
3.4.1 Introduction 
 
In studies of the human microbiome using next-generation sequencing, a limitation is its semi-
quantitative nature due to the fact that there are many potential biases beyond DNA extraction.  These 
include uneven PCR amplification of a mixed pool of template, primer bias (see Chapter 4), and the 
varying number of copies of the 16S rRNA gene in different organisms. Additional biases, specific to 
454 sequencing, may arise from the multiplexing of samples, the emulsion PCR step and the random 
bead deposition onto the PicoTiter plate. It is believed that, for 454 sequencing, read abundance is 
approximately quantitative within species but that between species comparisons can be biased. 
 
When this research project commenced, although mock communities had been studied using the 
pyrosequencing method, the communities had been constructed by plasmid cloning of 16S rRNA 
gene amplicons.  This approach however does not take into account 16S rRNA copy numbers or the 








Optical density (OD) versus colony forming unit (CFU) curves were constructed for the following 
organisms: Neisseria lactamica, Moraxella catarrhalis, Streptococcus pneumoniae, and Haemophilus 
influenzae. These organisms were chosen to reflect a mixed community - a mixture of Gram-positive 
and Gram-negative bacteria with different 16S rRNA gene copy numbers/genome. Each organism 
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was grown to exponential phase from single colonies in brain heart infusion (BHI) broth (hemin and 
NAD were added to the BHI broth in the case of Haemophilus influenzae). The bacteria were 
harvested and serial dilutions were plated to confirm CFU count. Defined mixtures (see Figure 13) 
were prepared and the DNA freshly extracted using Protocol ‘L’ (Section 3.1.3.3.). Each ‘unit’ of 
bacteria was equivalent to 1x106 CFUs. Quadruplicate PCRs were performed and the products pooled, 
and 454 sequencing using the 454 GS Junior instrument was carried out. 
 
3.4.4 Results 
Mock mixtures – pyrosequencing results 
 
DNA from nine different mock mixtures was successfully amplified and 4,077 sequencing reads were 
generated after denoising, chimera removal and rarefaction (453 sequencing reads per sample). 
Proportions of read abundance of each mixture were compared to the input proportions (Figure 16) 
after the read counts were adjusted for the number of copies of the 16S rRNA gene in each organism 
(Table 9). Mixtures of equal proportions were approximately preserved. Skewed mixtures of Gram-
negative and Gram-positive organisms designed to identify bias in differential lysis revealed that 
detection of bacteria down to 1% is feasible.   This was seen when a Gram-positive organism 
(Streptococcus pneumoniae) was present at 1% abundance in an entirely Gram-negative background 
(sample 33:33:1:33 in Figure 16), as well as a Gram-negative organism at 1% abundance (Neisseria 
lactamica) in a Gram-positive dominant sample (sample 9:0:90:1 in Figure 16).  
 
There was no significance difference (P=0.442) between the observed vs. actual proportions of the 
mixtures when compared using the Wilcoxon signed rank test (non-parametric; comparison of two 
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Table 9: Number of 16S rRNA genes per genome for each of the bacteria used in the bacterial 
mock mixtures 
Organism Number of 16S rRNA genes 
Neisseria lactamica 5 
Streptococcus pneumoniae 4 
Haemophilus influenzae 6 
Moraxella catarrhalis 4 
 
 
Figure 16: Bar charts showing proportions of bacteria in each mock mixture (left) alongside the 
observed proportions of sequencing reads (right). The exact proportions of Moraxella catarrhalis, 
Haemophilus influenzae, Streptococcus pneumoniae and Neisseria lactamica are shown in order at the 
bottom of each bar chart respectively.  
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3.4.4 Conclusion 
 
Although reassuring results were obtained from the mock mixture experiment, it is important to 
acknowledge that that the complexity of biological samples could be substantially higher and 
consequently adjustment for 16S rRNA copy numbers may well prove impossible without 
accompanying metagenomic data. When interpreting single or samples of lower complexity, this 
should however, pending on which bacteria are present, be considered, as the number of 16S rRNA 




From the four experiments conducted in the study and their findings it was determined that for the 
main study, the MP Bio Fast DNA Spin Kit for Soil for DNA extraction should be used for all faecal 
samples collected. . This kit gave comparable results to the standard laboratory protocols (Section 
3.1), gave reproducible results and was cost- and time- effective.  
 
With regard to faecal storage, the investigations above (Section 3.2) reassuringly revealed that 
samples left by the bedside at room temperature for a few hours prior to storage at -20oC would give 
an unchanged representation of the faecal microbiota, and that long-term storage of faecal samples at -
80oC would not significantly distort the microbial community. This was key in light of the feasibility 
of storing samples in a timely manner when collection was to be done by neonatal nurses whose 
primary responsibility was to care for the infant on a busy neonatal intensive care unit.  
 
In recognition that there would be instances, particularly in cases of NEC, were faecal samples 
obtained would be of low weight, the results of the weight validation study (Section 3.3) indicated the 
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validity of including data obtained from DNA extracted from faecal samples less than 200mg in 
weight.  
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Chapter 4 
Validation Work - Part II  
This chapter deals with investigations and discovery of the systematic undercounting of 
bifidobacteria, in 16S rRNA gene based studies.  It also details the development and verification of an 
improved primer set to detect bifidobacteria in faecal samples (written up and published: Sim et al. 





Microbes termed, from their appearance, bifidobacteria were first isolated from a faecal sample from 
a breast-fed infant in 1899 by the Paediatrician, Henry Tissier.87 He suggested that these organisms 
could be used to treat infants suffering from bacterial diarrhoea whom he found to have a low number 
of these ‘bifid’ organisms.87 Over one hundred years ago, the Nobel laureate Élie Metchnikoff 
proposed that “replacing or diminishing the number of ‘putrefactive’ bacteria in the gut with lactic 
acid bacteria could normalize bowel health and prolong life.”88 The term “probiotics” was coined in 
1965 and defined as ‘substances secreted by one organism which stimulate the growth of another’ but 
it was nearly a quarter of a century later, in 1989, Fuller re-defined probiotics as “live microbial 
supplements which beneficially affects the host animal by improving its microbial balance”.87  
 
The first use of bifidobacteria as probiotic agents in premature infants was published in 1997 by 
Kitajima et al.89 Since then there has been huge enthusiasm for the use of probiotics as a preventative 
strategy to prevent NEC. As the colonisation pattern of premature infants was a key element of the 
NeoM study, it was important to ensure that bifidobacteria would be detected robustly using the 16S 
rRNA gene amplicon next generation sequencing approach.   
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A discrepancy of bifidobacteria abundance in a 16S rRNA gene-based study was reported by Palmer 
et al.90 In this study the investigators sought to determine the development of the GI microbiota in 14 
term infants. Surprisingly, they found extremely low levels of bifidobacteria. This might have been 
due in part to the method of DNA extraction used in their study as it was not optimal for the lysis of 
Gram-positive bacteria (Chapter 3). Alternatively (or in addition) it might reflect mismatches in the 
forward primer to bifidobacterial sequences. They found that the overall amplification efficiency of 
DNA from bifidobacterial species was eight fold lower than that from non-bifidobacterial species 
using their primer set.   
 
Characterisation of the microbiota using 16S rRNA gene based sequencing depends on the premise 
that the PCR primers used for amplification are ‘universal’. However, it is impossible to design a truly 
universal primer pair that binds to the 16S rRNA gene of all eubacteria.  This is because the longest 
number of consecutive nucleotides in the gene that are 100 % conserved is 11 (Escherichia coli 16S 
rDNA positions 788 to 798), and in general, the number of sequential absolutely conserved 
nucleotides in other regions of the gene is four.91 Furthermore, when complex mixtures of bacteria are 
analysed, such as DNA extracted from faecal samples, there is decreased amplification efficiency due 
to differential annealing of universal primers resulting in bias against the detection of certain taxa.92  
 
As it is not possible to capture every taxa present – for example primer 967F93 will detect less than 
five percent of Bacteroidetes, primer 1492R94 detects only 61% of Actinobacteria and 54% of 
Proteobacteria 95 - a pragmatic choice of primers must be made, and researchers seek to ensure that 
organisms of particular interest are successfully amplified. Of note, mismatches towards the 3’ end 
are likely to lead to greater amplification inefficiency than that at the 5’ end.96 
 
How might primer bias be circumvented? The ‘universal’ primer set of choice can be optimised by 
introducing a degenerate base pair or an inosine residue at the positions of mismatch, or by adding 
taxa-specific primers to the primer pool. There are drawbacks with these approaches. For example, 
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overall annealing efficiency is reduced by including multiple degenerate bases as this has the effect of 
diluting the primer pool and therefore the number of templates which exactly match each primer 
sequence.96 Inosine forms a stable bond with all of the four nucleotides leading to erroneous PCR 
products.96 
 
We speculated that the commonly used primer set (357F/926R) recommended by the NIH Human 
Microbiome Project for 16S rRNA gene sequencing would under-detect bifidobacteria, based on the 
results of an in silico test which revealed a mismatch against the sequence of these organisms. A 
‘bifidobacteria-optimised’ primer set was designed by incorporating a degeneracy at the site of the 
mismatch and we set out to ascertain whether this would give a more accurate representation of the 
bifidobacterial community in DNA mixtures of mock bacterial communities and faecal samples, as 
compared to the NIH Human Microbiome Project primer set. It was also important to ensure that use 
of the ‘bifidobacteria-optimised’ universal primer set would not impact on the detection of other 
components of the microbiota. Fluorescence in situ hybridisation (FISH) was used as an independent 
method of confirming the proportion of bifidobacteria in faecal samples. 
 
4.2 Methods 
4.2.1 PCR primer design 
 
An in silico experiment was performed to assess how specific the original primer set 357F/926R  
 (357F – 5’ CCTACGGGAGGCAGCAG 3’, 926R – 5’ CCGTCAATTCMTTTRAGT 3’) was for 
bifidobacteria using the ARB software package97 and the SILVA 108 SSU Ref 16S rRNA database 
release73. Almost all bifidobacteria species (as well as some closely related Actinobacteria) were 
found to have a one base pair mismatch (C  T) to the 926R primer CCGTCAATTCMTTTRAGT  
(mismatch base C).  
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A new ‘bifidobacteria-optimised’ universal primer (926Rb) was designed in which a T/C redundancy 
was incorporated at the position of the mismatch: CCGTCAATTYMTTTRAGT (where Y is T or C). 
 
An in silico comparison of primer specificity of the 926Rb primer against the 926R primer using the 
Ribosomal Database Project’s (RDP) Probe Match tool was carried out.  Sequences longer than 1200 
bp and defined as good quality by the RDP were included in the analysis and 92.4 % of these had no 
mismatches with primer 926R compared to 94.5 % with 926Rb.  Although this may not appear to be a 
large increase, looking specifically at the order Bifidobacteriales, the difference was extremely 
marked: 926R matched only 0.2 % of sequences compared to 97.1 % with the ‘bifidobacteria-
optimised’ primer.  
 
4.2.2 Standard DNA Mixtures 
 
Pure cultures of Bifidobacterium dentium, Streptococcus pneumoniae and Moraxella catarrhalis were 
grown to mid-log phase and DNA extracted using the MP Bio Fast Soil DNA kit (as outlined in 
Chapter 2, Section 2.3.1), except that 200µl of culture broth was used as starting material.  
 
The Quant-iT, PicoGreen DNA assay was used to determine the total genomic DNA concentration as 
per Section 2.8. 
 
Varying proportions of Bifidobacterium dentium, Streptococcus pneumoniae and Moraxella 
catarrhalis DNA were added to produce pre-defined mixtures as shown in Table 10.  All three 
bacterial strains have 4 copies of the 16S rRNA operon and so the gene copy number is directly 
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Table 10: Proportions of Bifidobacterium dentium, Streptococcus pneumoniae and Moraxella 
catarrhalis DNA in each mixture. 






1 2% 49% 49% 
2 15% 50% 35% 
3 50% 25% 25% 
4 75% 5% 20% 
5 90% 5% 5% 
Table and legend reproduced from Sim et al. ‘Improved Detection of Bifidobacteria with Optimised 
16S rRNA-Gene Based Pyrosequencing’86 under the Creative Commons BY licence.  
 
4.2.3 Faecal samples and DNA extraction 
 
Faecal samples were collected from two separate cohorts: term infants were part of a separate study 
investigating the effect of nutrition and prebiotics in the first year of life on allergy prevention 
(PATCH study98) run by our collaborators, and pre-term infants were part of the NeoM cohort 
(Section 2.1). 
 
4.2.3.1 Faecal samples from term infants  
Faecal samples from five healthy term infants were collected at two time points: 4 weeks and 26 
weeks of age. The faecal samples were immediately frozen (-12oC to -20oC) and were transferred to -
80oC for storage within one week of sampling, until DNA extraction took place.  
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DNA was extracted by our PATCH study collaborators as described by Matsuki et al.99 except that 
DNA was re-suspended in 0.1ml of Tris-EDTA (pH 8.0). 
 
4.2.3.2 Faecal samples from pre-term infants  
Faecal samples from sixteen premature infants born at less than 32 weeks gestation who were all one 
month old were selected. Total DNA was extracted using the MP Bio Fast DNA for Soil kit (as 
outlined in Section 2.3.1).  
 
4.2.4 Barcoded 16S rRNA gene PCR and 454 pyrosequencing 
 
The V3-V5 regions of the bacterial 16S rRNA gene were amplified using primers 357F with adaptor 
B from 454 Life Sciences for pyrosequencing: 5’ 
CTATCCCCTGTGTGCCTTGGCAGTCTCAGCCTACGGGAGGCAGCAG 3’, and either the 
standard 926R or the ‘bifidobacteria-optimised’ primer 926Rb (Y in place of C, in bold): 5’ 
CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNNNNNNNNCCGTCAATTCMTTTRAGT 
3’. In addition the reverse primers included the 454 Life Sciences adaptor A and a unique 12 base-pair 
error-correcting Golay barcode (denoted by ‘Ns’, see Appendix 2).  
 
PCR was carried out as detailed in Section 2.7. The replicate amplicons were pooled, PEG 
precipitated (20%, MW 8 000 g/mol) and visualized by staining with ethidium bromide (10mg/mL) 
on a 1.0% agarose gel. Amplicons were pooled in equimolar concentrations after quantification using 
the PicoGreen assay as described in Section 2.9. Pyrosequencing was carried out on the 454 Life 
Sciences GS Junior instrument following the Roche Amplicon Lib-L protocol as per Section 2.10. 
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4.2.5 Bioinformatics 
 
Shotgun-processed data was processed as outlined in Section 2.15 except that chimera removal was 
performed using the program Perseus,52 instead of ChimeraSlayer. Identification of OTUs that were 
significantly different in abundance was carried out in QIIME using a paired T-test with Bonferroni 
correction.   
 
4.2.6 Fluorescence in situ hybridisation 
 
This work was carried out by our PATCH study collaborators. In order to enumerate the 
Bifidobacterium genus using FISH, the 16S rRNA-targeted oligonucleotide probe: Bif164-mod 5’- 
CATCCGGYATTACCACCC-3’ was used.100,101 The 5’ portion of the probe was labelled with Cy3. 
The method as described by Thiel et al.102 was followed with some modifications. Briefly, each faecal 
sample was fixed with 3% paraformaldehyde at 4°C for 16 hours. Following this, 1ml of the cell 
suspension was centrifuged at 8,000 g for 3 minutes and the cell pellet re-suspended in 500μl of PBS 
buffer, mixed with 500μl of ethanol and stored at -20°C until further use. Three µl of the fixed-cell 
suspension of the appropriate dilution (80, 160, 320 and 640 fold dilutions) was applied to chrome 
gelatine coated 18-well slides and dehydrated for 3 min each in 60%, 80% and 96% ethanol. After 
hybridization of the probe at 50°C for 16 hours, the slides were washed, dried, counterstained with 
4’,6-diamidino-2-phenylindole (DAPI) and mounted with Citifluor AF1. 
 
The scan^R screening station was used to acquire images and for analysis. The count and percentage 
of labelled bacteria per sample was determined in 25 positions divided over the well by counting all 
DAPI-stained bacteria and all doubly stained bacteria (DAPI and Cy3) in the same field of view using 
a quadruple band filter set. 
 




Two pyrosequencing runs were performed on the GS Junior platform. The first run consisted of DNA 
samples extracted from the standard bacterial mixes and the faecal samples collected from term 
infants. This produced 85,126 reads.  After denoising and chimera-removal, 60,794 high quality reads 
remained. These were demultiplexed according to barcode sequences. There were 37,977 reads 
assigned to the faecal samples, and 22,817 reads for the standard DNA mixtures. The second run 
consisted of DNA samples extracted from faecal samples from the premature infants. This run 
produced 66,802 reads, of which 30,259 high quality reads remained post denoising and chimera-
removal.  
 
4.3.2 Bacterial DNA mixtures 
 
The standard universal primers83 detected the relative proportions of Streptococcus pneumoniae and 
Moraxella catarrhalis sequences in correct relative proportions in the DNA mixtures.  The primers 
however, consistently failed correctly to quantify the bifidobacterial sequences present. The 
sequencing results as obtained using the standard universal primer set were similar to the actual 
proportions put into the mixture. However, the standard universal primer set was unable to amplify 
bifidobacterial sequences beyond a level of 1.6% (see Figure 17). 
 
  107  
 
 
Figure 17: Proportions of 454 sequencing reads obtained using both primer sets for each 
bacterial mock mixture. The ‘bifidobacteria-optimised’ universal primers (b) consistently detected 
higher proportions of Bifidobacterium dentium close to the amount that was present in the bacterial 
mixture compared to regular universal primers (u). Figure and legend reproduced from Sim et al. 
‘Improved Detection of Bifidobacteria with Optimised 16S rRNA-Gene Based Pyrosequencing’86 
under the Creative Commons BY licence. Figure created by Dr. Michael Cox.  
 
 
In contrast to this, results obtained using the ‘bifidobacteria-optimised’ universal primers showed a 
much better correlation with the proportions of the original bacterial DNA mixtures (Table 10, 
Figure 17). Bifidobacterial DNA was detected even at the lowest proportion (2%) present (Sample 
bB1, Figure 17). 
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4.3.3 Faecal samples from term infants 
4.3.3.1 Operational taxonomic unit (OTU) analysis  
Using both the standard universal primer set and the ‘bifidobacteria-optimised’ primer set gave 
similar results in terms of the most abundant phyla, which were Firmicutes and Actinobacteria, 
followed by Proteobacteria and Bacteroidetes. Although the faecal microbiota of all ten samples were 
distinct (Figure 18), it was obvious that there were more bifidobacterial reads in the samples analysed 
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Figure 18: Heatmap displaying the relative abundance of OTUs per sample.  Samples are 
grouped by hierarchical cluster analysis on the x-axis and by neighbour-joining phylogenetic tree with 
nearest neighbour interchange on the y-axis.  Samples amplified with ‘bifidobacteria-optimised’ 
primers are in red and with the standard primers in blue.  Bifidobacterial OTUs are highlighted in the 
red box. Figure and legend reproduced from Sim et al. ‘Improved Detection of Bifidobacteria with 
Optimised 16S rRNA-Gene Based Pyrosequencing’86 under the Creative Commons BY licence. 
Figure created by Geraint Barton. 
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4.3.3.2 Fluorescence in situ hybridisation (FISH) analysis  
FISH was used as an independent method of assessing the proportions of Bifidobacteria present in the 
term faecal samples. Table 11 shows the proportion of Bifidobacteria present in the faecal samples as 
a percentage of the total number of bacteria in faeces using FISH alongside the relative read 
abundances as obtained by 454-sequencing using both primer sets.  
 
Table 11: Relative proportions of faecal bifidobacteria in the ten faecal samples as determined 
by FISH and 454-sequencing using ‘bifidobacteria-optimised’ universal primers (926Rb) or 
regular universal primers (926R). 
Sample 926R 926Rb FISH 
P1 0.0% 0.2% 0.3% 
P2 1.0% 81.1% 61.2% 
P3 1.7% 69.0% 70.9% 
P4 0.4% 63.5% 75.8% 
P5 0.0% 0.2% 0.6% 
P6 4.4% 62.7% 67.3% 
P7 10.8% 74.1% 47.5% 
P8 5.3% 90.6% 75.0% 
P9 0.0% 16.9% 10.4% 
P10 0.1% 8.0% 67.0% 
Table and legend reproduced from Sim et al. ‘Improved Detection of Bifidobacteria with Optimised 
16S rRNA-Gene Based Pyrosequencing’86 under the Creative Commons BY licence. 
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In order to confirm on a quantitative basis the correlation between the proportions of bifidobacteria in 
the faecal samples as obtained using FISH and the sequencing results using the standard universal 
primers or ‘bifidobacteria-optimised’ primer set, the Pearson correlation was calculated between the 
three sets of results. The results are shown in Table 12. There is a significant correlation between the 
results obtained using FISH and the sequencing results obtained using the ‘bifidobacteria-optimised’ 
primer set (Table 11).  
 
Table 12: Correlation matrix (Pearson) showing the Pearson correlation coefficients and P-
values. N/A – not applicable. 
Variables 926Rb 926R FISH 
926Rb N/A 0.593 (P=0.07) 0.761 (P=0.01) 
926R 0.593 (P=0.07) N/A 0.297 (P=0.4) 
FISH 0.761 (P=0.01) 0.297 (P=0.4) N/A 
Table and legend reproduced from Sim et al. ‘Improved Detection of Bifidobacteria with Optimised 
16S rRNA-Gene Based Pyrosequencing’86 under the Creative Commons BY licence. Statistical 
analysis performed using the R statistical package. 
 
4.3.3.3 Principal Coordinate Analysis and statistics  
To ensure that the ‘bifidobacteria-optimised’ primer set did not skew the detection of other organisms 
or their abundances, a principal coordinate analysis (PCoA) was performed using the weighted 
UniFrac metric77 (Figure 19a). This revealed clustering of samples by the primer set used except for 
two pairs: P1 and P5 (circled). In these samples, bifidobacteria did not constitute a significant 
proportion of the microbiota (see Figure 18). The bifidobacterial sequences were removed from the 
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sample results and the principal coordinate analysis repeated (Figure 19b) and this then showed tight 
clustering of all sample pairs. This indicates that detection of bifidobacteria is the cause for the 
difference between the two PCoAs, and that the ‘bifidobacteria-optimised’ universal primers do not 
affect the quantitative detection of other bacteria. 
 
To put this on a quantitative footing, paired t-tests were performed to compare OTU abundance 
between the results as obtained using the ‘bifidobacteria-optimised’ universal primers and the regular 
universal primers and found that there was a significant difference in the read abundance of 
bifidobacteria. The ‘bifidobacteria-optimised’ universal primers detected a higher abundance of 
bifidobacteria compared to the regular universal primers (P=0.039, t=0.0026, with Bonferroni 
correction for multiple testing). Reassuringly, there were no significant differences between any of the 
other OTUs (P>0.05). 
 
4.3.4 Faecal samples from pre-term infants 
 
It was of interest to see if faecal samples collected from pre-term infants would contain bifidobacteria 
and at what abundance, as results from other studies have suggested that premature infants are not 
generally colonised with these organisms, or are colonised at low levels. Similar to the results 
obtained from the faecal samples from term infants, a discrepancy was found in the detection and 
quantitation of bifidobacteria in the faecal samples from term infants (Figure 20). 
 
Two infants born at each gestational week from 24 weeks to 31 weeks were chosen. A sample from 
each infant at the age of one month was selected, as this is when the faecal microbiota was likely to 
have stabilised. It was notable that even an infant born as prematurely as 24 weeks had a faecal 
microbiota which had bifidobacteria as a substantial component by the time he was one month old. 
One twin pair was included in the analysis - infants 15 and 16. Interestingly, infant 15, in whom 
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bifidobacteria forms a substantial component of the faecal microbiota, was fed entirely with maternal 
breast milk from the time of birth, whereas infant 16, started on formula after a few weeks to help 
increase weight gain, revealed no bifidobacterial sequences in the DNA sample. 
 
Figure 19: Principal Coordinate Analysis using the weighted UniFrac metric. (A) Sample pairs 
P9, P10 and in particular P1 and P5 cluster tightly together. These samples contain small or moderate 
numbers of bifidobacteria reads. (B) After removing bifidobacteria sequences from the analysis, all 
sample pairs cluster tightly showing that the main differences between the sets are due to the 
bifidobacteria sequences. u = regular universal primers (926R), b – ‘bifidobacteria-optimised’ 
universal primers (926Rb). Table and legend reproduced from Sim et al. ‘Improved Detection of 
Bifidobacteria with Optimised 16S rRNA-Gene Based Pyrosequencing’86 under the Creative 
Commons BY licence. Figure created by Dr. Michael Cox. 
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Figure 20: Barcharts showing the microbial composition in faecal samples from pre-term 
infants as obtained using the ‘bifidobacteria-optimised’ primer set (B) or the regular universal 
primer set (U). Bifidobacterial OTUs are displayed in red and all other OTUs in shades of blue. The 
gestation at birth of each infant is shown below the sample ID. Use of the ‘bifidobacteria-optimised’ 




The ‘bifidobacteria-optimised’ primer set consistently detected a higher abundance of bifidobacterial 
sequences and more accurately estimated the levels of bifidobacteria present in both bacterial mock 
mixtures and faecal samples. Use of the ‘bifidobacteria-optimised’ primer set did not skew the 




  115  
4.5 Discussion 
 
This experiment demonstrated the importance of selecting appropriate primers for 16S rRNA gene 
based microbiota studies. Use of the regular universal primers to characterise the faecal microbiota of 
premature infants (Figure 20) would have led to the erroneous conclusion that bifidobacteria only 
form a very minor component of the microbiota, if at all. Detection of bifidobacteria is of crucial 
importance, particularly as the use of these organisms as a probiotic agent is becoming increasingly 
widespread in the NICU setting as a potential method to prevent the development of NEC (Chapter 
1, Section 1.4.4). One of the properties of a probiotic is that it must be able to colonise the host, and 
this should therefore be assessed in probiotic trials. As demonstrated using bacterial mock mixtures 
(Figure 17), the regular universal primers were not even able to accurately determine the presence or 
absence of bifidobacteria, let alone give a quantitative estimate. 
 
Other recent studies such as that conducted by Walker et al.103 have also shown a similar bias against 
the detection of bifidobacteria in faecal samples using standard V1-V3 16S rRNA gene primers, 
highlighting the fact that this is a widespread problem and the necessity of verifying that the selected 
primer set will amplify the target organisms.  
 
It is also essential to ensure that the detection of other organisms is not impaired when choosing a 
primer that successfully amplifies the target organism and we have shown that the ‘bifidobacteria-
optimised’ primer set is able to faithfully represent the microbial community of the sample. This 
primer set was therefore chosen to be used for the NeoM study rather than the regular universal 
primers used by the Human Microbiome Project.   
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Chapter 5 NeoM Study: Clinical Data 
The NeoM Study commenced recruitment in January 2011 for a period of two years. Longitudinal 
faecal samples from each participant were collected from the point of recruitment until 
discharge/death, alongside detailed daily clinical information as outlined in Chapter 2. This chapter 
goes through recruitment figures, NEC case distribution during the study period, cohort demographics 





Three hundred and sixty nine infants were recruited out of 388 eligible infants. Figure 21 shows the 
breakdown of participants by site and gestational age whilst Table 13 shows the number of multiple 
births by site. No parents withdrew their infant/s from the study. Site A is a tertiary neonatal centre 
which cares for the smallest, most premature infants, compared to Site B which is a secondary 
neonatal centre. This is reflected by Site A having a much higher proportion of infants born at under 
28 weeks gestation compared to Site B. 
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Figure 21: Breakdown of cohort by site and gestational age. 
 
Table 13: Distribution of multiple births by site. 
 Site A Site B Total (infants) 
Number of sets of twins 29 24 53 (106) 
Number of sets of triplets 5 5 10 (30) 
Number of sets of quadruplets 1 0 1 (4) 
 
Infants were recruited on average within two days of birth (median). The main reasons for late 
recruitment (two days after birth) were: 1) babies transferred to the unit for continuing care (e.g. two 
sets of twins were admitted for continuing care to one of the units one month after they were born), 2)   
inability to gain consent from parents as mother at a different hospital (ex utero transfer of baby) and 
3)  mother being unwell post delivery. 
 
 
  119  
5.2 Sample collection 
 
Ten thousand nine hundred and twenty eight faecal samples, 337 groin swabs and 1,029 incubator 
swabs were collected and archived at -80oC. In addition gut tissue specimens were collected from 
eight infants; N8, N12, N14, N19, N21, N24, N27 and N28 (Table 14). 
Table 14: Details of gut tissue specimens from NEC infants. 
Study 
number 
Sample type Site of disease Samples collected 
N8 
 
Fresh Jejunum Jejunum 




Fresh Ileum Ileum 
Intestinal luminal contents from the same site of the gut 
tissue collected 




Post mortem Ileum + ileal 
caecal junction 
Ileum 
Intestinal luminal contents from the same site of the gut 
tissue collected (ileum) 
Ileal caecal junction 
Intestinal luminal contents from the same site of the gut 





Distal ileum Healthy distal ileum 
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N24 
 
Fresh Distal ileum Diseased gut 
Healthy gut margin 




















Intestinal luminal contents from the same site of the gut 
tissue collected 
 
5.3 NEC cases 
 
Twenty-eight babies developed NEC over the two year study period. Ten infants had Bell Stage 1, 2 
with Bell Stage 2, and 16 with Bell Stage 3(Section 1.3.1). Figure 22 outlines the distribution of the 
cases with respect to site and Bell staging. There were patterns time-wise in relation to occurrence of 
cases, for example in months 1-3 there were seven cases, months 9-11 four cases and month 22 four 
cases. Out of the Bell Stage 2/3 infants, there were 6 twin pairs discordant for NEC. There was one set 
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Figure 22: Cumulative cases of NEC during the two year study. All infants who developed NEC 
during the study are identified on the y-axis, with the month of study shown on the x-axis. Hatching 
represents hospital site and Bell Staging. Rectangles represent duration of infant admission on the 
neonatal unit. Circles denote date of NEC diagnosis. In several instances infants were transferred 
between sites, for example, infant N2 was initially admitted to Site A, but was later transferred to Site 
B where she developed NEC. Infants who were not included in the final analysis (see Section 5.4) are 
indicated by an asterisk on the y-axis. Figure reproduced from Sim K et al. ‘Dysbiosis anticipating 
necrotizing enterocolitis in very premature infants’104 under the Creative Commons BY licence. 
Figure created by Dr. Alex Shaw. 
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5.4 Infants included in the final analysis 
 
Twelve Bell Stage 2/3 infants and 36 matched controls were included in the final analysis based on 
the availability of samples, matched controls, and good quality sequencing data (Chapter 6). Due to 
the heterogeneous nature of Bell Stage 1 infants (see Section 1.3.1), only results generated from the 
twelve Bell Stage 2/3 infants were used to distinguish clinical and microbial differences from the 
matched controls. Clinical and sequencing data from the Bell Stage 1 infants were used to assess the 
screening model constructed (Chapter 7), and were included in the culture sub-study (Chapter 8). 
 
Eight NEC infants could not be included in any aspects of the analysis (indicated by asterisks in 
Figure 22). Six of these infants had NEC Bell Stage 2/3 - two infants did not have samples in the two 
weeks prior to diagnosis and 4 infants lacked sufficient sequencing data. The remaining two infants 
who were not included in the analysis had NEC Bell Stage 1. They were excluded because they 
lacked appropriate controls. 
 
Demographics and clinical characteristics including intravenous antibiotic use, feeding regime, and 
respiratory support were compared between the cases and controls, and also between cases that were 
and were not included in the final analysis. Table 15 lists the characteristics that were compared, with 
parameters that are significant indicated by asterisks.  
 
Compared to controls, cases were more likely to born at site A (P=0.0001). Cases who were analysed 
compared to those who were not were likely to be older at the time of NEC diagnosis (P=0.0001), 
receive more days of maternal expressed breast milk (MEBM) or donor expressed breast milk 
(DEBM) (P<0.05), and require more days of continuous positive airways pressure (CPAP) with or 
without supplemental oxygen (P<0.05).  
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Table 15 – Summary of the cohort demographics – Cases with NEC Bell stage 2/3 (analysed (12) 
and not analysed (6)) and controls. 
 Cases analysed 
(N = 12) 
Cases not 
analysed (N = 6) 
Controls  
(N = 36) 
Demographics    
  Male (%) 5 (41.7) 3 (50.0) 17 (47.2) 






  Mean gestation at birth (IQR days)     





  Mean postnatal age at D0 (IQR), days 27·5 (20·8-37·5) * 7·2 (4·5-10·0) * N/A 
  Mean postnatal age at sample taken 
  closest to D0 (IQR) 
26·0 (19-36·3) N/A 24·4 (18·0-34·8) 
  Birth hospital    
    Site A (%) 11 (91.7)** 5 (83.3)  21 (58.3)** 
    Site B (%) 1 (8.3)** 0 (0) 7 (19.4)** 
    Other (%) 0 (0.0)** 1 (17.7)  8 (22.2)** 
  Ethnicity    
    Black (%) 2 (16.7) 2 (33.3) 8 (22.2) 
    White (%) 5 (41.7) 2 (33.3) 18 (50.0) 
    Asian (%) 2 (16.7) 1 (16.7) 6 (16.7) 
    Mixed (%) 2 (16.7) 1 (16.7) 3 (8.3) 
    Unknown (%) 1 (8.3) 0 (0) 1 (2.8) 
  Mode of delivery    
    CS (%) 7 (58.3) 3 (50.0) 18 (50.0) 
    VD (%) 5 (41.7) 3 (50.0) 18 (50.0) 
Maternal characteristics    
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  Maternal IVAB use at delivery (%) 2 (16.7) 2 (33.3) 11 (30.6) 
  Maternal PROM (%) 2 (16.7) 2 (33.3) 9 (25.0)  
  Maternal sepsis/chorioamnionitis (%) 3 (25.0) 2 (33.3) 6 (16.7) 
Condition at birth    
  Lowest pH recordeda in the first 24  
  hours, (IQR)  
7·2 (7·2-7·3) 7·2 (7·1-7·2) 7·2 (7·1-7·3) 
  Lowest base excess recordeda in the  
  first 24 hours, (IQR) 
-5·5 (-6·8 - -
2·65)) 
-7·4 (-8·8 - -4·9)) -6·3 (-9·1- -3·5) 
  APGAR at 5 minutes, (IQR) 7·8 (7·0-9·0) 8·2 (8·0-9·0) 7·4 (7·0-9·0) 
Intravenous antibiotic use    
  Mean number of days of IVABb  
  during first week of life (IQR), days 
2·1 (0·8-3·0) 2·2 (0·5-2·8) 2·6 (2·0-3·0)  
  Mean number of cumulative days of  
  IVABb use prior to D0 (IQR), days 
3·7 (1·2-3) 2·8 (2·0-3·8) 3·6 (2·0-4·0) 
Feeding regime     
  Mean number of days received    
  MEBM prior to D0 (IQR), days 
22·8 (15·0-30·8) 4·0 (2·3-6·0)*** 25·3 (18·0-33·0) 
  Mean number of days received  
  DEBM prior to D0 (IQR), days 
11·9 (7·5-13·3) 3·7 (0·25-5·5)*** 7·8 (4·0-9·0) 
  Mean number of days received  
  formula milk prior to D0 (IQR), days 
0·7 (0-0) 1·0 (0-0) 0·4 (0-0) 
Respiratory support requirement    
  Number of days requiring ventilation  
  support (HFOV or conventional  
  ventilation) prior to D0 (IQR), days 
1·8 (0-2·3) 3·8 (2·0-4·5) 3·3 (0-2·8) 
  Mean number of days requiring  
  CPAP (no oxygen), prior to D0  
7·2 (1-10·8) 1·5 (0-2·8)*** 8·2 (0-13·8) 
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  (IQR), days 
  Mean number of days requiring  
  CPAP with supplemental oxygen,  
  prior to D0 (IQR), days 
16·8 (1·8-26·5)  1·8 (0-2·3)*** 8·2 (0-13·8)  
 Mean number of days requiring NP     
 oxygen, prior to D0 (IQR), days 
1·1 (0-0) 0 (0-0) 2·6 (0-4·0) 
 Mean number of days not requiring  
 any respiratory support, prior to D0 
(IQR), days 
0·7 (0-0) 0 (0-0) 4·8 (4·0-10·1) 
Presence of PDA (%) 2 (16.7) 2 (33.3) 8 (22.2) 
Table reproduced from Sim K et al. ‘Dysbiosis anticipating necrotizing enterocolitis in very 
premature infants’104 under the Creative Commons BY licence. Abbreviations – IQR, interquartile 
range, D0, day of NEC diagnosis or postnatal age of matched control; CS, Caesarean-section; VD, 
vaginal delivery; IVAB, intravenous antibiotics; PROM, prolonged rupture of membranes; MEBM, 
maternal expressed breast milk; DEBM, donor expressed breast milk; HFOV, high frequency 
oscillation ventilation; CPAP, continuous positive airways pressure; NP, nasal prong; PDA, patent 
ductus arteriosus. aLowest value recorded from cord/free flowing capillary/arterial/venous blood gas, 
bFirst line IVAB for suspected early onset sepsis = Co-Amoxiclav, or Benzylpenicillin and 
Gentamicin (if ex utero transfer), second line IVAB = Vancomycin and Piperacillin/Tazobactam, * 




The NeoM study achieved a good recruitment rate with over 95% eligible infants enrolled into the 
study and the majority of the infants entering into the study within two days of birth.  There were no 
withdrawals from the study. Consequently the NeoM study achieved a good representation of infants 
born at less than 32 weeks on the NICU, and collected a vast number of samples throughout their 
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admission. Consistent with Site A being a tertiary neonatal centre, infants were born at a younger 
gestational age at this site compared to Site B. This is also reflected by the fact that there are more 
NEC cases from Site A. As estimated, 7.6% of the participants in the study developed NEC. Some 
cases appeared to occur in clusters, for example in months 1-3, months 9-11 and month 22. 
 
The cases which were not included in the final analysis were at a younger postnatal age at the time of 
NEC diagnosis. As it proved impossible to gain consent early enough it was not possible to collect 
preceding samples. The finding that cases that were included in the final analysis received more days 
of MEBM or DEBM and required more days of CPAP with or without supplemental oxygen was 
interesting but confounded by the fact that all cases developed NEC at an older postnatal age.  
 
The clinical data from the NeoM study highlights some of the difficulties and ethical considerations 
encountered when recruiting premature neonates to a research study. The birth of a premature infant is 
shrouded in uncertainty and worry, and it is a particularly difficult time to approach vulnerable 
parents. For this reason, the NeoM study was introduced as an ecological study of colonisation of the 
gastrointestinal tract, in which the aim was to collect every faecal sample from every baby born under 
32 weeks completed gestation. As NEC is a terrifying proposition which can be fatal, and only occurs 
in 5-10% of the infants (mainly in those who have survived the initial stormy first few days/weeks), it 
was deemed inappropriate to discuss the disease during the first encounter with the parents. If an 
infant did go on to develop severe NEC the parent was re-approached at that time to request 
permission to collect a small piece of gut tissue if their baby required surgery.  
 
Due to local operational procedures, so as to not jeopardise recruitment to other ongoing research 
studies, the NeoM study was only granted access to approach parents 24–48 hours after the birth of 
their baby. As premature infants tend to defecate for the first time only after a few days this did not 
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significantly impact on the collection of the first meconium/faecal sample. Ethical permission was 
gained however to seek antenatal consent, but it was difficult to maintain this because there were a 
substantial number of women who were admitted with suspected preterm labour but who did not go 
on to deliver an infant prematurely, and due to insufficient personnel it proved impractical to see 
every woman in suspected preterm labour. 
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Chapter 6 NeoM Study: Sequencing Data  
In this chapter the findings of the NeoM Study sequencing data are presented and discussed. The first 
half of the chapter focuses on data from control infants (healthy premature neonates) and examines 
the development of the gastrointestinal microbiota and factors influencing its composition as well as 
the variation in alpha diversity with respect to different clinical factors such as postnatal age, mode of 
delivery and antibiotic use. The second half of the chapter focuses on the sequencing results obtained 
from the faecal samples from NEC infants with comparisons to the microbiota of the healthy 
premature neonates and investigations of the microbiota of NEC gut tissue specimens. 
 
6.1 454 pyrosequencing and initial data processing 
 
DNA extracted from 779 faecal samples collected from NEC infants prior to diagnosis and matched 
control samples successfully underwent quadruplicate PCRs, library preparation and 454 sequencing 
as outlined in Sections 2.7 – 2.10. A total of four 454 sequencing runs were carried out using the GS 
FLX machine. Denoising and chimera removal (Section 2.15) resulted in a final number of 3,831,901 
reads (data has been deposited at the European Nucleotide Archive (ENA)105 under accession number 
PRJEB6345). The mean number of reads was 4,919 per sample. The number of reads per sample was 
rarefied to 1,000 as rarefaction curves demonstrated this to be sufficient to capture diversity using the 
Shannon-Weaver diversity index (Figure 23). Sequences that were present only once in the dataset 
(singletons) and OTUs found in only one sample were removed after the alpha diversity was 
calculated (Section 2.15 – 2.16). 
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Figure 23: Rarefaction curves for sequencing data. A randomised selection of 10% of the 
rarefaction curves for the dataset. Black dashed line shows the chosen cut off value for rarefaction. 
Figure reproduced from Sim K et al. ‘Dysbiosis anticipating necrotizing enterocolitis in very 
premature infants’104 under the Creative Commons BY licence. Figure created by Dr. Alex Shaw. 
 
6.2 Alpha diversity of the faecal microbiota of control infants  
 
Prior to rarefaction and singleton removal the Shannon-Weaver  index was calculated for the 
microbial community in each faecal sample.The concept of alpha diversity  is covered in Section 
2.16. 
 
Important factors that have been thought to influence the diversity of the faecal microbiota in 
premature infants are: postnatal age,106 corrected gestational age,107 mode of delivery108 and antibiotic 
use.34  The influence of each of  these is considered separately below. The Shapiro-Wilks test was 
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applied to the calculated Shannon-Weaver index values to assess normality. The test indicated that the 
data was unlikely to have arisen from a normal distribution and therefore the Wilcoxon rank sum test 
was used to perform the statistical tests.  
 
6.2.1 Alpha diversity and increasing postnatal age 
 
Alpha diversity values, calculated from one faecal sample per control infant from the time periods day 
1 to 4, day 5 to 7, week 2, week 3, week 4, week 5, week 6, were included in the analysis in order to 
avoid bias arising from using multiple samples from each infant:. Where multiple samples existed for 
an infant in the same time period, samples closest to the end of the time period were selected.  
There was an increase in the Shannon-Weaver diversity index of faecal samples collected in the first 
week and week 6, and an increase in all three diversity indices from week 5 to week 6 as shown in 
Figure 24. This suggests that the faecal microbial community becomes increasingly complex as the 
infants get older, with a mixture of different organisms present at higher abundancies.  
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Figure 24: Box plots showing the median and interquartile range of the Shannon-Weaver Index 
of faecal samples collected from control infants vs. postnatal age. One sample from each infant per 
time period as shown on the x-axis was used for the analysis. Asterisks represent P values < 0.05. 
 
6.2.2 Alpha diversity and increasing corrected gestational age 
 
Alpha diversity values were calculated from one faecal sample from each postnatal week of life from 
every control infant to avoid bias from using multiple samples from an infant. Where multiple 
samples existed for an infant in the same time period, samples closest to the end of each week were 
selected. The corrected gestational age of an infant was calculated by adding their postnatal age to the 
gestational age at birth (i.e. an infant born at 27 weeks and three days who is now five days old  has a 
corrected gestational age of 28 weeks and one day.) Interestingly the Shannon-Weaver index indicates 
that  infants of a lower corrected gestational age have a lower diversity as shown in Figure 25.  
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Figure 25: Box plots showing the median and interquartile range of the Shannon-Weaver Index 
of faecal samples collected from control infants vs. corrected gestational age. One faecal sample 
from each infant collected during each postnatal week was used for the analysis. The corrected 
gestational age (calculated by adding the gestational age at birth and the postnatal age together) is 
displayed on the x-axis. The number of completed gestational weeks is shown. Outliers are denoted 
by the white circles. The lines above the boxplots show significant differences between the lowest 
corrected gestational age (on the left) and any higher corrected gestational ages. Asterisks represent P 
values < 0.05 and apply to the every comparison shown: e.g. the Shannon-Weaver index is 
significantly different between the faecal samples collected from infants at 25 weeks corrected 
gestation and those collected at 29, 30, 33, 34 and 35 weeks corrected gestation. 
 
6.2.3 Alpha diversity and different methods of delivery  
 
Alpha diversity values calculated from one faecal sample per control infant from the time periods day 
1 to 4, day 5 to 7, week 2, week 3, week 4, week 5, week 6 were included in the analysis in order to 
avoid bias arising from using multiple samples from each infant. Where multiple samples existed for 
an infant in the same time period, samples closest to the end of the time period were selected. Alpha 
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diversity values within each time period were then categorised according to the mode of delivery of 
each infant (C-section or vaginal delivery Figure 26). Within each time period, the alpha diversity 
was compared between the C-section and vaginal delivery group. There were no significant 
differences found between the diversity the two groups in any of the time periods. 
 
Figure 26: Box plots showing the median and interquartile range of the Shannon-Weaver Index 
of faecal samples collected from control infants vs. delivery method with increasing postnatal 
age. One sample from each infant per time period as shown on the x-axis was used for the analysis. 
The boxplots are divided by mode of delivery at each time period – C = C-section delivery, V = 
vaginal delivery. Outliers are denoted by the white circles.  
 
6.2.4 Alpha diversity and different durations of antibiotic usage 
 
The alpha diversity of faecal samples collected in the second week of life (as close as possible to day 
14 of life) was calculated and plotted against duration of antibiotic usage in the first week of life. 
Twenty four of the infants, from whom a sample was available for analysis, had received one or more 
days of antibiotics whilst three infants had received no antibiotics.  
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The indication for antibiotic use was suspected sepsis. A peak in antibiotic usage of two to three days 
was observed, in line with the time when blood culture results would have been available. If the blood 
culture results were negative and there were no continuing clinical concerns, antibiotics would have 
been discontinued.  
 
There were no infants who had culture positive blood stream infection. In the cases where antibiotics 
were continued, the blood culture results were negative, but the infant may have had raised 
inflammatory markers or was clinically unwell and therefore additional days of antibiotics were 
given. There was no significant differences between the diversity and number of days of antibiotic use 
(Figure 27) although this may be due to the small numbers of infants contributing to the data points. 
 
Figure 27: Shannon-Weaver Index of faecal samples collected in week two of life plotted against 
number of days of antibiotic use at birth. The number of infants contributing to each data point is 
indicated at the bottom of each plot.   
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6.3 Development of the normal gastrointestinal microbiota in premature neonates 
 
The mode of delivery and postnatal age are both factors which influence the composition of the 
gastrointestinal microbiota in both term and preterm infants.108,109 A study by Dominguez-Bello et 
al.109 indicated that samples collected in the first days of life reflect the composition of the maternal 
microbiome. Figure 28 shows the difference in the microbiota by method of delivery and week of 
life. Overall, irrespective of delivery mode, the most abundant OTUs were Klebsiella, Escherichia, 
Staphylococcus (1), Enterococcus, and Bifidobacterium. (For ease of reading, OTU names are 
capitalised and will not be italicised in order to distinguish them from taxa which are not OTU labels.) 
A list of the top 50 OTUs found in faecal samples from the control infants (accounting for 99.9% of 
the sequencing reads) and their overall abundances can be found in Appendix 4. 
 
The generalised linear model function in R (see Section 2.18) was used to determine which OTUs 
were associated with the two different delivery modes and with increasing postnatal age. Vaginal 
delivery was associated with the OTUs Escherichia and Clostridium (2) (P=0.0009 and P =0.04 
respectively), and caesarean section with Clostridium (1) (P=0.02). OTU abundances which increased 
with increasing postnatal age were Bifidobacterium and Klebsiella (P=0.009 and P=0.02), whereas 
Staphylococcus (1) and (2) and Streptococcus (1) decreased in abundance (P<0.0001, P=0.03, and 
P=0.04, respectively).  
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Figure 28: Overall microbial composition in faecal samples collected from infants at different 
postnatal ages split by delivery method. The OTUs are shown in the legend. The postnatal week of 
life of the infants contributing to each bar chart and the number of infants included are displayed at 
the bottom of the bar charts. Figure reproduced from Sim K et al. ‘Dysbiosis anticipating necrotizing 
enterocolitis in very premature infants’104 under the Creative Commons BY licence. Figure created by 
Dr. Alex Shaw. 
 
6.4 Alpha diversity: Comparisons between NEC infants compared to Control infants 
 
Alpha diversity values were calculated for faecal samples collected from infants just prior to NEC 
diagnosis and matched control samples but no significant differences were found (P=0.72) (Figure 
29). 
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Figure 29: Shannon-Weaver Index of faecal samples collected from NEC infants just prior to 
diagnosis compared to matched controls.  
 
6.5 Beta diversity of NEC and control infants 
 
In order to compare the difference between faecal samples collected from NEC infants just prior to 
NEC diagnosis and matched control samples, the beta diversity was calculated (weighted UniFrac 
metric) as outlined in Section 2.17. Figure 30 shows a principal coordinate analysis produced using 
the weighted UniFrac metric of NEC and control samples. Samples from NEC infants appear to form 
two distinct clusters. One of these NEC clusters appeared to be centred around the Klebsiella taxon. In 
contrast the samples from the control infants appeared to be more heterogeneous compared to those 
from the infants with NEC. 
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Figure 30: Principal coordinate analysis of the UniFrac metric calculated from the microbiota 
of faecal samples collected from NEC infants prior to diagnosis and matched controls. 
Predominant taxa are indicated by the grey circles. Samples from NEC infants are depicted by the 
blue circles, and samples from control infants are shown in red.  
 
6.6 Development of the gastrointestinal microbiota in infants with NEC 
 
When considering samples collected closest to the day of NEC diagnosis in the twelve Bell stage 2/3 
infants, the most abundant OTUs were Klebsiella, Clostridium (1), Staphylococcus (1), and 
Enterococcus, as shown in the heatmap in Figure 31. A list of the top 50 OTUs (99.9% of sequencing 
reads) derived from all of the faecal samples from the Bell stage 1, 2 and 3 infants and their 
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abundances can be found in Appendix 4. In order to compare OTU abundance difference in NEC and 
control samples (n = 36) while accounting for clinical confounders, a linear model was used. The top 
13 OTUs were considered (accounting for 95% of the reads), and a model constructed for each OTU 
together with the clinical factors shown in Table 15 and/or case/control status of the samples 
correlated with OTU abundance. This showed the Clostridium (1) OTU to be significantly associated 
with cases (P=0.006) (mean = 135 reads in cases, 26 in controls). The Klebsiella OTU was found to 
be at higher levels in NEC cases although this was not statistically significant.  
 
Figure 31:  Heatmap showing the 13 most abundant OTUs present in the faecal microbiota of 
NEC and control infants. Faecal samples from NEC infants collected just prior to diagnosis are 
shown on the left (denoted by an ‘N’) and those from matched controls are displayed on the right 
(denoted by a ‘C’). Figure reproduced from Sim K et al. ‘Dysbiosis anticipating necrotizing 
enterocolitis in very premature infants’104 under the Creative Commons BY licence. Figure created by 
Dr. Alex Shaw. 
 
When the development of the microbiota is shown for each individual NEC case two distinct patterns 
emerge. The first has a rapid increase of the Clostridium (1) OTU just prior to diagnosis.  The second 
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pattern is one that is persistently dominated by high levels of the Klebsiella OTU present from just 
after birth until diagnosis (see Figure 32). This is consistent with the cluster around the Klebsiella 
OTU in the principal coordinate analysis in Figure 30. There is one outlier – N19 which does not fit 
into either pattern.  
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6.7 GI microbiota in discordant NEC twins 
 
Four twin pairs discordant for NEC had sufficient data for comparison. Information on zygosity and 
pertinent clinical information are shown in Table 16. Three of the NEC infants had high levels of the 
Clostridium (1) OTU preceding diagnosis (see Figure 33). The microbial composition looks 
strikingly different in twin pairs N15-C50, N21-C23 and N26-C35.  
 
Interestingly, in twin pair N26 – C35, there was also a high amount of the Clostridium (1) OTU 
present in both infants. On reviewing the clinical metadata, it became apparent the mother of twins 
N26-C35 had started a course of oral antibiotics for mastitis on day 33, and that both of her twins 
were entirely fed on maternal expressed milk at that time. It may therefore be that the antibiotics taken 
by the mother had had an impact on the faecal microbiota of the babies. It is also interesting that both 
N26 and C35 commenced on breast milk fortifier on day 33 (Table 16) which has been speculated to 
affect the GI microbiota. C35 required a seven-day course of antibiotics five days after he was born 
for suspected sepsis and this may account for the very different GI microbial composition compared 
to his twin, N26.  
 
Zygosity was interesting to consider and one might expect that monochorionic-diamniotic twins 
would have a more similar GI microbiota than dichorionic-diamniotic twin pair. No striking patterns 
were seen in this sub-study, but this may be due to the fact that there were only two sets of twins in 
each category.  
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Figure 33: Faecal microbiota progression in twin pairs discordant for NEC. The faecal microbial 
composition for each day of life is depicted by the bar charts, with the legend indicating which OTUs 
are present. Samples from NEC infants are indicated by the red bar above the bar chart, and samples 
from control infants by the blue bar. The day of life the faecal sample was collected on is shown on 
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N15 Dichorionic – 
diamniotic 
C-section Nil Nil DEBM + 
MEBM from 




C50 Dichorionic – 
diamniotic 
C-section Nil Nil DEBM from 
day 2, for 9 
days, MEBM 









for 3 days 
Nil DEBM from 
day 2 for 9 days, 
and on day 12 
and19, MEBM 
from day 3 
onwards 
Coarctation 







for 3 days 
Nil DEBM from 
day 2 for 9 days, 
and on day 12 
and 20, MEBM 
from day 3 
onwards, 
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formula from 
day 20 




for 3 days 
Nil DEBM + 
MEBM from 
day 1 onwards 
 




for 3 days 
Nil DEBM + 
MEBM from 




C-section Nil Nil DEBM from 
day 1 for 15 
days, MEBM 
from day 3 
onwards. Breast 
milk fortifier 
from day 33. 
Blood 
transfusion 







C-section Nil Tazocin + 
Vancomycin 
on day 5 for 




day 1 for 20 
days, MEBM 
from day 3 
onwards. Breast 
milk fortifier 
from day 33. 
 
Twin pairs are listed sequentially: N15-C50, N21-C23, N24-C32 and N26-C35. 
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6.8 Tissue associated microbiota in NEC infants 
 
As described in Section 2.3 and Section 5.2, fresh gut tissue, intestinal contents at the site of disease 
and/or swabs of the intestinal contents were collected at the time of surgery where possible and were 
either stored at -80oC or underwent DNA extraction within one hour. As mentioned in Section 5.2 and 
shown in Chapter 5, Table 14, several samples were unfortunately placed in formalin or were post 
mortem samples. Using the optimised DNA extraction protocol (Section 2.4.3), high concentrations 
of DNA were obtained (range: 44.2ng/µl – 705.9ng/µl, mean = 333.0ng/µl) and therefore sequencing 
was attempted for all DNA samples extracted from gut tissue.  
 
Out of the eight NEC infants, who had had gut tissue/intestinal contents collected, only five had 
sufficient sequencing data for analysis (rarefied to 800 reads) (Figure 34). The failure of 
amplification may be due to the presence of human DNA in the sample which was likely to be the 
cause of the high concentrations, and an extraction protocol optimised to remove human DNA should 
be implemented in the future. 
 
 
Overall, there was a predominance of the Klebsiella OTU in the tissue associated microbiota for all of 
the infants in all the different types of tissue sample, with Escherichia as the second most dominant 
OTU. Where possible, the closest faecal sample collected prior to surgery is also shown for 
comparison. Although there were only two infants where sequencing data from faecal samples was 
available for comparison with gut tissue (N14 and N24) and so a formal statistical test was not carried 
out, there appears to be greater diversity in the faecal samples compared to the tissue samples, 
although it should be noted that the gut tissues were not collected concurrently with  the faecal 
sample. 
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Figure 34: Microbial composition of the tissue associated microbiota and intestinal contents 
from infants with NEC. The bar charts indicate the microbial composition as depicted by the legend. 
The day of NEC diagnosis (D0) is shown at the top of each bar chart. The day of life when the sample 
was collected is shown beneath the bar charts with the type of sample below this. Sample type key: F 
= faeces (nearest faecal sample to surgery date), IC = intestinal contents at site of disease, ICp = 
pelleted intestinal contents at site of disease, ICs = swab of intestinal contents at site of disease, IlealC 
= diseased tissue from the ileal caecal junction, Ileum = diseased tissue from the ileum, Dgut = 
diseased gut, Hgut = healthy gut.  
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The Klebsiella and Escherichia OTUs accounted for well over 95% of the reads in this sub-study. To 
investigate whether these two apparently distinct OTUs actually originated from the same sequence 
but were classified as two OTUs due to varying sequence length, the representative sequence of these 
two OTUs were compared and aligned using BLAST (Basic Local Alignment Search Tool).110 The 
sequences were both 400 base pairs in length and differed by 3.3% (see alignment Figure 35). It is 
recognised that members of the Enterobacteriaceae family, to which both Klebsiella and Escherichia 
belong, are particularly difficult to differentiate on 16S rRNA sequence and this will be explored 
further in Chapter 8. 
 
 
Figure 35: Alignment of the Klebsiella and Escherichia OTUs using BLAST (Basic Local 
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6.9 Discussion 
 
6.9.1 Development of the normal gastrointestinal microbiota in premature infants 
 
The healthy foetus has been traditionally considered to be microbiologically sterile. This view has 
been challenged by recent non-culture based studies which have detected bacterial DNA present in 
amniotic fluid, umbilical cord blood, placental surfaces and fetal membranes from mothers and 
healthy infants born at term. Caution should be taken while interpreting these results as these findings 
do not equate to infection with live organisms, and contamination is a substantial problem when 
processing low biomass samples. There have been several studies reporting characterisation of the 
‘meconium microbiome’ in premature infants, suggesting that there may be a breach of the amnion 
prior to birth, with the quantity of bacterial DNA present being inversely proportional to gestational 
age,111-113 i.e. there is a higher quantity of bacterial DNA present in the meconium of those infants 
born the most prematurely. These findings are consistent with infection being an important cause of 
preterm labour. 
 
The major ‘colonisation event’ of the GI microbiota is birth. The infant gut is thought to be seeded 
with organisms originating from the birth canal or maternal GI tract if they are born by vaginal 
delivery, or with skin commensals if born by C-section.109 Initially the GI microenvironment is 
relatively aerobic, allowing facultative anaerobes such as Enterobacteriaceae to thrive. As oxygen is 
utilised, the microenvironment becomes increasingly anaerobic, and organisms such as Bacteroides 
and bifidobacteria flourish.45  
 
In this study differences were found between the faecal microbial community in infants who were 
born by different delivery methods, although no OTUs traditionally associated with the skin 
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microbiota (e.g. Staphylococcus) were found to be associated with delivery by C-section (Figure 28). 
Changes in the microbial community were also seen with increasing postnatal age, with the 
abundance of Bifidobacterium OTU increasing as infants became older. 
 
6.9.2 Diversity of the faecal microbiota  
 
Sequencing results from weekly faecal samples from 53 control infants were analysed to investigate 
the impact of postnatal age, gestational age, mode of delivery and antibiotic usage on the alpha 
diversity as assessed by the Shannon-Weaver index. A comparison between the alpha diversity of 
samples collected just prior to NEC diagnosis and matched control samples was also undertaken. 
 
Considering the first week of life versus week six, an increase in the alpha diversity of the community 
was seen. This is in line with other published studies on the faecal microbiota in premature infants.45 
Considering corrected gestational age, infants between 25 and 28 weeks corrected gestation had in 
general a lower alpha diversity in their faecal microbiome than infants between 32 and 34 weeks 
corrected gestation. It should be noted however that since corrected gestational age is a composite 
measure of the gestational age the infant is born at and the postnatal age, this observation may in part 
be due to the increasing postnatal age.  
 
There was no difference in the diversity index of samples collected from infants born by different 
delivery methods. Interestingly, there also did not appear to be a profound impact on diversity with 
greater days of antibiotic use as might have been anticipated. This may be a consequence of removal 
by the antibiotics of the one or two more abundant OTUs and retention of the numerous lower-
abundance OTUs. This would result in an inflated diversity estimate. The lack of effect of antibiotics 
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on the microbiota may however be artifactual, since the data set was of limited size (Figure 27). To 
resolve this further investigation will be required using a much larger dataset.  
 
Comparing the alpha diversity between samples collected from infants developing NEC just prior to 
diagnosis compared with matched controls, no differences were found.  This however may be due to 
the presence of more than one microbial pattern of NEC as indicated by the results of the principal 
coordinate analysis (Figure 30) and the individual time series (Figure 32).  
 
6.9.3 Development of the gastrointestinal microbiota in infants with NEC 
 
In this current study, the most striking finding was the apparent division, based on their faecal 
microbiota, of the NEC infants into two groups. There was a distinct cluster seen in the principal 
coordinate analysis (Figure 30) in which the Klebsiella OTU is a dominant component in the 
microbiota.  This finding was also supported by the results of the individual NEC infants’ time series 
(Figure 32). The second group of NEC infants had a very different developing faecal microbial 
pattern, with a notable rapid increase in the Clostridium (1) OTU prior to diagnosis. There was a 
single outlier to the two groups, NEC infant 19 (N19 in Figure 32).  
 
The two faecal microbiota signatures may be a reflection of the anaerobicity of the GI 
microenvironment. The group in which the Klebsiella OTU is present at high levels is indicative of a 
relatively oxygen-rich microenvironment (see Section 7.10.2), whereas the group with a large 
proportion of the Clostridium (1) OTU in the microbiota is a marker of an anaerobic 
microenvironment.  
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This provides insight into the results of infant N19, whose faecal microbiota consisted of Veillonella, 
Bifidobacterium, Clostridium (2) and Anaerococcus OTUs. These are typical anaerobes, similar to the 
organism/s that would make up the Clostridium (1) OTU, and it is plausible to speculate that if the 
infant encountered the organism/s associated with this OTU, he could have been colonised with it and 
had a faecal microbial pattern similar to that of the second group.  
 
6.9.4 The faecal microbiota in twins discordant for NEC 
 
Samples from discordant twins are interesting to study as the unaffected infant of a twin pair is an 
ideal control being the same gestational age and postnatal age, sharing the same in utero environment, 
and once on maternal breast milk - fed the same milk. Furthermore, they may even have a similar GI 
microbiota – as suggested by a study conducted by Goodrich et al..114 This group used 16S rRNA 
gene characterisation to examine faecal samples from 171 monozygotic and 245 dizygotic adult twin 
pairs and found that the microbial community was more similar in monozygotic than dizygotic twins. 
There are currently no published studies on the comparison of the microbial community of faecal 
samples collected during infancy from monozyogotic twins and dizygotic twins born prematurely. As 
the faecal microbiota changes rapidly during infancy, and premature infants are exposed to the NICU 
environment and clinical interventions during this crucial period, a study looking at the longitudinal 
changes of the faecal microbiota in early life in these infants may reveal different results. Faecal 
samples from the 64 sets of multiple births in the NeoM study (Chapter 5, Table 13) can be used to 
address this. 
 
In this sub-study there were two sets of dichorionic-diamniotic and monochorionic-diamniotic twins. 
It is interesting that the microbiota within each twin pair were distinct from one another, except for 
N24-C32 where there was only one sample (first week of life) available for comparison. This suggests 
that the microbiota has a different developmental trajectory in infants with NEC, even in the context 
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of genetically similar hosts. In contrast, Stewart et al.115, authors of the only 16S-rRNA gene based 
study published to date focused on twins discordant for NEC, concluded that the microbiota looked 
more similar in genetically related individuals, despite disease status. The study however was 
primarily based on DGGE analysis and a detailed microbial composition was not provided, except for 
a single twin pair where 454 sequencing was carried out which demonstrated an increase in 
Escherichia sp. prior to NEC diagnosis compared to the healthy twin.  
 
6.9.5 Tissue associated microbiota in NEC infants 
 
Although study of the microbiota from readily accessible faecal samples of NEC infants can give 
insights into the disease, determining the microbiota directly associated with the diseased gut tissue 
should be valuable in uncovering the underlying pathophysiology of NEC. One fundamental issue 
with all studies studying the tissue associated microbiota is accessibility to the tissue and 
understanding what the results actually represent. As surgery is performed in critically unwell 
premature infants, bowel preparation is not carried out and the bowel is full of faecal content. In the 
present study the tissue samples obtained were washed multiple times prior to DNA extraction. Whilst 
the tissue appeared macroscopically clear of faecal matter, it was not possible to determine if the 
samples were cleaned to the same extent. Thus the results that were obtained may in fact be more 
indicative of the intestinal content at the site of resected tissue than the true mucosal-associated 
microbiota. Certain bacteria may also be more adherent than others to the mucosa and these could 
have been over-represented.  
 
There has been one 16S-rRNA gene next-generation sequencing based study of the mucosa-associated 
microbiota116 where samples from 16 NEC infants were compared to 10 controls. The investigators 
found that infants with NEC had a higher number of 16S rRNA gene sequences compared with 
control infants, but found no defined microbial pattern associated with NEC. There was a trend 
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towards decreased diversity in the tissue samples from NEC infants compared to controls.  
Clostridium was found to be present more commonly in NEC samples, but this was not statistically 
significant. Interestingly, five ‘clusters’ were identified based on the abundance of 
Enterobacteriaceae, Clostridiaceae, Bacterioidaceae, Prevotella and Klebsiella, and one 
heterogenous group. In the Enterobacteriaceae group (the largest cluster) the mean abundance of the 
most predominant OTU was more than 90% in 5 out of 11 samples, similar to our findings. It is, 
however, difficult to interpret these findings as there is no indication of how the samples were washed 
prior to extraction, and controls were much older (postnatal age = 94 days) than NEC infants 
(postnatal age = 19 days). Differences in the microbiota may therefore have been due to the large 
disparity in postnatal age between groups. Furthermore, the control group mainly consisted of NEC 
survivors who underwent surgery for reversal of their stoma/fistula and the resulting microbiota may 
be extremely different in infants who do not have an intact functioning bowel. 
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Being able to discriminate between an infant with NEC and an infant with sepsis or who appears 
unwell, is of crucial importance for a neonatologist. Early diagnosis of NEC or identification of 
infants at high risk of NEC would be invaluable as it would enable treatment to be commenced 
promptly with the real potential of preventing progression of disease. As mentioned previously 
(Section 1.3), it can be difficult to distinguish an infant with suspected NEC from another with sepsis. 
It is important to get the diagnosis correct as cessation of enteral feeds and administration of multiple 
antibiotics can have profound side effects as discussed in Section 1.3.2. The aim of the work 
presented in this chapter therefore was to identify clinical variables and OTU data that may 
differentiate Bell stage 2/3 NEC infants from controls, and their application as a screening tool to 
predict NEC status of infants. 
 
7.2 Univariate analysis of OTU data and clinical factors in cases and controls 
 
Univariate analysis using the top 13 OTUs present in faecal samples collected just prior to NEC 
diagnosis in infants with NEC (n = 12) and matched controls (n = 36) (see Chapter 6, Figure 31) and 
the clinical factors listed in Chapter 5, Table 15 as variables was performed in order to identify 
differences between the 12 NEC Bell stage 2/3 cases and the 36 controls. The most significant 
discriminators were found to be the number of Clostridium (1) OTU reads and the number of days of 
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continuous positive airway pressure required with supplemental oxygen (CPAP oxygen). The mean 
number of Clostridium (1) OTU reads (135) prior to diagnosis in the NEC Bell stage 2/3 infants was 
used to calculate an odds ratio of 2.5 (95% confidence interval (CI), 1.2 – 5.2), P=0.02. The odds ratio 
for CPAP oxygen days was 1.5 (95% CI 1.1 – 2.3), P=0.04, based on an infant requiring an average 
of seven days of respiratory support with CPAP oxygen.  
 
7.3 Multivariate analysis of clinical factors in cases and controls 
 
Multivariate analysis using the stepwise generalised linear model function in R was performed with 
the following clinical factors included in the model to distinguish between cases and controls: 
gestational age, maternal antibiotic use during labour, chorioamnionitis, presence of prolonged 
rupture of membranes, “worst” (lowest) pH, “worst” (most negative) base excess (BE), APGAR at 5 
minutes, gender, birth hospital, ethnicity, weight, antibiotic use, number of cumulative days of 
antibiotic use, number of days given donor milk, maternal milk or formula, presence of a patent 
ductus arteriosus (PDA), number of required days of CPAP with no supplementary oxygen, number 
of required days of CPAP with supplementary oxygen, and number of required days of high 
frequency oscillation ventilation/conventional ventilation. There were three variables in the resulting 
model: CPAP with supplementary oxygen (P=0.01), maternal antibiotic use during labour (P=0.03), 
and birth hospital; other – P=0.4 or site A – P=0.3, - two being significant. An analysis of variance 
indicated that retaining the birth hospital did not significantly improve the model (P=0.08). The 
Akaike Information Criterion (AIC) (a measure which allows comparison of statistical models) of the 
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7.4 Incorporation of OTU data into the multivariate analysis 
 
The two significant clinical factors were retained (CPAP with supplementary oxygen and maternal 
antibiotic use during labour), and each OTU was added individually to the model and interaction 
enabled. In line with the results of the univariate analysis, the addition of the Clostridium (1) OTU 
improved the model significantly (P=0.0008), AIC: 46.3. Individually all three terms were also 
significant - maternal antibiotic use during labour (P=0.02), required days of CPAP with 
supplementary oxygen (P=0.003), and Clostridium (1) (P=0.002). These are important discriminators, 
and potential risk factors for the development of NEC. 
 
A further round of modelling was performed whereby the remaining OTUs were added individually to 
the model and interaction again enabled. The single OTU which produced the best model was 
Klebsiella (AIC 40.1). In this model, maternal antibiotic use during labour was no longer a significant 
term and was removed. The final model had two significant terms; the number of Clostridium (1) 
OTU reads (based on the mean number of Clostridium (1) reads [135], the adjusted OR was 6.2 [95% 
CI, 1.8 – 21.7; P=0.004]), and an interactive term – the number of Klebsiella OTU reads and the 
number of CPAP oxygen days required prior to diagnosis. Based on the mean number of Klebsiella 
OTU reads in NEC Bell stage 2/3 infants (559) and a seven day CPAP oxygen requirement, the 
adjusted OR was 4.6 (95% CI, 1.2 – 17.0, P =0.02). 
 
7.5 Exploring the interactive term CPAP oxygen * Klebsiella OTU  
 
By plotting the number of CPAP oxygen days against the number of Klebsiella OTU reads, the nature 
of the interactive term could be discerned (Figure 36). A cluster of NEC cases whose faecal 
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microbiota have high levels of Klebsiella OTU reads can be observed in the fourth quartile, whilst the 
controls are spread evenly over the scatterplot.  
 
Figure 36: Number of Klebsiella OTU reads plotted against number of days CPAP with 
supplementary oxygen required by quartiles prior to diagnosis in NEC infants and matched 
controls. Black crosses represent NEC cases with high numbers of Klebsiella OTU reads present in 
their faecal microbiota, filled circles represent NEC cases with a high proportion of Clostridium (1) 
OTU reads present in their faecal microbiota, and controls are indicated by open circles. Figure 
adapted from Sim K et al. ‘Dysbiosis anticipating necrotizing enterocolitis in very premature 
infants’104 under the Creative Commons BY licence. Figure created by Dr. Alex Shaw. 
 
From the multivariate analysis, NEC risk associated with high numbers of Clostridium (1) OTU reads 
was shown to be independent of CPAP oxygen requirement.  As can be seen from Figure 36 this is 
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evident in that infants with NEC who had a microbiota with a high proportion of Clostridium (1) OTU 
reads distributed evenly across the quartiles. 
 
7.6 Stratification of NEC cases into two separate groups: ‘Clostridium-associated’ NEC and ‘Klebsiella OTU-associated’ NEC 
 
Cases of NEC were stratified according to which term contributed most towards NEC risk – 
Clostridium (1) reads or Klebsiella OTU reads * CPAP oxygen days. Using the co-efficients 
generated by the model and the corresponding values for each sample (Section 7.5) two categories of 
NEC were obtained: ‘Clostridium-associated’ NEC (n = 4) and ‘Klebsiella OTU-associated’ NEC (n 
= 7).  The seven cases of ‘Klebsiella OTU-associated’ NEC had significantly higher numbers of 
Klebsiella OTU reads in the samples closest to diagnosis (mean = 870) compared to control samples 
(mean = 450) (P <0.0001). These two groups of NEC infants had an entirely different microbiota 
development as had been identified previously (Chapter 6, Figures 30 and 32). One case (N19) did 
not fall into either group.  
 
7.7 Alpha Diversity of faecal samples from infants with ‘Clostridium-associated’ NEC and ‘Klebsiella OTU-associated’ NEC 
 
In the light of two distinct groups of NEC being identified, alpha diversity was investigated 
individually and found to differ significantly –Shannon-Weaver index (P=0.004), for the 
‘Clostridium-associated’ NEC and the ‘Klebsiella OTU-associated’ NEC faecal samples collected just 
prior to diagnosis. Faecal samples collected from infants with ‘Clostridium-associated’ NEC were 
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found to have a higher alpha diversity compared to those collected from ‘Klebsiella OTU-associated’ 
NEC as illustrated in Figure 37. 
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 Figure 37: Box plots showing median and interquartile range of the Shannon-Weaver Index of 
faecal samples from infants with ‘Clostridium-associated’ NEC and ‘Klebsiella OTU-associated’ 
NEC. Faecal samples from infants with ‘Clostridium-associated’ NEC have a significantly higher 
alpha diversity compared to those from ‘Klebsiella OTU-associated’ NEC. Asterisks represent P 
values <0.05. 
 
7.8 ‘Clostridium-associated’ and ‘Klebsiella OTU-associated’ NEC – separate clinical entities? 
 
To determine if there were clinical differences between the two categories of NEC the difference in 
clinical characteristics (Chapter 5, Table 15) were investigated. There were no differences in the 
demographics or postnatal age of NEC diagnosis. In addition, markers of severity such as Bell 
staging, requirement for surgery and death were also compared and again no differences were seen 
(Table 17). The two groups identified based on microbiota signatures did not form two distinct 
clinical entities.  
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Table 17: Comparison of demographics, clinical characteristics and markers of severity in 
infants with ‘Clostridium-associated’ and ‘Klebsiella OTU-associated’ NEC. 
 ‘Clostridium-associated’ 
NEC (n = 4) 
‘Klebsiella OTU-
associated’ NEC (n = 7) 
Demographics   
  Male (%) 4 (100) 2 (29) 
  Mean birth weight (IQR), g 921.3 (775.0-1043.8) 753.6 (675.0-765.0) 
  Mean gestation at birth (IQR), days 195.8 (187.0 – 202.3) 182.3 (177.5-182.5) 
  Mean postnatal age at D0 (IQR), days 25.5 (19.0 – 28.0) 29 (24.0-37.5) 
  Birth hospital   
    Site A (%) 4 (100) 6 (86) 
    Site B (%) 0 (0) 1 (14) 
  Ethnicity   
    Black (%) 1 (25) 1 (14) 
    White (%) 2 (50) 3 (43) 
    Asian (%) 0 (0) 3 (43) 
    Mixed (%) 1 (25) 0 (14) 
  Mode of delivery   
    CS (%) 2 (50) 2 (29) 
    VD (%) 2 (50) 5 (71) 
Maternal characteristics   
  Maternal IVAB use at delivery (%) 1 (25) 0 (0) 
  Maternal PROM (%) 0 (0) 2 (29) 
  Maternal sepsis/chorioamnionitis (%) 1 (25) 2 (29) 
Condition at birth   
  Lowest pH recordeda in the first 24 
hours, (IQR)  
7.1 (7.1 – 7.2) 7.2 (7.2-7.3) 
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  Lowest base excess recordeda in the 
first 24 hours, (IQR) 
-8.5 (-12.2 - -5.1) -4.4 (-5.0 - -3.1) 
  APGAR at 5 minutes, (IQR) 7.5 (7.3 – 8.3) 8.0 (7.0-9.0) 
Intravenous antibiotic use   
  Mean number of days of IVABb 
during first week of life (IQR), days 
1.5 (0-3.0) 2.7 (2.0-2.5) 
  Mean number of cumulative days of 
IVABb use prior to D0 (IQR), days 
1.5 (0-3.0) 4.9 (2.0-5.5) 
Feeding regime    
  Mean number of days received 
MEBM prior to D0 (IQR), days 
23.3 (16.5 – 26.8) 23.0 (13.5 – 32.0) 
  Mean number of days received 
DEBM prior to D0 (IQR), days 
10.0 (9.3 – 11.8) 13.0 (6.5 – 14.0) 
  Mean number of days received 
formula milk prior to D0 (IQR), days 
0 (0-0) 0.86 (0-0) 
Respiratory support requirement   
  Number of days requiring ventilation 
support (HFOV or conventional 
ventilation) prior to D0 (IQR), days 
1.5 (0-2.5) 1.7 (0.5-1.5) 
  Mean number of days requiring 
CPAP (no oxygen), prior to D0 (IQR), 
days 
10.8 (0.8 -20.0) 4.7 (1.5 -7.0) 
  Mean number of days requiring 
CPAP with supplemental oxygen, 
prior to D0 (IQR), days 
8.8 (0.8-16) 22.6 (16.5-31.5) 
  Mean number of days requiring NP 
oxygen, prior to D0 (IQR), days 
2.5 (0-3.0) 0 (0-0) 
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 Mean number of days not requiring 
any respiratory support, prior to D0 
(IQR), days 
2.0 (0-2.0) 0 (0-0) 
Presence of PDA (%) 0 (0) 2 (29) 
Markers of severity   
Bell stage 2  0 (0) 1 (14) 
Bell stage 3 4 (100) 6 (86) 
Surgery required 2 (50) 3 (43) 
Death 4 (100) 3 (43) 
Abbreviations – IQR, interquartile range, D0, day of NEC diagnosis or postnatal age of matched 
control; CS, Caesarean-section; VD, vaginal delivery; IVAB, intravenous antibiotics; PROM, 
prolonged rupture of membranes; MEBM, maternal expressed breast milk; DEBM, donor expressed 
breast milk; HFOV, high frequency oscillation ventilation; CPAP, continuous positive airways 
pressure; NP, nasal prong; PDA, patent ductus arteriosus. aLowest value recorded from cord/free 
flowing capillary/arterial/venous blood gas, bFirst line IVAB for suspected early onset sepsis = Co-
Amoxiclav, or Benzylpenicillin and Gentamicin (if ex utero transfer), second line IVAB = 
Vancomycin and Piperacillin/Tazobactam 
 
7.9 Prediction of NEC status and ‘at risk’ period prior to NEC diagnosis 
 
Focusing on the two significant factors– Clostridium (1) reads, and the interactive Klebsiella * CPAP 
oxygen term, risk scores were calculated for each of the two ‘NEC sub-groups’ for all the data from 
NEC cases (n = 12) closest to diagnosis (i.e. clinical data and 16S rRNA sequencing reads generated 
from faecal samples collected just prior to diagnosis) and their controls (n = 36). This allowed correct 
classification of 10 of the NEC cases, and 25 of the control infants, with a sensitivity of 0.83, and 
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specificity of 0.69. The two misclassified cases, infants N19 and N24, were both diagnosed with NEC 
around the first week of life (see Chapter 6, Figure 32).  
 
In order to determine when infants were at greatest risk of developing NEC, longitudinal data from 
each NEC infant prior to diagnosis were analysed. Using the same calculated threshold based on the 
coefficients produced by the final model used to dichotomise the NEC cases (Section 7.6), infants 
were identified to be at risk of developing ‘Clostridium-associated’ NEC an average of 5 days (SD 5 
days) prior to diagnosis, and ‘Klebsiella OTU-associated’ NEC an average of 12 days (SD 6 days) 
prior to diagnosis. This is consistent with the trajectories of the microbial composition in the faecal 
samples in the two NEC groups in that there is a rapid increase in the number of Clostridium (1) OTU 
reads in the week preceding diagnosis (P=0.004) in the ‘Clostridium-associated’ group whilst for the 
‘Klebsiella OTU-associated’ group consistently high levels of the Klebsiella OTU are observed in the 
2 weeks prior to diagnosis (see Chapter 6, Figure 30). 
 
Next the risk scores were then applied to the Bell stage 1 infants. It is important to note that these 
infants are a very heterogenous group, and only one of the infants went on to develop definite NEC. 
For this reason the Bell stage 1 infants were not used in the final sequence analysis (Chapter 6) or in 
the univariate and multivariate analysis. Sequencing data generated from faecal samples from eight of 
the Bell stage 1 infants was used to calculate risk scores for these infants and two were classified as 
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7.10 Discussion 
7.10.1 ‘Clostridium-associated’ NEC and ‘Klebsiella OTU-associated NEC’ groups 
 
Consideration of clinical factors and the faecal microbial OTUs of the NEC infants has resulted in two 
categories with distinct microbial signatures being identified: the ‘Clostridium-associated’ NEC group 
and the ‘Klebsiella OTU-associated’ NEC group. The alpha diversity of faecal samples from these 
two groups of NEC infants was found to differ, with the ‘Clostridium-associated’ NEC infants having 
higher diversity in the samples collected prior to diagnosis compared to those with ‘Klebsiella OTU-
associated’ NEC.  This may reflect a difference in the pathogenesis related to these two distinct 
signatures. If, for example, NEC in the ‘Clostridium-associated’ group is caused by a pathogenic 
Clostridium perfringens strain (as has been previously speculated), then one would expect the 
development of the gastrointestinal microbiota, and therefore the associated diversity in samples from 
these infants, to be similar to that of a healthy premature infant, with the symptoms of NEC being 
caused by toxins produced by the Clostridium sp.. In the case of the ‘Klebsiella OTU-associated’ 
NEC group, in which faecal samples are hugely dominated by the Klebsiella OTU resulting in very 
low microbial diversity, it may be that the implicated agent is an organism with low intrinsic 
virulence, and the symptoms of NEC only emerge when the organism is present in overwhelming 
quantities. Identification of these OTUs is therefore important and will be investigated further in 
Chapter 8.  
 
Interestingly, these two NEC groups were not associated with distinct clinical phenotypes. One would 
have anticipated that there would be differences in the clinical manifestation of NEC based on the 
different organisms found to dominate the faecal microbiota and the organisms’ potentially different 
mechanisms of action. For example, Dittmar et al. found that infants with NEC who had Clostridium 
perfringens present in their faeces had a more severe clinical course, with a higher mortality rate.117 
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Our data do not bear out this proposition, although concededly this may be due to the small numbers 
in the sub-analysis.  
 
7.10.2 The gut microenvironment and the microbiota 
 
The Klebsiella * CPAP Oxygen interactive term suggests a possible relationship between the resident 
microbes and their microenvironment. Enterobacteriaceae, the family of which Klebsiella is a 
member, are facultative anaerobes and are able to survive in the presence of oxygen, unlike strict 
anaerobes such as Clostridium. Due to the nature of the oxygen delivery system through CPAP, 
oxygen inevitably enters the gut. Indeed, regular decompression of the stomach via a nasogastric tube 
is part of routine care of an infant requiring CPAP. It seems plausible that the microenvironment of 
the gut may be altered to a more oxygenated state with the prolonged use of CPAP and supplemental 
oxygen, leading to an altered microbiota dominated by facultative anaerobic organisms such as 
Enterobacteriaceae. In support of this proposition, no association between the Klebsiella OTU and 
the use of CPAP without supplemental oxygen (i.e. CPAP in which air is delivered to the infant) was 
observed and neither was an association with the use of nasal prong oxygen (oxygen delivered 
without the use of CPAP, at a much lower pressure).  
 
The persistence of high levels of Enterobacteriaceae in some of the infants with NEC may represent a 
failure of the gut to be colonised with anaerobes. As discussed earlier (Section 6.9.1), facultative 
anaerobes are replaced by obligate anaerobes in the normal succession of GI microbiota. One 
possibility accounting for the failure of the GI microbiota of these infants to mature may be due to the 
physical environment of the gut being unfavourably altered by the use of CPAP and oxygen, but this 
might not be the entire reason behind the persistently high levels of Enterobacteriaceae. Interestingly, 
dysbiosis with high levels of Enterobacteriaceae has also been described in the GI microbiota of 
patients with inflammatory bowel disease.118 Enterobacteriaceae have been shown to flourish in the 
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context of gut inflammation due to their ability to utilise the by-products of the host inflammatory 
response such as N-oxides and nitrates.119 It is therefore possible that the pathogenesis of NEC itself 
contributes to the persistence of these organisms.  
 
7.10.3 NEC screening tool 
 
Although validation will be required with a separate study, it was encouraging to find that application 
of a simple ‘screening model’ to predict NEC status allowed correct classification - on average five to 
twelve days before they became ill - of ten out of the twelve NEC infants in the NeoM cohort. The 
two cases that were misclassified were both diagnosed with NEC in the first week of life. The lack of 
sequencing data for this time period due to the difficulty encountered in obtaining faecal samples (as 
mentioned in Section 5.5) means that it is possible there is a separate microbial signature for NEC 
occurring in the first week of life that could not be identified in the present study.  
 
Being able to identify infants at high risk of NEC early would enable not only prompt treatment but 
also reduction of interventions that may increase their risk. For example, many premature infants are 
started on donor milk if their mother is unable to provide their own milk. Donor milk however is 
reserved for the most premature infants and eventually infants will transition to formula milk (a 
recognised risk factor for NEC – see Section 1.4.1) if maternal breast milk is not available. The 
‘screening model’ could alert the clinician that a particular infant had a ‘high risk’ faecal microbiota 
and that the baby should continue to receive donor milk.  
 
Stratification of premature infants on the NICU into ‘high risk’ and ‘low risk’ of NEC may be 
particularly helpful to differentiate between possible NEC and possible sepsis, for the management of 
these conditions differs. Although of course specific NEC treatment would not be instigated on the 
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finding of a ‘high-risk’ faecal microbiota alone, it would provide evidence to start treatment in a 
scenario of uncertainty. This may prevent an infant from progressing from ‘suspected’ to ‘definite’ 
NEC and thence requiring surgery. The practicalities of implementing a screening tool based on the 
findings of this present study will be discussed later (Chapter 9). 
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Chapter 8 NeoM Study: Culture Investigations 
8.1 Introduction 
 
With the identification of two ‘microbial signatures’ associated with NEC (Chapter 7), an important 
next step was to try and determine if there was a particular species that could be ascribed to each of 
the two OTUs (the Clostridium (1) OTU and the Klebsiella OTU). In particular, it was of interest to 
see if the Clostridium (1) OTU was in fact C. perfringens as the latter has been long considered to be 
a candidate cause of NEC. The evidence linking C. perfringens with NEC as well as a discussion of 
C. perfringens and known human diseases associated with it, and results obtained from exploring the 
Clostridium (1) OTU using culture techniques, are the focus of the first half of this chapter. The 
second half of the chapter presents results from the culture work investigating the Klebsiella OTU and 
includes an in silico experiment exploring the heterogeneity of the Klebsiella OTU, as well as 
discussion of the difficulties that are encountered when identifying species within the 
Enterobacteriaceae family.   
 
8.1.1 Background: Clostridium perfringens and human diseases 
 
C. perfringens is a Gram-positive, anaerobic microbe able to produce heat-resistant endospores. It is a 
common commensal of the adult human GI tract and can be found in the environment,  primarily in 
soil.120 C. perfringens strains can be classified into five toxinotypes (Table 18) based on the presence 
of four toxins. It has been branded ‘the most prolific toxin-producer among known 
microorganisms’.121 By definition, all strains of C. perfringens contain the chromosomally encoded 
dermonecrotic alpha toxin gene (cpa) which has phospholipase C and sphingomyelinase activities 
underlying the pathogenesis of gas gangrene.122 The other extracellular toxins encoded 
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chromosomally are: perfringolysin O (PFO, also known as θ-toxin), collagenase (κ-toxin), and 
hyaluronidase (µ-toxin).  Other toxin genes are found on plasmids: cpb (beta toxin), cpb2 (beta2 
toxin), etx (epsilon toxin), ia and ib (iota toxin), netB (NetB – necrotic enteritis toxin B-like), and tpeL 
(TpeL – toxin C. perfringens large cytotoxin).121  The cpe gene encoding the C. perfringens 
enterotoxin can be found on the chromosome or on a plasmid.120 
 
Table 18: C. perfringens toxinotypes based on the presence of the four toxins: alpha, beta, 
epsilon and iota. 
C. perfringens type Toxin  Alpha Beta Epsilon Iota A + - - - B + + + - C + + - - D + - + - E + - - +  
Besides gas gangrene, C. perfringens also causes food poisoning and “enteritis necroticans” in 
humans. The C. perfringens enterotoxin encoded by cpe causes active fluid and electrolyte secretion 
into the gut lumen causing watery diarrhoea. The toxin also destroys intestinal epithelial cells.120 C. 
perfringens type C, and in particular, the β-toxin, is thought to be the causative agent for the disease 
“enteritis necroticans” – Pigbel - a disease described in children in Papua New Guinea in the 1950s 
to1960s. At periodic ritual meat feasts, high amounts of protein were consumed by the 
undernourished children123 and the high protein load led to the proliferation of C. perfringens type C 
either already present in the GI microbiota, or in contaminated meat that was consumed. Beta-toxin is 
normally inactivated by trypsin, but due to the low amounts of trypsin that would be present in an 
individual on a low protein diet, combined with the simultaneous consumption of sweet potatoes (a 
regular staple food in Papua New Guinea) which contain high levels of a trypsin inhibitor, high levels 
of the toxin accumulated resulting in development of the disease - vomiting, diarrhoea, abdominal 
pain and blood in the faeces.120 Pigbel has a mortality of up to 36.0%.124 
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C. perfringens is currently a problem in the poultry industry, as a major cause of necrotic enteritis in 
chickens. There is active research in the field, attempting to characterise new toxins and potential 
vaccine targets. In the past two years alone five new toxin genes have been described: netE, netG, 
becA, and becB.125,126 
 
8.1.2 C. perfringens-associated NEC 
 
C. perfringens has been a longstanding contender as a causative agent of NEC, as an enteric gas-
producing organism potentially responsible for the pneumatosis coli (gas in the bowel wall) 
characteristically found in affected infants. Indeed, in the 1970s, NEC was termed ‘gas gangrene of 
the bowel’. As noted above, Dittmar et al.117 reported that infants with NEC who had C. perfringens 
isolated from faeces had an earlier onset of disease, more severe clinical course, larger extent of 
gangrene and higher mortality rate than infants with NEC in whom C. perfringens was not found.  
 
De la Cochetiere et al.58 have also reported finding C. perfringens in faecal samples collected from 
infants who later went on to develop NEC. In animal studies, NEC-like caecal lesions similar to those 
seen in human infants have been induced by orally inoculating gnotobiotic quails with  C. 
perfringens.127  
 
8.2 Exploration of the Clostridium (1) OTU 
8.2.1 Identification of the Clostridium (1) OTU 
 
As 16S rRNA gene characterisation cannot always be used to discriminate beyond the genus level, a 
variety of culture and molecular methods were used to identify which Clostridium species were 
present in the faecal samples collected from NEC infants. An alcohol shock method was adopted in 
order to eliminate non-sporing organisms, after which those that survived the procedure were cultured 
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on fastidious anaerobic agar under anaerobic conditions (see Chapter 2, Section 2.11 for full details). 
The method is designed to optimise the growth of Clostridium species. 
 
A faecal sample closest to NEC diagnosis from each of the twelve Bell stage 2/3 infants and eight 
Bell stage 1 infants was selected for culture (if enough faecal material was available post DNA 
extraction), together with a faecal sample each infant’s matched contemporaneous control (defined as 
an infant resident on the same site on the same day as the index case – these are not necessarily the 
same controls as those matched for the sequencing study in Chapter 6). The faecal sample from the 
contemporaneous control was collected on the same day as that of the faecal sample from its matched 
NEC case. All morphologically distinct colonies isolated were regrown to produce purity plates, and 
isolates were identified using MALDI-TOF (Section 2.11 – 2.12). 
 
In each case where a sample had the Clostridium (1) OTU present at an abundance of greater than 
0.5% of sequencing reads, C. perfringens was identified by MALDI-TOF (Table 19). The 
Clostridium (2) OTU (ninth most abundant OTU – see Chapter 6, Figure 31) was found to 
correspond to Clostridium butyricum being isolated by culture, (although in one case (C15) where 
there was a high level of the Clostridium (1) OTU and a low level of the Clostridium (2) OTU 
present, only C. perfringens was isolated). A further Clostridium OTU was rarely identified – 
accounting for only 0.06% of sequencing reads in the overall dataset (see Appendix 4). This 
Clostridium (3) OTU corresponded to either Clostridium butyricum or Clostridium paraputrificum 




  177  
Table 19: NEC and Control Infants Clostridium OTU 16S rRNA gene sequencing data with 
corresponding MALDI-TOF results from faecal samples collected just prior to NEC diagnosis 
and their matched controls. 
 
Samples from NEC infants (red) have an ID starting with ‘N’, samples from contemporaneous 
controls (blue) start with ‘C’. Case/control pairs have the same ID number, i.e. N11 and C11 are 
case/control pairs. The number of sequencing reads of the Clostridium OTU and corresponding 
percentage (reads are rarefied to 1,000 per sample) are indicated by the colour code as shown in the 
key. Clostridial species isolated from the faecal samples and identified by MALDI-TOF are shown in 
the last column of the table. 
 
1 2 3
N1 1 0 0 0
N2 3 0 0 0
N3 1 740 0 0  C. perfringens
N4 1 0 0 0
N11 1 0 0 0
N12 3 0 0 0
N14 3 0 0 0
N15 3 456 0 0  C. perfringens
N16 1 0 0 0
N18 2 5 0 0  C. perfringens
N19 3 0 0 19  C. paraputrificum
N20 1 0 0 0
N21 3 429 0 0  C. perfringens
N22 1 0 0 0
N23 3 0 0 0
N24 3 0 0 0
N26 3 849 0 0  C. perfringens
C1 Key # Sequencing reads % of reads
C2 0 - 4 <0.5%
C3 5 - 9 >0.5% - <1%
C4 10 - 49 >1% - <5%
C11 0 0 34  C. butyricum 50 - 99 >5% - <10%
C12 0 0 0 100 - 199 >10% - <20%
C14 0 0 0 200 - 499 >20% - <50%
C15 175 8 0  C. perfringens 500 - 749 >50% - <75%
C16 304 416 0  C. perfringens, C. butyricum 750 -1000 > 75%
C18 94 0 0  C. perfringens
C19 0 0 0
C20 0 0 0
C21 0 0 0
C22 0 0 0
C23 0 0 0
C24 0 0 0
N26
Clostridium OTU # Clostridial species isolated by cultureBell StageID
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8.2.2 Toxin typing and fluorescent Amplified Fragment Length Polymorphism (fAFLP) typing of Clostridium species 
 
All isolates identified as C. perfringens by the MALDI-TOF were submitted for toxin typing by the 
Public Health England Foodborne Pathogens reference service (Section 2.13). The results 
corroborated those obtained by the MALDI-TOF.  Every C. perfringens isolate was found to have the 
alpha toxin gene present. The beta2 toxin gene was additionally found in three NEC infants but no 
control infants. None of the other major toxin genes (beta, epsilon, iota, cpe) were found (Table 20).  
 
To address the question of whether NEC-associated C. perfringens strains might be spreading from 
infant to infant, the relatedness of the isolates was determined using fAFLP. This work was carried 
out by the Public Health England Foodborne Pathogens reference service (Section 2.14).  
Interestingly, every isolate was found to be different on fAFLP, including isolates from the two 
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Table 20: Presence of alpha and beta2 toxin genes and fAFLP type of all C. perfringens isolates 
grown from faecal samples collected just prior to NEC diagnosis and matched controls. 
Patient ID Bell stage Alpha toxin gene present Beta2 toxin gene present fAFLP
a type 
N3 1   CLP.51 
N7 3   CLP.55 
N15b 3   CLP.58 
N18c 2   CLP.52 
N21 3   CLP.54 
N26 3   CLP.56 
C15b -   CLP.57 
C16 -   CLP.60 
C18c -   CLP.53 
aFluorescent Amplified Fragment Length Polymorphism, b,c are case/control pairs, b is also a twin pair 
 
8.3 Identification of the Enterobacteriaceae OTU 
 
A non-culture methodology was adopted for characterising the microbiota of faecal samples from the 
NeoM study as it is recognised that culture techniques may miss a large proportion of organisms 
(Section 1.6). Using faecal samples that have been frozen also introduces difficulties, as recovery of 
certain Enterobacteriaceal species may not be possible due to the freeze thaw procedure. These 
organisms are not as hardy compared to the clostridial spores which are known to survive under the 
toughest conditions. Despite these two potential difficulties, a culture sub-study was performed in an 
attempt to identify the Enterobacteriaceal specie/s associated with the Enterobacteriaceae OTU.  
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Faecal samples produced by infants with NEC just prior to diagnosis together with faecal samples 
from contemporaneous controls (as per Section 2.11.2) were cultured on CHROMagar Orientation 
plates (Section 2.11.2) (if enough faecal material was available post DNA extraction).   CHROMagar 
Orientation facilitates easy identification of Enterobacteriaceal species based on colony colour and 
size. All morphologically different colonies were then regrown to produce purity plates and bacterial 
species identified by MALDI-TOF (Section 2.12).  
 
Table 21 lists the organisms present in the faecal samples as identified using culture, compared with 
the identities obtained from 16S rRNA gene sequencing. A variety of Enterobacteriaceal species were 
isolated using the CHROMagar Orientation plates: Enterobacter aerogenes, Enterobacter cloacae, 
Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, and Serratia marcescens. In comparison 
to the results for the Clostridium (1) OTU where there is an obvious relationship with the isolation of 
C. perfringens, the ‘constituents’ of the Klebsiella OTU appeared to be heterogeneous. For example, 
the faecal sample from NEC infant N2 contained a high number (> 750) of sequencing reads 
designated as belonging to the Klebsiella OTU, and there were no other Enterobacteriaceal OTUs 
present (there were zero sequencing reads for the other four OTUs – Enterobacteriaceae, 
Enterobacteriaceae (1), Escherichia, and Proteus). Despite this, on culture two different 
Enterobacteriaceal species - Escherichia coli and Enterobacter cloacae – were isolated from this same 
faecal sample. In other instances (faecal samples from infants N18, N22 and C18), where again only 
sequencing reads belonging to the Klebsiella OTU were found to be present, one Klebsiella species 
was isolated, alongside another non-Klebsiella species (Escherichia coli, Enterobacter cloacae). 
Consequently unlike the situation obtaining with the Clostridium (1) OTU, ascribing a single 
Enterobacteriaceal species to the Klebsiella OTU was not possible.  
 
A Klebsiella species was isolated from 15 of the 26 faecal samples which had more than 0.5% 
abundance of the Klebsiella OTU. The two Klebsiella species that were identified were Klebsiella 
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pneumoniae and Klebsiella oxytoca. In one faecal sample (infant N20), both of these organisms were 
found to present. In all cases where the Escherichia OTU was present in the faecal sample, except for 
the sample from C2, an Escherichia species was not isolated by culture. Additionally no Proteus 
species were recovered from the faecal sample from infant N16.   
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8.4 Enterobacteriaceae family and16S rRNA gene sequencing 
 
Due to the relatively conserved sequence within the 16S rRNA gene,128 definitive identification of 
bacteria within the Enterobacteriaceae family was not feasible from the V3-V5 data reported here. To 
explore this further an in silico experiment was performed.  
 
Five 16S rRNA gene sequences from each of the six organisms identified through the culture study 
were obtained from the SILVA73 reference database: Enterobacter aerogenes, Enterobacter cloacae, 
Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, and Serratia marcescens (SILVA 
sequence identifiers provided in Appendix 3). The sequences were trimmed so that only the V3-V5 
regions that were amplified in the NeoM study and used for analysis were retained (sequence length = 
400bp). The resulting sequences together with the two representative sequences for the Klebsiella and 
Escherichia OTUs (Figure 35) were then aligned and a phylogram constructed using MEGA 6.0.6 
(Figure 38).129 The full alignment of all the sequences as constructed using MUSCLE130 can be found 
in Appendix 3. The phylogram in Figure 38 depicts clustering of the five sequences for each of the 
six organisms and the two representative sequences. Branch lengths represent the pairwise distance 
between taxa. The maximum number of nucleotide differences between the sequences was 19.  
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Figure 38: Phylogram constructed using the neighbour-joining algorithm with 1,000 bootstraps 
using the p-distance calculated from the distance matrix obtained after the multiple sequence 
alignment of five sequences from each of the following six organisms: Enterobacter aerogenes, 
Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, and Serratia 
marcescens, as well as the representative sequence of the Klebsiella and Escherichia OTUs. 
Branch lengths represent the pairwise distance between taxa.  
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An alternative way to visualise these data is by means of a matrix of the percentage similarity between 
all of the sequences. Although the full matrix is shown in Appendix 3, in order to illustrate the 
maximum similarity between the sequences a simplified matrix, where one representative sequence 
from each organism with the highest percentage similarity was taken, is shown in Figure 39. Using 
this example, based on clustering at 97% similarity all of the organisms could mistakenly be classified 
as Klebsiella pneumoniae. This illustrates the point that even though the representative Klebsiella 
OTU sequence clusters with the K. pneumoniae sequences, it is not possible to discern which species 
it is. 
 





16S rRNA sequencing-based studies are useful in giving an overview of the microbial community, but 
it is clear that additional work is needed to identify organisms beyond the genus, and in certain cases, 
family level: i.e. to determine what species are present. In the present study, by conducting further 
experiments it was possible to identify Clostridium perfringens as the Clostridium (1) OTU.  It was 
not however possible to unpack the Klebsiella OTU due to high sequence similarity of the 16S rRNA 
gene between members of the Enterobacteriaceae family based on clustering at 97% similarity (see 
Section 8.4). Strategies to gain better taxonomic resolution include clustering at 98% or 99% 
similarity (Figure 39), using a different primer set encompassing alternative variable regions of the 
16S rRNA gene, or sequencing a different gene (e.g. rpoB gene) altogether. 
K. pneumoniae E. cloacae E. aerogenes K. oxytoca S. marcescens E.coli
K. pneumoniae x 100 100 99 98 98
E. cloacae 100 x 100 99 98 98
E. aerogenes 100 100 x 99 98 98
K. oxytoca 99 99 99 x 97 99
S. marcescens 98 98 98 97 x 98
E.coli 98 98 98 99 98 x
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Contrary to our original expectation, it was intriguing to find that every C. perfringens isolate was a 
distinct strain: a considerable relief from an infection-control perspective. The presence of the beta2 
toxin in three of the NEC infants but none of the controls is of particular interest as hinting at a 
possible pathogenic process underlying C. perfringens-associated NEC (see discussion below Section 
8.5.1). 
 
One of the main drawbacks of this culture sub-study is that it is not quantitative, compromising 
comparisons with the sequencing data. In the cases where an organism is grown but no sequencing 
reads are present (for example N4 in Table 21) it is plausible to suppose that the sequencing depth 
was inadequate. By rarefying down to 1,000 reads per sample, detection of a microbe present at 0.1% 
is possible but organisms at lower abundance will probably be missed. Ideally, culture experiments 
should be carried out multiple times with fresh faecal samples, to ensure that the results are 
reproducible.  
 
Discrepancies between the sequencing and culture results may also have arisen from potential kit 
contamination (DNA extraction),131  misclassification of either the sequencing data or MALDI-TOF 
identification assignments, or a reflection of methodological biases relating to the culture growth 
conditions and an inadequate culture depth.  
 
8.5.1 The beta2 toxin gene 
 
Three of the isolates from NEC infants were found to possess the beta2 toxin gene, which was not 
present in any isolates from control infants. This plasmid-encoded toxin was first identified from a C. 
perfringens isolate from a piglet with necrotic enteritis.132 It has since been found in isolates from 
other animals suffering from gastrointestinal diseases such as typhlocolitis.121 More recently the beta2 
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toxin gene has been found in isolates from humans with both sporadic and antibiotic-associated 
diarrhoea,121 and shown to be toxic to human colorectal epithelial (CaCo-2) cells.133 It is therefore 
possible that the beta2 toxin plays a role in the destruction of the intestinal epithelium in NEC. 
 
There are two forms of the beta2 toxin gene – one which produces an active toxin and the other which 
encodes a truncated non-functional product due to the presence of a premature stop codon. 
Interestingly, full length protein production can be restored by aminoglycoside treatment.134 This is 
potentially significant in the context of NEC, as aminoglycosides are a commonly used class of 
antibiotics within the neonatal unit. One of the infants who developed NEC (N3) who was found to 
have the beta2 toxin gene present in his faecal sample had prior aminoglycoside use. Rapid screening 
for the presence of the beta2 toxin gene in infants with NEC may therefore be important if 
aminoglycoside antibiotic treatment is being considered. 
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Chapter 9 Discussion and future work 
In this chapter are summarised the main findings of the NeoM study, put into context with recently 
published literature on the faecal microbiota and NEC. The significance of the two microbial 
signatures identified in the study and possible mechanisms of action will be discussed and current and 
future research in these areas will be outlined. The potential clinical applications of findings from the 
NeoM study will be discussed highlighting the current limitations.  
 
The basis of the NeoM study was to use16S rRNA gene characterisation of longitudinal faecal 
samples collected from healthy premature infants and infants who developed NEC to identify faecal 
microbial signatures anticipating the disease. In order to ensure that the results obtained were robust, a 
substantial amount of validation of the methods was required prior to commencing the study. Each 
step of the study was examined: the impact of the time that faecal samples were left by the bedside of 
the infant (Section 3.2); the effect of storage of the faecal samples at -80oC (Section 3.2); the weight 
of faeces used for extraction (Section 3.3); the DNA extraction methods (Section 3.1); the primer set 
used (Chapter 4); and the ability of 454 pyrosequencing to faithfully represent a bacterial mixture 
(Section 3.4). A protocol for the collection and processing of the samples was produced based on 
these results. 
 
9.1 Summary of the NeoM cohort and main findings 
 
A two year cohort of 369 premature infants born at less than 32 weeks gestation was established, with 
almost every faecal sample produced by each participant from the point of recruitment (around the 
time of birth) until discharge/death collected, as well as detailed daily clinical information (Chapter 
5, Table 15). 
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Analysis of the 454 sequencing results revealed differences in the GI microbiota of healthy premature 
infants depending on their mode of delivery and postnatal age (Chapter 6, Figure 28). The diversity 
of faecal samples collected from these control infants was found to increase with increasing postnatal 
and gestational age (Chapter 6, Figure 24 and 25).  
 
Two different pre-morbid faecal microbial signatures were found to be associated with the 
development of NEC: 1) a bloom of C. perfringens (as identified by culture) and 2) persistently high 
levels of the Klebsiella OTU from around the time of birth until diagnosis. Contrary to what might 
have been expected based on current literature, these two ‘NEC subsets’ did not differ in their clinical 
phenotype.  
 
To characterise further the strains of C. perfringens that were isolated, toxin typing and fAFLP were 
performed. Interestingly, the beta2 toxin gene was found in three of the C.perfringens isolates from 
NEC infants but not in any isolates from control infants, and all isolates were found to be distinct on 
fAFLP (Section 8.2). Combining the detailed clinical information collected (Chapter 5, Table 15) 
with the sequencing data allowed identification of infants at increased risk of NEC between 5 and 12 
days prior to symptom onset (Section 7.9).  
 
9.2 Microbial signatures of NEC 
9.2.1 C. perfringens - mechanism of action in NEC 
 
C. perfringens is a known pathogen harbouring many toxins (see Section 8.1.1). Given that 
pneumatosis coli is found in infants with NEC, the pathogenesis may seem obvious - proliferation of 
C. perfringens and consequently the alpha toxin, resulting in destruction of the intestinal epithelium 
leading to the presence of gas in the bowel wall. Furthermore, the beta2 toxin may also play a role, 
causing widespread cytotoxicity. In vitro studies have revealed that the supernatant collected from 
cultures of C. perfringens can digest human intestinal epithelial cell tight junction proteins.135  
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There are however several questions that remain to be answered, particularly when one considers how 
ubiquitous C. perfringens is both in the environment and the adult GI tract.  
1)  Is C. perfringens commonly found in the GI microbiota of premature neonates?  
2)  When are they colonised and how?  
3)  Why do only some of the premature neonates who are colonised with high levels of C. 
perfringens develop NEC or gastrointestinal disease?  
The last of these questions is particularly pertinent as in the current study in two sets of twins 
discordant for NEC, all four infants had high levels of C. perfringens in their faecal microbiota 
(Chapter 6, Figure 34).  
 
9.2.2 Clostridia in preterm infants 
 
Ferraris et al.136 studied 76 premature neonates born at less than 36 weeks gestation from three 
different NICUs.  They collected weekly faecal samples from shortly after birth until discharge in 
order to characterise clostridial colonisation. They found that all of these infants, who were still in 
hospital at week seven of life were colonised with one or more Clostridium species. C. perfringens 
was the most common with 46.1% of the infants being colonised, followed by C. butyricum (44.7%), 
C. difficile (42.1%) and C. paraputrificum (22.4%). The most important factor in determining 
clostridial colonisation was NICU site. While antibiotic usage decreased the amount of Clostridium 
present in the sample, it did not have an effect on the incidence of colonisation. The authors did not 
find any association between method of delivery and clostridial colonisation. They suggested that 
infants acquire Clostridium from the NICU environment, especially as the percentage of infants that 
were colonised increased from 27.4% in the first week, to 100% by week 7 (although it is important to 
note that out of a total of 76 infants only 8 contributed to this data point). As Clostridia form spores 
and are difficult to eradicate from the environment, the hypothesis that the source of the Clostridium 
is the NICU environment is certainly plausible. Unfortunately, Ferraris et al. did not provide a 
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breakdown for the incidence of colonisation of the individual Clostridium species at each week of 
hospitalisation. 
 
In contrast to Ferraris et al. in the present study the presence of C. perfringens was found to be 
associated with C-section delivery in the controls (see Chapter 6, Figure 28). The abundance of the 
organism was found to increase with postnatal age, likely due to the change in the gut 
microenvironment to more anaerobic conditions thereby allowing Clostridia to thrive.  
 
Why however do only some premature infants who are colonised with high levels of C. perfringens in 
their faecal microbiota develop NEC? It may be that despite the presence of high level of C. 
perfringens, the other bacterial members of the GI microbiota (the community structure) are key in 
determining outcome. For example, in one of the twin pairs, Bifidobacterium constituted a major 
component of the faecal microbiota in the healthy twin (Chapter 6, Figure 34). Supernatant from a 
Bifidobacterium sp. has been shown to inhibit the growth of C. perfringens.137 Interestingly, 
Lactobacillus fermentum is able to silence C. perfringens beta2 toxin production without affecting 
bacterial viability.138 Another possibility is that it is the strain of C. perfringens with which an infant 
is colonised that is important. As discussed in Section 8.1.1, C. perfringens may contain a variety of 
toxins, and it may be a combination of these toxins that leads to disease development. 
 
9.2.3 C. perfringens – current and future work 
 
There are a number of interesting areas that are merit further investigation, some of which are 
currently being explored: 
 
Characterisation of the entire NeoM cohort with respect to the prevalence of C. perfringens. 
There is a paucity of data with regards to the prevalence of C. perfringens in premature infants. To 
address this, weekly faecal samples from every baby in the NeoM cohort, have been processed for 
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clostridial culture (as per Section 2.11.1), with 685 isolates recovered. Characterisation of all of these 
isolates will provide a picture in unprecedented detail of the prevalence of C. perfringens colonisation 
in premature infants, and also inform when colonisation occurs.  By combining the culture data with 
the extensive metadata it will be possible to study the influence of factors such as mode of delivery, 
type of feeds, postnatal age and antibiotics on C. perfringens colonisation.  
 
Toxin typing of C. perfringens isolates. A collaboration with Dr Ron Dixon at The University of 
Lincoln is in place.  Dr Dixon has extensive expertise with characterisation of C. perfringens in the 
context of isolates collected from poultry. His group is currently developing a novel ribotyping 
scheme and has designed an extended toxin panel to test isolates. Results from preliminary work 
carried out on a subset of the isolates already obtained and stored (from the culture of the weekly 
samples mentioned above) have revealed that a high percentage of the isolates possess multiple 
toxins. Many different toxins genes have been found to be present including cpb2, cpe, netB, pfoA and 
the recently described becA and becB. It may very well be the presence of these multiple toxins that is 
resulting in the development of NEC.  
 
Quantitative C. perfringens alpha and beta toxin PCR assay 
It is possible that there is a threshold quantity of C. perfringens required to cause NEC. A quantitative 
PCR assay has therefore been developed using the amount of 16S rRNA gene (see below section 
9.4.4) as a denominator, and the amount of alpha toxin gene (one copy present per C. perfringens 
genome) as the numerator. In addition a quantitative PCR assay for the beta2 toxin gene has been 
designed. While of course the results of the toxin gene assays do not provide information on gene 
expression, using the in-house C. perfringens qPCR assay and the DNA extracted from longitudinal 
faecal samples from infants who developed NEC, it will be possible to establish whether there is an 
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Whole genome sequencing and plasmid sequencing  
In order to look for differences between the strains from an infant with NEC and his matched control 
(twin pair), whole genome sequencing of two of the C. perfringens strains has been conducted and 
genomes are currently being assembled. Sequencing of further isolates from NEC and control infants 
is planned.  
 
9.2.4 ‘Klebsiella OTU-associated’ NEC 
 
The present study’s findings of high levels of Enterobacteriaceae in faecal samples prior to NEC 
diagnosis are consistent with other 16S rRNA gene-based NEC microbiota studies. In addition to the 
study by Wang et al. described in Section 1.7 who found an abundance of Gammaproteobacteria in 
faecal samples collected from NEC infants, Mai et al.139 also identified an increase in Proteobacteria 
in faecal samples from NEC infants in the week preceding diagnosis. Stewart et al.115 have reported 
an increase in faecal E. coli proportions in an infant who developed NEC, but not in the healthy 
control twin, and also found Enterobacter to be associated with NEC in a separate study of premature 
infants.140 A study conducted by Morrow et al.141 found two microbial signatures to be associated with 
NEC – one dominated by Firmicutes, with the other dominated by Proteobacteria. Torazza et al.,142 
analysing faecal samples collected in the first week of life, found a higher amount of Proteobacteria 
two weeks prior to NEC diagnosis and found a ‘novel signature sequence’ which the authors 
described as ‘distinct from but matching closest to Klebsiella pneumoniae’, associated with 
developing NEC later on. Claud et al.143 using a metagenomic approach to analyse faecal samples 
collected from a twin pair discordant for NEC showed that the majority of the differentially abundant 
genes in the NEC infant were associated with carbohydrate metabolism and could be related to the 
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9.2.5 The gastrointestinal microbiota and the host response 
 
Whilst there may be a clear mechanism for disease in the ‘Clostridium-associated’ NEC with the 
production of toxin and damage of the gut tissue, how might an Enterobacteriaceae-dominated 
microbiota lead to NEC? The answer may lie in interactions with Toll-like receptor 4 (TLR 4). 
 
Enterobacteriaceae are Gram-negative organisms and their cell walls contain abundant 
lipopolysaccharide (LPS), the ligand for TLR4. In a premature infant with high levels of TLR4 
expressed on gut tissues, a predominance of Enterobacteriaceae can lead to TLR4 over-activation 
(see Section 1.8). This potentiates disruption of the intestinal epithelium through apoptosis of 
enterocytes, and intestinal stem cells. The innate immune response activation coupled with a 
disintegrating intestinal epithelium potentiates systemic sepsis and NEC (Figure 40).  
 
 
Figure 40: Effects of TLR 4 over activation by LPS from Gram-negative bacteria. The binding of 
LPS to TLR 4 leads to both activation of the innate immune system as well destruction of the 
intestinal epithelium, leading to the development of NEC. Adapted from Hackam et al.144 
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Regulation of TLR 4 via TLR 9 
What prevents all premature infants from developing NEC, especially those who have a microbiota 
dominated by Gram-negative organisms? The extent of TLR 4 signalling in enterocytes is regulated 
by another important innate immune receptor, Toll-Like Receptor 9 (TLR 9). The ligand for TLR 9 is 
CpG DNA: DNA with a motif containing a ‘C – phosphate – G’ in the centre. Decreased expression 
of TLR 9 in humans, and TLR 9-knockout mice have been shown to have increased NEC severity.63 
 
Given the role of TLR 9 in modulating the TLR 4 response, Good et al.145 hypothesised that DNA 
extracted from a probiotic may confer protection against the development of NEC. The investigators 
first showed that live Lactobacillus rhamnosus HN001 prevented the development of NEC in both a 
well-established murine and porcine model of NEC. They then went on to demonstrate that the DNA 
extracted from these organisms reduced the severity of NEC in both animal models. Going one step 
further, Gribar et al.63 demonstrated that parenteral administration of CpG DNA to mice protected 
against the development of moderate to severe NEC. 
 
The CpG motif ‘GTCGTT’ has been found to be among the most potent for stimulating human TLR 
9.146 It is interesting to consider the prevalence of this motif in the genomes of different organisms 
(Table 22). The genomes of Lactobacillus and Bifidobacterium, both widely used probiotic agents, 
have a high density of this motif per Mb which may be anticipated to stimulate TLR 9, down-
regulating TLR 4. In comparison, C. perfringens has an extremely low motif frequency. It is possible 
that this is another mechanism that C. perfringens potentiates the development of NEC. In the context 
of a GI microbiota with a significant proportion of Gram-negative organisms, displacement of high 
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Table 22: Frequency of the GTCGTT motif by Mb for Bifidobacterium bifidum, Lactobacillus 
delbrueckii and C. perfringens. 
 
The frequency of the GTCGTT motif present in reference genomes taken from the National Center for 
Biotechnology Information147 for Bifidobacterium bifidum and Lactobacillus delbrueckii, and the 
genome sequence from a Clostridium perfringens strain isolated from a NeoM infant with NEC 
(Section 9.2.3) was determined using the grep command in the Linux command-line terminal, and 
normalised per Mb according to genome size. 
 
9.2.6 Enterobacteriaceae - future work 
 
Identification of Enterobacteriaceae: A metagenomic analysis of faecal samples from 11 NEC 
infants and their matched controls is currently ongoing. This includes six of the ‘Klebsiella OTU-
associated’ NEC infants. Metagenomic analysis will enable species level identification as well as the 
detection of any potential virulence genes. 
 
Identification of CpG frequency and other immuno-stimulatory CpG motifs: 
The metagenomic analysis will also enable the hypothesis to be tested that there is a difference in the 
abundance of CpG motifs in faecal samples collected from NEC infants compared to controls. It is 
anticipated that total faecal bacterial DNA from controls will have a higher abundance of CpG motifs. 
In calculating CpG frequency present in each faecal sample it will be important to perform 
normalisation based on the biomass of the sample (see below, Section 9.4.4). 
Organism Motif frequency per Mb 
Bifidobacterium bifidum BGN4 681 
Lactobacillus delbrueckii ATCC 11842  555 
Clostridium perfringens 22 
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The metagenomic data will additionally provide the opportunity for the identification of other 
potentially ‘protective’ CpG motifs present in high levels in the control samples compared to NEC 
samples. To perform this analysis, we are collaborating with the Genomics Research Group at Public 
Health England, who have created a software pipeline that identifies CpG motifs and their frequency 
from metagenomic data. In addition, an in vitro cell assay based on that developed by Gribar et al.63 is 
being established to test whether identified CpG motifs incorporated in synthetic oligonucleotides are 
able to negate the actions of TLR 4 activation through LPS. 
 
9.3 Clinical applications 
 
There are potentially both direct and indirect clinical applications of the results from the current study.  
 
9.3.1 Screening  
 
The current study has shown that it is possible to identify premature infants at high risk of NEC 5 to 
12 days preceding diagnosis based on the abundance of two OTUs – Clostridium (1) and Klebsiella, 
and the number of days of CPAP with supplemental oxygen required by the infant (Chapter 7). In 
order to identify infants at risk of NEC in a timely manner, faecal samples from infants thought to 
have a high background risk of NEC e.g. those born at less than 32 weeks gestation, could be 
routinely collected three times a week and constituent parts of the microbiota analysed. Whilst it is of 
course impractical to propose a full 16S rRNA gene survey of faecal samples, this is not required: a 
microarray chip containing key sequences, such as that used in the Identibac system,148 could be 
utilised. Another approach might be to perform a quantitative PCR of the 16S rRNA gene (to provide 
an estimate of biomass) as well as the C. perfringens alpha toxin, and an Enterobacteriaceae assay to 
assess the proportion of C. perfringens or Enterobacteriaceae present in a faecal sample. If the 
ongoing metagenomic study results in identification of a species associated with the ‘Klebsiella OTU’ 
  199  
then the assay could be even more focussed. DNA extraction is now automatable and can be carried 
out in ~ one to two hours, and clinical microbiology laboratories are already set up to carry out 
quantitative PCR assays. Results could therefore be returned to the clinician within approximately six 
hours, thereby playing an important, and timely, role in the clinical management of the infant. For 
example, infants deemed at high risk of NEC would then remain on donor milk as opposed to 
transitioning to formula milk, or infants showing early signs of NEC could be commenced on 
treatment for NEC immediately, using more targeted antibiotics. In infants where C. perfringens is 
found, targeted antibiotic therapy could be undertaken. A separate assay to identify the presence of the 
beta2 toxin gene could additionally be performed, and if present, administration of aminoglycosides 
should be avoided. 
 
9.3.2 Prevention of NEC using probiotics and CpG DNA 
 
From the current study it was interesting to note that the ‘Klebsiella OTU-associated’ NEC infants 
had an immature GI microbiota (Section 7.10). The corollary of this is that the relatively oxygen rich 
environment may affect the ability of anaerobes to thrive – including organisms such as 
bifidobacteria, commonly used as a probiotic agent.  
 
PiPS (Probiotics in Premature Infants Study)149 was a large multi-centred randomized controlled trial 
set in the UK testing the hypothesis that it might be possible to prevent NEC through the 
administration of Bifidobacterium breve BGG. 1,310 premature infants were recruited to the study. 
The recently published PiPS results were disappointing: no advantage was apparently conferred by 
administering the probiotic agent to the infants.149 One reason for the failure of the intervention may 
be the relatively hostile aerobic nature of the premature GI tract microenvironment. One possibility of 
enhancing the growth of anaerobic organisms may be to include a second microbe which utilises 
oxygen thereby ensuring a stable oxygen depleted environment.150 Such an approach is well 
established in the yoghurt industry. 
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Although administration of lactobacilli have also been used in an attempt to prevent NEC,151 there 
have been safety concerns, with reports of septicaemia caused by the same probiotic strain given to 
the infants.152 For this reason, probiotic formulations designed for premature infants more commonly 
contain bifidobacteria. 
 
Could CpG DNA be employed as a pharmaceutical agent to protect against NEC? Gribar et al.’s 
murine model (Section 9.2.5) required the DNA to be delivered parenterally, by intraperitoneal 
injection.63 Parenteral injection of free DNA in humans is out of the question (raising concerns 
whether it would induce autoimmunity and diseases such as systemic lupus erythematosus). A safe 
method of delivery of DNA will likely be to the mucosal surface directly, either as oligonucleotides, 
or as killed, or live, “probiotic” bacteria. In the last instance, replication of the bacteria ensures that 
there will be a constant supply of CpG DNA, and thus continual modulation of the immune response.  
 
9.4 Limitations of the study 
9.4.1 Infants developing NEC in the first week of life 
 
An important limitation of the present study is that babies who develop NEC in the first week or so of 
life were systematically less likely to have provided sequential samples for analysis, and were 
therefore underrepresented within the cohort. One could, however, speculate that NEC developing in 
these infants may be additionally influenced by some other complication of early extra-uterine life. Of 
note, case N19 who did not fit into either the ‘Clostridium-associated’ or ‘Klebsiella OTU-associated’ 
NEC groups, developed NEC on day eight of life.  
 
In the present study antenatal recruitment was originally attempted with the intention that samples 
from infants were collected directly after birth.  It transpired however that this type of recruitment was 
difficult to maintain with the staffing resources that were available, as there were many women who 
came to hospital suspected to be in premature labour but did not go onto deliver. In future studies, if 
  201  
ethically approved, faecal samples could be collected and stored, and consent obtained 
retrospectively. 
 
9.4.2 Identification of the viral and fungal components of the gastrointestinal microbiota 
 
The current study was focused on the bacterial component of the GI microbiota. There have been 
scattered reports however identifying viruses such as rotavirus to be associated with NEC.153 
Recently, there has been an interest in bacteriophages as they are thought to play an important role in 
regulating bacterial members. These are further areas that are currently being addressed (see below 
Section 9.5.1). 
 
9.4.3 Inheritance of the microbiota – from mother to baby 
 
It would of course have been desirable in the NeoM study to be able to compare the infant faecal 
microbiota to that of his/her mother, and also to analyse the maternal milk microbiome to ascertain the 
contribution of the mother’s microbiota to her offspring. Adding this arm to the study was deliberated 
at the outset, but decided against as it was anticipated that it would be a deterrent to mothers/parents 
agreeing to join a study for which near 100% recruitment was considered essential. For this reason 
ethical approval was obtained for collection of a groin surface swab of each infant, as a surrogate for 
the microbiota that the baby would have been exposed to in utero. The groin swab may also be 
considered to be more representative in the cases where a baby had been born by C-section. In the 
end, however, it proved difficult to collect these samples shortly after birth as invariably the infants 
required medical stabilisation which included insertion of invasive lines and associated skin cleansing.   
 
A sample of maternal expressed breast milk from the NeoM Study mothers was not requested as in 
the first days after delivery it can be difficult for a mother to express milk, and every drop has to be 
given to her baby. Non-culture studies based on 16S rRNA gene characterisation have shown that 
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some of the most predominant organisms in the milk microbiome are Staphylococcus and 
Streptococcus, organisms that are found to be those associated with the skin microbiota.154,155 Given 
the nature of how a mother expresses milk, these findings are likely to be due to contamination, 




An intrinsic limitation to the interpretation of 16S rRNA data generated from next-generation 
sequencing is that the results are effectively presented as proportions, due to the need for normalising 
the concentration of each amplicon to add to the sequencing library. This has implications for 
interpreting the results as even though an OTU may appear to be a substantial component, it may in 
fact  represent a small number of organisms overall. In cases where a specific pathogen may be 
responsible for a disease, and the bacterial burden is important in determining the severity of disease, 
then ascertaining the total biomass becomes crucial. One way to address this is to apply a quantitative 
real-time PCR assay based on the 16S rRNA gene to quantify the number of copies of the 16S rRNA 
gene present in a DNA sample.  The number of copies present can be adjusted to take into account the 
weight of the sample extracted, so that an estimate of bacteria per gram of faeces can be calculated. 
This however, is not without its own problems as there are different copy numbers of the 16S rRNA 
gene in different species (ranging from one to fifteen), and in some cases this may even vary within 
the same species.156  
 
Other research groups such as Palmer et al. have simply calculated the amount of bacteria per gram of 
faeces based on the average number of 16S rRNA genes found in bacteria – 4.2. It is possible to 
improve on this and get a more accurate estimate by inferring the number of 16S rRNA genes using 
programs such as PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of 
Unobserved States),157 which matches the target 16S rRNA gene fragment against a genome reference 
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database. Even more accurate of course would be to conduct a metagenomics study where true 
quantitation is feasible but the cost would be prohibitive when dealing with a substantial collection.  
 
 
9.5 Future work 
9.5.1 Viruses, fungi and bacteriophages 
 
The metagenomic analysis of 11 NEC infants and their matched controls currently ongoing (Section 
9.2.6) will allow us to establish, for these infants, their full GI microbiota - viral and fungal as well as 
bacterial components.  
 
A collaboration with Prof Wigneshweraraj at Imperial College London has also been established to 
trial the extraction of bacteriophages from several faecal samples and if successful the phages 
obtained will also undergo sequencing. 
 
9.5.2 The question of environment 
 
Ferraris et al. in their study of 76 premature neonates, suggested that the NICU environment was the 
original source of the Clostridium spp. in the baby’s faeces (Section 9.2.2).  In the NeoM study, if an 
infant was cared for in an incubator, weekly incubator swabs were collected with the view to using 
them to see if organisms could be detected on the incubator prior to their appearance in the infants’ 
faecal microbiota.   
 
Since completion of the work presented in this thesis, a small pilot study has been conducted 
sequencing DNA extracted from 36 incubator swabs. Only eleven samples generated sufficient and 
reliable sequencing data (>200 reads). Interestingly, the top seven OTUs were: Staphylococcus, 
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Enterobacteriaceae, Sphingomonadaceae, Ralstonia, Propionibacterium, Streptococcus and 
Corynebacterium. Clostridium was only one of the very minor OTUs. This is very much a small pilot 
study and a more extensive study characterising the full set of 947 incubator swab extracted DNAs is 
warranted in order to draw robust conclusions in relation to mode of transmission of the microbes. 
 
9.6 The role of bacteria in NEC  
 
While NEC cannot be classified as an infectious disease in the traditional sense (i.e. fulfilling Koch’s 
postulates), it is clear that bacteria do play a key role in its pathogenesis. The picture that has been 
emerging from the numerous recent non-culture GI microbiota studies in premature infants is that 
dysbiosis of the faecal microbiota precedes NEC diagnosis. Groups from countries around the world 
have described a predominance of Proteobacteria prior to symptom onset (Section 9.2.4), while others 
have implicated specific organisms such as Clostridia, or found a partition in the results similar to this 
study, where two microbial signatures were found. Reflecting this antecedent dysbiosis of the faecal 
microbiota, very recent studies analysing by mass spectrometry volatile organic components of faeces 
have shown that it is possible to discern a mass spectrometry signature identifying infants who are at 
risk of developing NEC two to three days before disease onset.13  
 
It is clear from the one and a half centuries of research, that no one organism can be labelled the 
‘cause of NEC’. What has become apparent is that the host has as important a role to play as the 
bacteria, and that when the two meet, a distorted microbiota combined with a vulnerable premature 
neonate with an over-exuberant immune response may lead to NEC. Studies such as NeoM which 
provide data and resources to help the scientific community to understand the contribution of the 
microbiota to NEC bring us one step forward towards preventing, or designing more specific 
treatment of, the disease by modulating or manipulating the microbiota to a more ‘healthy’ state 
through the use of probiotics, targeted antibiotics or even altering the gut microenvironment. 
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Appendix 1 
 
 Data collection sheets for infants recruited to the NeoM study 
o Admission proforma 
o Daily summary form 
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Appendix 2 
 
Golay barcodes used for 454 pyrosequencing 
  
  230  
Barcode sequence Barcode ID Barcode sequence Barcode ID AACGCACGCTAG 338R_bif1 ACTCGATTCGAT 338R_bif51 AACTCGTCGATG 338R_bif2 ACTCGCACAGGA 338R_bif52 AACTGTGCGTAC 338R_bif3 ACTCTTCTAGAG 338R_bif53 AAGAGATGTCGA 338R_bif4 ACTGACAGCCAT 338R_bif54 AAGCTGCAGTCG 338R_bif5 ACTGATCCTAGT 338R_bif55 AATCAGTCTCGT 338R_bif6 ACTGTACGCGTA 338R_bif56 AATCGTGACTCG 338R_bif7 ACTGTCGAAGCT 338R_bif57 ACACACTATGGC 338R_bif8 ACTGTGACTTCA 338R_bif58 ACACATGTCTAC 338R_bif9 ACTTGTAGCAGC 338R_bif59 ACACGAGCCACA 338R_bif10 AGAACACGTCTC 338R_bif60 ACACGGTGTCTA 338R_bif11 AGACCGTCAGAC 338R_bif61 ACACTAGATCCG 338R_bif12 AGACGTGCACTG 338R_bif62 ACACTGTTCATG 338R_bif13 AGACTGCGTACT 338R_bif63 ACAGACCACTCA 338R_bif14 AGAGAGCAAGTG 338R_bif64 ACAGAGTCGGCT 338R_bif15 AGAGCAAGAGCA 338R_bif65 ACAGCAGTGGTC 338R_bif16 AGAGTAGCTAAG 338R_bif66 ACAGCTAGCTTG 338R_bif17 AGAGTCCTGAGC 338R_bif67 ACAGTGCTTCAT 338R_bif18 AGATACACGCGC 338R_bif68 ACAGTTGCGCGA 338R_bif19 AGATCGGCTCGA 338R_bif69 ACATCACTTAGC 338R_bif20 AGATCTCTGCAT 338R_bif70 ACATGATCGTTC 338R_bif21 AGATGTTCTGCT 338R_bif71 ACATGTCACGTG 338R_bif22 AGCACACCTACA 338R_bif72 ACATTCAGCGCA 338R_bif23 AGCACGAGCCTA 338R_bif73 ACCACATACATC 338R_bif24 AGCAGCACTTGT 338R_bif74 ACCAGACGATGC 338R_bif25 AGCAGTCGCGAT 338R_bif75 ACCAGCGACTAG 338R_bif26 AGCATATGAGAG 338R_bif76 ACCGCAGAGTCA 338R_bif27 AGCCATACTGAC 338R_bif77 ACCTCGATCAGA 338R_bif28 AGCGACTGTGCA 338R_bif78 ACCTGTCTCTCT 338R_bif29 AGCGAGCTATCT 338R_bif79 ACGACGTCTTAG 338R_bif30 AGCGCTGATGTG 338R_bif80 ACGAGTGCTATC 338R_bif31 AGCGTAGGTCGT 338R_bif81 ACGATGCGACCA 338R_bif32 AGCTATCCACGA 338R_bif82 ACGCAACTGCTA 338R_bif33 AGCTCCATACAG 338R_bif83 ACGCGATACTGG 338R_bif34 AGCTCTCAGAGG 338R_bif84 ACGCGCAGATAC 338R_bif35 AGCTGACTAGTC 338R_bif85 ACGCTATCTGGA 338R_bif36 AGCTTGACAGCT 338R_bif86 ACGCTCATGGAT 338R_bif37 AGGACGCACTGT 338R_bif87 ACGGATCGTCAG 338R_bif38 AGGCTACACGAC 338R_bif88 ACGGTGAGTGTC 338R_bif39 AGGTGTGATCGC 338R_bif89 ACGTACTCAGTG 338R_bif40 AGTACGCTCGAG 338R_bif90 ACGTCTGTAGCA 338R_bif41 AGTACTGCAGGC 338R_bif91 ACGTGAGAGAAT 338R_bif42 AGTAGTATCCTC 338R_bif92 ACGTGCCGTAGA 338R_bif43 AGTCACATCACT 338R_bif93 ACGTTAGCACAC 338R_bif44 AGTCCATAGCTG 338R_bif94 ACTACAGCCTAT 338R_bif45 AGTCTACTCTGA 338R_bif95 ACTACGTGTGGT 338R_bif46 AGTCTCGCATAT 338R_bif96 ACTAGCTCCATA 338R_bif47 AGTGAGAGAAGC 338R_bif97 ACTATTGTCACG 338R_bif48 AGTGCGATGCGT 338R_bif98 ACTCACGGTATG 338R_bif49 AGTGGATGCTCT 338R_bif99 ACTCAGATACTC 338R_bif50 AGTGTCACGGTG 338R_bif100  
  231  
Barcode sequence Barcode ID Barcode sequence Barcode ID AGTGTTCGATCG 338R_bif101 CAAGTGAGAGAG 338R_bif151 AGTTAGTGCGTC 338R_bif102 CACACGTGAGCA 338R_bif152 AGTTCAGACGCT 338R_bif103 CACAGCTCGAAT 338R_bif153 AGTTCTACGTCA 338R_bif104 CACAGTGGACGT 338R_bif154 ATAATCTCGTCG 338R_bif105 CACATCTAACAC 338R_bif155 ATACACGTGGCG 338R_bif106 CACATTGTGAGC 338R_bif156 ATACAGAGCTCC 338R_bif107 CACGACAGGCTA 338R_bif157 ATACGTCTTCGA 338R_bif108 CACGGACTATAC 338R_bif158 ATACTATTGCGC 338R_bif109 CACGTCGATGGA 338R_bif159 ATACTCACTCAG 338R_bif110 CACGTGACATGT 338R_bif160 ATAGCTCCATAC 338R_bif111 CACTACTGTTGA 338R_bif161 ATAGGCGATCTC 338R_bif112 CACTCAACAGAC 338R_bif162 ATATCGCTACTG 338R_bif113 CACTCTGATTAG 338R_bif163 ATATGCCAGTGC 338R_bif114 CACTGGTATATC 338R_bif164 ATCACGTAGCGG 338R_bif115 CACTGTAGGACG 338R_bif165 ATCACTAGTCAC 338R_bif116 CAGACATTGCGT 338R_bif166 ATCAGGCGTGTG 338R_bif117 CAGACTCGCAGA 338R_bif167 ATCCGATCACAG 338R_bif118 CAGAGGAGCTCT 338R_bif168 ATCCTCAGTAGT 338R_bif119 CAGATACACTTC 338R_bif169 ATCGATCTGTGG 338R_bif120 CAGATCGGATCG 338R_bif170 ATCGCGGACGAT 338R_bif121 CAGCACTAAGCG 338R_bif171 ATCGCTCGAGGA 338R_bif122 CAGCATGTGTTG 338R_bif172 ATCGTACAACTC 338R_bif123 CAGCGGTGACAT 338R_bif173 ATCTACTACACG 338R_bif124 CAGCTAGAACGC 338R_bif174 ATCTCTGGCATA 338R_bif125 CAGGTGCTACTA 338R_bif175 ATCTGAGCTGGT 338R_bif126 CAGTACGATCTT 338R_bif176 ATCTGGTGCTAT 338R_bif127 CAGTCACTAACG 338R_bif177 ATCTTAGACTGC 338R_bif128 CAGTCGAAGCTG 338R_bif178 ATGACCATCGTG 338R_bif129 CAGTGATCCTAG 338R_bif179 ATGACTCATTCG 338R_bif130 CAGTGCATATGC 338R_bif180 ATGAGACTCCAC 338R_bif131 CAGTGTCAGGAC 338R_bif181 ATGATCGAGAGA 338R_bif132 CATACCAGTAGC 338R_bif182 ATGCACTGGCGA 338R_bif133 CATAGACGTTCG 338R_bif183 ATGCAGCTCAGT 338R_bif134 CATAGCGAGTTC 338R_bif184 ATGCCTGAGCAG 338R_bif135 CATATACTCGCA 338R_bif185 ATGCGTAGTGCG 338R_bif136 CATATCGCAGTT 338R_bif186 ATGGATACGCTC 338R_bif137 CATCAGCGTGTA 338R_bif187 ATGGCAGCTCTA 338R_bif138 CATCATGAGGCT 338R_bif188 ATGGCGTGCACA 338R_bif139 CATCGTATCAAC 338R_bif189 ATGGTCTACTAC 338R_bif140 CATCTGTAGCGA 338R_bif190 ATGTACGGCGAC 338R_bif141 CATGAGTGCTAC 338R_bif191 ATGTCACCGTGA 338R_bif142 CATGCAGACTGT 338R_bif192 ATGTGCACGACT 338R_bif143 CATGGCTACACA 338R_bif193 ATGTGTCGACTT 338R_bif144 CATGTAATGCTC 338R_bif194 ATTATCGTGCAC 338R_bif145 CATGTCTCTCCG 338R_bif195 ATTCTGTGAGCG 338R_bif146 CATTCGATGACT 338R_bif196 CAACACGCACGA 338R_bif147 CATTGTCTGTGA 338R_bif197 CAACTATCAGCT 338R_bif148 CCAGATGATCGT 338R_bif198 CAACTCATCGTA 338R_bif149 CCAGTGTATGCA 338R_bif199 CAAGATCGACTC 338R_bif150 CCATACATAGCT 338R_bif200  
  232  
Barcode sequence Barcode ID Barcode sequence Barcode ID CCGACTGAGATG 338R_bif201 CTACATCTAAGC 338R_bif251 CCGATGTCAGAT 338R_bif202 CTACGCGTCTCT 338R_bif252 CCTAGTACTGAT 338R_bif203 CTACTACAGGTG 338R_bif253 CCTCTCGTGATC 338R_bif204 CTACTGATATCG 338R_bif254 CGAAGACTGCTG 338R_bif205 CTAGAACGCACT 338R_bif255 CGAATCGACACT 338R_bif206 CTAGAGACTCTT 338R_bif256 CGACAGCTGACA 338R_bif207 CTAGCGAACATC 338R_bif257 CGACATGCTATT 338R_bif208 CTAGGTCACTAG 338R_bif258 CGACTTATGTGT 338R_bif209 CTAGTCAGCTGA 338R_bif259 CGAGAGTTACGC 338R_bif210 CTATAGTCGTGT 338R_bif260 CGAGCAGCACAT 338R_bif211 CTATCAGTGTAC 338R_bif261 CGAGGCTCAGTA 338R_bif212 CTATCTAGCGAG 338R_bif262 CGAGTCTAGTTG 338R_bif213 CTATGCTTGATG 338R_bif263 CGAGTTGTAGCG 338R_bif214 CTCAATGACTCA 338R_bif264 CGATAGATCTTC 338R_bif215 CTCAGTATGCAG 338R_bif265 CGATATTCATCG 338R_bif216 CTCATGTACAGT 338R_bif266 CGATCGAGTGTT 338R_bif217 CTCCACATGAGA 338R_bif267 CGATGCACCAGA 338R_bif218 CTCCTACTGTCT 338R_bif268 CGATGTCGTCAA 338R_bif219 CTCGAGAGTACG 338R_bif269 CGCACATGTTAT 338R_bif220 CTCGATTAGATC 338R_bif270 CGCACTCTAGAA 338R_bif221 CTCGCACATATA 338R_bif271 CGCAGACAGACT 338R_bif222 CTCGTGGAGTAG 338R_bif272 CGCAGCGGTATA 338R_bif223 CTCTCTACCTGT 338R_bif273 CGCATGAGGATC 338R_bif224 CTCTGAAGTCTA 338R_bif274 CGCGATAGCAGT 338R_bif225 CTCTGCTAGCCT 338R_bif275 CGCGTAACTGTA 338R_bif226 CTGAACGCTAGT 338R_bif276 CGCTAGAACGCA 338R_bif227 CTGACACGACAG 338R_bif277 CGCTTATCGAGA 338R_bif228 CTGAGATACGCG 338R_bif278 CGGAGTGTCTAT 338R_bif229 CTGAGCAGAGTC 338R_bif279 CGGCGATGTACA 338R_bif230 CTGCAGTACTTA 338R_bif280 CGTAAGTCTACT 338R_bif231 CTGCTGCGAAGA 338R_bif281 CGTACAGTTATC 338R_bif232 CTGGACTCATAG 338R_bif282 CGTACTAGACTG 338R_bif233 CTGGAGCATGAC 338R_bif283 CGTAGAACGTGC 338R_bif234 CTGGCTGTATGA 338R_bif284 CGTATCTGCGAA 338R_bif235 CTGTATCGTATG 338R_bif285 CGTATGCTGTAT 338R_bif236 CTGTCTCTCCTA 338R_bif286 CGTCAACGATGT 338R_bif237 CTGTGACATTGT 338R_bif287 CGTCACGACTAA 338R_bif238 CTGTGGATCGAT 338R_bif288 CGTCAGACGGAT 338R_bif239 CTGTTCGTAGAG 338R_bif289 CGTCGATCTCTC 338R_bif240 CTTAGCACATCA 338R_bif290 CGTGACAATGTC 338R_bif241 CTTGATGCGTAT 338R_bif291 CGTGATCTCTCC 338R_bif242 CTTGTGTCGATA 338R_bif292 CGTGCATTATCA 338R_bif243 GAACATGATGAG 338R_bif293 CGTGTACATCAG 338R_bif244 GAACTGTATCTC 338R_bif294 CGTGTGATCAGG 338R_bif245 GAAGAGTGATCA 338R_bif295 CGTTACTAGAGC 338R_bif246 GAAGCTACTGTC 338R_bif296 CGTTATGTACAC 338R_bif247 GAAGTCTCGCAT 338R_bif297 CGTTCGCATAGA 338R_bif248 GAATGATGAGTG 338R_bif298 CTAACGCAGTCA 338R_bif249 GACACTCGAATC 338R_bif299 CTACACAAGCAC 338R_bif250 GACAGCGTTGAC 338R_bif300  
  233  
Barcode sequence Barcode ID Barcode sequence Barcode ID GACAGGAGATAG 338R_bif301 GCACGACAACAC 338R_bif351 GACAGTTACTGC 338R_bif302 GCACTCGTTAGA 338R_bif352 GACATCGGCTAT 338R_bif303 GCACTGAGACGT 338R_bif353 GACCACTACGAT 338R_bif304 GCAGCACGTTGA 338R_bif354 GACCGAGCTATG 338R_bif305 GCAGCCGAGTAT 338R_bif355 GACGAGTCAGTC 338R_bif306 GCAGGATAGATA 338R_bif356 GACGATATCGCG 338R_bif307 GCAGGCAGTACT 338R_bif357 GACGCAGTAGCT 338R_bif308 GCAGTATCACTG 338R_bif358 GACGCTAGTTCA 338R_bif309 GCAGTTCATATC 338R_bif359 GACGTTGCACAG 338R_bif310 GCATAGTAGCCG 338R_bif360 GACTAACGTCAC 338R_bif311 GCATATAGTCTC 338R_bif361 GACTAGACCAGC 338R_bif312 GCATCGTCAACA 338R_bif362 GACTCACTCAAT 338R_bif313 GCATGTGCATGT 338R_bif363 GACTCGAATCGT 338R_bif314 GCATTGCGTGAG 338R_bif364 GACTGATCATCT 338R_bif315 GCCACTGATAGT 338R_bif365 GACTGCATCTTA 338R_bif316 GCCAGAGTCGTA 338R_bif366 GACTGTCATGCA 338R_bif317 GCCTATACTACA 338R_bif367 GACTTCAGTGTG 338R_bif318 GCGACTTGTGTA 338R_bif368 GAGAATACGTGA 338R_bif319 GCGAGATCCAGT 338R_bif369 GAGACAGCTTGC 338R_bif320 GCGATATATCGC 338R_bif370 GAGAGAATGATC 338R_bif321 GCGGATGTGACT 338R_bif371 GAGAGCTCTACG 338R_bif322 GCGTACAACTGT 338R_bif372 GAGATGCCGACT 338R_bif323 GCGTATCTTGAT 338R_bif373 GAGCAGATGCCT 338R_bif324 GCGTTACACACA 338R_bif374 GAGCATTCTCTA 338R_bif325 GCTAAGAGAGTA 338R_bif375 GAGCTGGCTGAT 338R_bif326 GCTAGATGCCAG 338R_bif376 GAGGCTCATCAT 338R_bif327 GCTAGTCTGAAC 338R_bif377 GAGTAGCTCGTG 338R_bif328 GCTATCACGAGT 338R_bif378 GAGTATGCAGCC 338R_bif329 GCTATTCGACAT 338R_bif379 GAGTCTGAGTCT 338R_bif330 GCTCAGTGCAGA 338R_bif380 GAGTGAGTACAA 338R_bif331 GCTCGCTACTTC 338R_bif381 GAGTGGTAGAGA 338R_bif332 GCTGATGAGCTG 338R_bif382 GATACGTCCTGA 338R_bif333 GCTGCTGCAATA 338R_bif383 GATAGCTGTCTT 338R_bif334 GCTGGTATCTGA 338R_bif384 GATAGTGCCACT 338R_bif335 GCTGTAGTATGC 338R_bif385 GATATGCGGCTG 338R_bif336 GCTGTGTAGGAC 338R_bif386 GATCAGAAGATG 338R_bif337 GCTTACATCGAG 338R_bif387 GATCCGACACTA 338R_bif338 GCTTCATAGTGT 338R_bif388 GATCGCAGGTGT 338R_bif339 GCTTGCGAGACA 338R_bif389 GATCGTCCAGAT 338R_bif340 GGACGTCACAGT 338R_bif390 GATCTATCCGAG 338R_bif341 GGATCGCAGATC 338R_bif391 GATCTCATAGGC 338R_bif342 GGCAGTGTATCG 338R_bif392 GATCTTCAGTAC 338R_bif343 GGCGACATGTAC 338R_bif393 GATGATCGCCGA 338R_bif344 GGCGTACTGATG 338R_bif394 GATGCATGACGC 338R_bif345 GGCTATGACATC 338R_bif395 GATGTCGTGTCA 338R_bif346 GGTATACGCAGC 338R_bif396 GATGTGAGCGCT 338R_bif347 GGTCACTGACAG 338R_bif397 GATTAGCACTCT 338R_bif348 GGTCGTAGCGTA 338R_bif398 GCAATAGCTGCT 338R_bif349 GGTGCGTGTATG 338R_bif399 GCACATCGAGCA 338R_bif350 GTACAAGAGTGA 338R_bif400  
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Barcode sequence Barcode ID Barcode sequence Barcode ID GTACGGCATACG 338R_bif401 TACACGATCTAC 338R_bif451 GTACTCTAGACT 338R_bif402 TACAGATGGCTC 338R_bif452 GTAGACTGCGTG 338R_bif403 TACAGTCTCATG 338R_bif453 GTAGAGCTGTTC 338R_bif404 TACATCACCACA 338R_bif454 GTAGATGCTTCG 338R_bif405 TACCGCTAGTAG 338R_bif455 GTAGCAACGTCT 338R_bif406 TACGATGACCAC 338R_bif456 GTAGCGCGAGTT 338R_bif407 TACGCGCTGAGA 338R_bif457 GTAGCTGACGCA 338R_bif408 TACGGTATGTCT 338R_bif458 GTAGTGTCTAGC 338R_bif409 TACGTGTACGTG 338R_bif459 GTATATCCGCAG 338R_bif410 TACTAATCTGCG 338R_bif460 GTATCCATGCGA 338R_bif411 TACTACATGGTC 338R_bif461 GTATGACTGGCT 338R_bif412 TACTGCGACAGT 338R_bif462 GTATGCGCTGTA 338R_bif413 TACTGGACGCGA 338R_bif463 GTATGTTGCTCA 338R_bif414 TACTTACTGCAG 338R_bif464 GTCAACGCGATG 338R_bif415 TACTTCGCTCGC 338R_bif465 GTCACGACTATT 338R_bif416 TAGACTGTACTC 338R_bif466 GTCATATCGTAC 338R_bif417 TAGAGAGAGTGG 338R_bif467 GTCATTCACGAG 338R_bif418 TAGATAGCAGGA 338R_bif468 GTCCATAGCTAG 338R_bif419 TAGATCCTCGAT 338R_bif469 GTCGACTCCTCT 338R_bif420 TAGCACACCTAT 338R_bif470 GTCGCTGTCTTC 338R_bif421 TAGCATCGTGGT 338R_bif471 GTCGTAGCCAGA 338R_bif422 TAGCCTCTCTGC 338R_bif472 GTCGTGTGTCAA 338R_bif423 TAGCGACATCTG 338R_bif473 GTCTACACACAT 338R_bif424 TAGCGGATCACG 338R_bif474 GTCTATCGGAGT 338R_bif425 TAGCTCGTAACT 338R_bif475 GTCTCATGTAGG 338R_bif426 TAGCTGAGTCCA 338R_bif476 GTCTCTCTACGC 338R_bif427 TAGGTATCTCAC 338R_bif477 GTCTGACAGTTG 338R_bif428 TAGTCGTCTAGT 338R_bif478 GTCTGGATAGCG 338R_bif429 TAGTGCTGCGTA 338R_bif479 GTCTTCGTCGCT 338R_bif430 TAGTGTGCTTCA 338R_bif480 GTGACCTGATGT 338R_bif431 TAGTTGCGAGTC 338R_bif481 GTGACTGCGGAT 338R_bif432 TATACGCGCATT 338R_bif482 GTGAGGTCGCTA 338R_bif433 TATCAGGTGTGC 338R_bif483 GTGATAGTGCCG 338R_bif434 TATCGCGCGATA 338R_bif484 GTGCAATCGACG 338R_bif435 TATCTCGAACTG 338R_bif485 GTGCACATTATC 338R_bif436 TATGCACCAGTG 338R_bif486 GTGGCGATACAC 338R_bif437 TATGCGAGGTCG 338R_bif487 GTGTACCTATCA 338R_bif438 TATGGCACACAC 338R_bif488 GTGTCTACATTG 338R_bif439 TATTCGTGTCAG 338R_bif489 GTGTGCTATCAG 338R_bif440 TCAACAGCATCG 338R_bif490 GTGTGTGTCAGG 338R_bif441 TCAATCTAGCGT 338R_bif491 GTGTTGCAGCAT 338R_bif442 TCACAGATCCGA 338R_bif492 GTTAGAGCACTC 338R_bif443 TCACGATTAGCG 338R_bif493 GTTCGCGTATAG 338R_bif444 TCACTATGGTCA 338R_bif494 GTTGACGACAGC 338R_bif445 TCACTGGCAGTA 338R_bif495 GTTGTATACTCG 338R_bif446 TCACTTCTCGCT 338R_bif496 TAACAGTCGCTG 338R_bif447 TCAGACAGACCG 338R_bif497 TAACTCTGATGC 338R_bif448 TCAGATCCGATG 338R_bif498 TAAGCGCAGCAC 338R_bif449 TCAGCCATGACA 338R_bif499 TACACACATGGC 338R_bif450 TCAGCTCAACTA 338R_bif500  
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Barcode sequence Barcode ID Barcode sequence Barcode ID TCAGGACTGTGT 338R_bif501 TGAGCACACACG 338R_bif551 TCAGTACGAGGC 338R_bif502 TGAGCGATTCTG 338R_bif552 TCAGTCGACGAG 338R_bif503 TGAGGATGATAG 338R_bif553 TCAGTGACGTAC 338R_bif504 TGAGTCACTGGT 338R_bif554 TCATCGCGATAT 338R_bif505 TGAGTTCGCTAT 338R_bif555 TCATCTGACTGA 338R_bif506 TGATAGTGAGGA 338R_bif556 TCATGGTACACT 338R_bif507 TGATCAGAAGAG 338R_bif557 TCCACGTCGTCT 338R_bif508 TGATGCTAACTC 338R_bif558 TCCAGTGCGAGA 338R_bif509 TGATGTGTGACC 338R_bif559 TCCGTCGTCTGT 338R_bif510 TGCAGAGCTCAG 338R_bif560 TCCTAGCAGTGA 338R_bif511 TGCATTACGCAT 338R_bif561 TCCTCTGTCGAC 338R_bif512 TGCGCGAATACT 338R_bif562 TCCTGAGATACG 338R_bif513 TGCGTATAGTGC 338R_bif563 TCGAATCACAGC 338R_bif514 TGCGTCAGTTAG 338R_bif564 TCGACTCCTCGT 338R_bif515 TGCGTGGTAGAC 338R_bif565 TCGAGACGCTTA 338R_bif516 TGCTACCATGAG 338R_bif566 TCGAGCGAATCT 338R_bif517 TGCTAGTCATAC 338R_bif567 TCGAGGACTGCA 338R_bif518 TGCTATATCTGG 338R_bif568 TCGATACTTGTG 338R_bif519 TGCTCAGTATGT 338R_bif569 TCGATGAACTCG 338R_bif520 TGCTCGTAGGAT 338R_bif570 TCGCATGAAGTC 338R_bif521 TGCTCTAGTGGA 338R_bif571 TCGCGTATTAGT 338R_bif522 TGCTGTGAGCTA 338R_bif572 TCGCTAGTGAGG 338R_bif523 TGGATATGCGCT 338R_bif573 TCGGCTACAGAG 338R_bif524 TGGCTCTACAGA 338R_bif574 TCGTACGTCATA 338R_bif525 TGGTCATCACTA 338R_bif575 TCGTCGATAATC 338R_bif526 TGTACACGGCGA 338R_bif576 TCGTGATGTGAC 338R_bif527 TCGTGTCTATAG 338R_bif528 TCGTTCACATGA 338R_bif529 TCTACGGAGAGC 338R_bif530 TCTACTCGTAAG 338R_bif531 TCTAGCGTAGTG 338R_bif532 TCTAGTTAGTCG 338R_bif533 TCTCACTAGGTA 338R_bif534 TCTCCGCATGTC 338R_bif535 TCTCGTAATCAG 338R_bif536 TCTCTAGAGCAT 338R_bif537 TCTCTCCGTCGA 338R_bif538 TCTGAGTCTGAG 338R_bif539 TCTGCGTACTAA 338R_bif540 TCTGCTAGATGT 338R_bif541 TCTGTTGCTCTC 338R_bif542 TCTTAGACGACG 338R_bif543 TGAACGCTAGCT 338R_bif544 TGACATCAGCGG 338R_bif545 TGACCATATCGT 338R_bif546 TGACGCGATGCA 338R_bif547 TGACGGACATCT 338R_bif548 TGAGACGTGCTT 338R_bif549 TGAGAGAGCATA 338R_bif550  
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Appendix 3 
 
 SILVA database sequence identifier for 16S rRNA sequences of Enterobacter aerogenes, 
Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, and 
Serratia marcescens. 
 Full alignment of 16S rRNA gene trimmed sequences from Enterobacter aerogenes, 
Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, and 
Serratia marcescens. 
 Matrix of percentage similarity between the sequences above. 
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Organism SILVA database sequence identifier  


























Enterobacter aerogenes AB244467.1.1462 
AB244436.1.1463 





SILVA database sequence identifier for 16S rRNA gene sequences of Enterobacter aerogenes, 
Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, and Serratia 
marcescens. 
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Escherichia_coli_2            CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGGUGCAAGCGUUAAUCGGAAUUACU Escherichia_coli_1            CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Escherichia_coli_3            CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Escherichia_OTU               CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Serratia_marcescens_1         CUAACUCCGUGCCAGCAGCCGUGGUAAUAGGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Serratia_marcescens_2         CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAACCACU Serratia_marcescens_4         CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Serratia_marcescens_5         CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Serratia_marcescens_3         CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUACAAGCGUUAAUCGGAAUUACU Escherichia_coli_4            CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Escherichia_coli_5            CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_oxytoca_1          CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_oxytoca_2          CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_oxytoca_3          CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_oxytoca_4          CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_oxytoca_5          CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Enterobacter_cloacae_1        CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Enterobacter_cloacae_2        CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Enterobacter_cloacae_3        CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Enterobacter_cloacae_4        CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Enterobacter_aerogenes_1      CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Enterobacter_cloacae_5        CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Enterobacter_aerogenes_2      CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Enterobacter_aerogenes_3      CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Enterobacter_aerogenes_4      CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Enterobacter_aerogenes_5      CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_pneumoniae_1       CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_pneumoniae_4       CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_pneumoniae_5       CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_OTU                -UAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_pneumoniae_2       CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU Klebsiella_pneumoniae_3       CUAACUCCGUGCCAGCAGCCGCGGUAAUACGGA-GGGUGCAAGCGUUAAUCGGAAUUACU                                ******************** ******* *** **** ****************  ***  Escherichia_coli_2            GGGCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCU Escherichia_coli_1            GGGCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCU Escherichia_coli_3            GGGCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCU Escherichia_OTU               GGGCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCU Serratia_marcescens_1         GGGUGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCSCGGGCUCAACCU Serratia_marcescens_2         GGGCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCU Serratia_marcescens_4         GGGCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCU Serratia_marcescens_5         GGGCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCU Serratia_marcescens_3         GGGCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCU Escherichia_coli_4            GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Escherichia_coli_5            GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_oxytoca_1          GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_oxytoca_2          GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_oxytoca_3          GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_oxytoca_4          GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_oxytoca_5          GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Enterobacter_cloacae_1        GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Enterobacter_cloacae_2        GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Enterobacter_cloacae_3        GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Enterobacter_cloacae_4        GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Enterobacter_aerogenes_1      GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Enterobacter_cloacae_5        GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Enterobacter_aerogenes_2      GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Enterobacter_aerogenes_3      GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Enterobacter_aerogenes_4      GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Enterobacter_aerogenes_5      GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_pneumoniae_1       GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_pneumoniae_4       GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_pneumoniae_5       GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_OTU                GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_pneumoniae_2       GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU Klebsiella_pneumoniae_3       GGGCGUAAAGCGCACGCAGGCGGUCUGUCAAGUCGGAUGUGAAAUCCCCGGGCUCAACCU                               *** ******************** *** ***** ************ ************  Escherichia_coli_2            GGGAA-CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGU Escherichia_coli_1            GGGAA-CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGU Escherichia_coli_3            GGGAA-CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGU Escherichia_OTU               GGGAA-CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGA-GGGGGUAGAAUUCCAGGU Serratia_marcescens_1         GGGAAUCUGCAUUUGAAACUGGCAAGCUAGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGU Serratia_marcescens_2         GGGAA-CUGCAUUUGAAACUGGCAAGCUAGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGU Serratia_marcescens_4         GGGAA-CUGCAUUUGAAACUGGCAAGCUAGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGU Serratia_marcescens_5         GGGAA-CUGCAUUUGAAACUGGCAAGCUAGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGU Serratia_marcescens_3         GGGAA-CUGCAUUUGAAACUGGCAAGCUAGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGU 
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Escherichia_coli_4            GGGAA-CUGCAUUCGAAACUGGCAGGCUUGAGUCUCGUAGAGGGGGGGGGAAUUCCAGGU Escherichia_coli_5            GGGAA-CUGCAUUCGAAACUGGCAGGCUUGAGUCUCGUAGAGGGGGGUGGAAUUCCAGGU Klebsiella_oxytoca_1          GGGAA-CUGCAUUCGAAACUGGCAGGCUGGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Klebsiella_oxytoca_2          GGGAA-CUGCAUUCGAAACUGGCAGGCUGGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Klebsiella_oxytoca_3          GGGAA-CUGCAUUCGAAACUGGCAGGCUGGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Klebsiella_oxytoca_4          GGGAA-CUGCAUUCGAAACUGGCAGGCUGGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Klebsiella_oxytoca_5          GGGAA-CUGCAUUCGAAACUGGCAGGCUGGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Enterobacter_cloacae_1        GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Enterobacter_cloacae_2        GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Enterobacter_cloacae_3        GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Enterobacter_cloacae_4        GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Enterobacter_aerogenes_1      GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Enterobacter_cloacae_5        GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Enterobacter_aerogenes_2      GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Enterobacter_aerogenes_3      GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Enterobacter_aerogenes_4      GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Enterobacter_aerogenes_5      GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Klebsiella_pneumoniae_1       GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Klebsiella_pneumoniae_4       GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Klebsiella_pneumoniae_5       GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Klebsiella_OTU                GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGA-GGGGGUAGAAUUCCAGGU Klebsiella_pneumoniae_2       GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU Klebsiella_pneumoniae_3       GGGAA-CUGCAUUCGAAACUGGCAGGCUAGAGUCUUGUAGAGGGGGGUAGAAUUCCAGGU                               ***** ******  ** ******* *** ****** ***** *****  ***********  Escherichia_coli_2            GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Escherichia_coli_1            GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Escherichia_coli_3            GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Escherichia_OTU               GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGG-CCCCUGGAC Serratia_marcescens_1         GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Serratia_marcescens_2         GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Serratia_marcescens_4         GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Serratia_marcescens_5         GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Serratia_marcescens_3         GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Escherichia_coli_4            GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Escherichia_coli_5            GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_oxytoca_1          GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_oxytoca_2          GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_oxytoca_3          GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_oxytoca_4          GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_oxytoca_5          GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Enterobacter_cloacae_1        GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Enterobacter_cloacae_2        GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Enterobacter_cloacae_3        GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Enterobacter_cloacae_4        GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Enterobacter_aerogenes_1      GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Enterobacter_cloacae_5        GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Enterobacter_aerogenes_2      GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Enterobacter_aerogenes_3      GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Enterobacter_aerogenes_4      GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Enterobacter_aerogenes_5      GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_pneumoniae_1       GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_pneumoniae_4       GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_pneumoniae_5       GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_OTU                GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_pneumoniae_2       GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC Klebsiella_pneumoniae_3       GUAGCGGUGAAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGAC                               ************************************************** *********  Escherichia_coli_2            GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Escherichia_coli_1            GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Escherichia_coli_3            GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Escherichia_OTU               GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Serratia_marcescens_1         GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Serratia_marcescens_2         GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Serratia_marcescens_4         GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Serratia_marcescens_5         GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Serratia_marcescens_3         GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Escherichia_coli_4            GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Escherichia_coli_5            GAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_oxytoca_1          AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_oxytoca_2          AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_oxytoca_3          AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_oxytoca_4          AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_oxytoca_5          AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Enterobacter_cloacae_1        AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Enterobacter_cloacae_2        AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU 
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Enterobacter_cloacae_3        AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Enterobacter_cloacae_4        AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Enterobacter_aerogenes_1      AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Enterobacter_cloacae_5        AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Enterobacter_aerogenes_2      AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Enterobacter_aerogenes_3      AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Enterobacter_aerogenes_4      AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Enterobacter_aerogenes_5      AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_pneumoniae_1       AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_pneumoniae_4       AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_pneumoniae_5       AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_OTU                AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_pneumoniae_2       AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU Klebsiella_pneumoniae_3       AAAGACUGACGCUCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGU                                ***********************************************************  Escherichia_coli_2            CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Escherichia_coli_1            CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Escherichia_coli_3            CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Escherichia_OTU               CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Serratia_marcescens_1         CCACGCUGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Serratia_marcescens_2         CCACGCUGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Serratia_marcescens_4         CCACGCUGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Serratia_marcescens_5         CCACGCUGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Serratia_marcescens_3         CCACGCUGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Escherichia_coli_4            CCACGCCGUAAACGAUGUCUACUUGGAGGUUGUGCCCCUGAGGCGUGGCUUCCGGAGCUA Escherichia_coli_5            CCACGCCGUAAACGAUGUCUACUUGGAGGUUGUGCCCCUGAGGCGUGGCUUCCGGAGCUA Klebsiella_oxytoca_1          CCACGCUGUAAACGAUGUCGACUUGGAGGUUGUUCCCUUGAGGAGUGGCUUCCGGAGCUA Klebsiella_oxytoca_2          CCACGCUGUAAACGAUGUCGACUUGGAGGUUGUUCCCUUGAGGAGUGGCUUCCGGAGCUA Klebsiella_oxytoca_3          CCACGCUGUAAACGAUGUCGACUUGGAGGUUGUUCCCUUGAGGAGUGGCUUCCGGAGCUA Klebsiella_oxytoca_4          CCACGCUGUAAACGAUGUCGACUUGGAGGUUGUUCCCUUGAGGAGUGGCUUCCGGAGCUA Klebsiella_oxytoca_5          CCACGCUGUAAACGAUGUCGACUUGGAGGUUGUUCCCUUGAGGAGUGGCUUCCGGAGCUA Enterobacter_cloacae_1        CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Enterobacter_cloacae_2        CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Enterobacter_cloacae_3        CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Enterobacter_cloacae_4        CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Enterobacter_aerogenes_1      CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Enterobacter_cloacae_5        CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Enterobacter_aerogenes_2      CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Enterobacter_aerogenes_3      CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Enterobacter_aerogenes_4      CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Enterobacter_aerogenes_5      CCACGCCGUAAACGAUGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Klebsiella_pneumoniae_1       CCACGCCGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Klebsiella_pneumoniae_4       CCACGCCGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Klebsiella_pneumoniae_5       CCACGCCGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Klebsiella_OTU                CCACGCCGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Klebsiella_pneumoniae_2       CCACGCUGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA Klebsiella_pneumoniae_3       CCACGCUGUAAACGAUGUCGAUUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUA                               ****** ************ * *********** *** ***** ****************  Escherichia_coli_2            ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Escherichia_coli_1            ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Escherichia_coli_3            ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Escherichia_OTU               ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Serratia_marcescens_1         ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Serratia_marcescens_2         ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Serratia_marcescens_4         ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Serratia_marcescens_5         ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Serratia_marcescens_3         ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Escherichia_coli_4            ACGCGUUAAGUAGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Escherichia_coli_5            ACGCGUUAAGUAGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Klebsiella_oxytoca_1          ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Klebsiella_oxytoca_2          ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Klebsiella_oxytoca_3          ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Klebsiella_oxytoca_4          ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Klebsiella_oxytoca_5          ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Enterobacter_cloacae_1        ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Enterobacter_cloacae_2        ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Enterobacter_cloacae_3        ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Enterobacter_cloacae_4        ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Enterobacter_aerogenes_1      ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Enterobacter_cloacae_5        ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Enterobacter_aerogenes_2      ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Enterobacter_aerogenes_3      ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Enterobacter_aerogenes_4      ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Enterobacter_aerogenes_5      ACGCGUUAAGUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Klebsiella_pneumoniae_1       ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA 
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Klebsiella_pneumoniae_4       ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Klebsiella_pneumoniae_5       ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Klebsiella_OTU                ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Klebsiella_pneumoniae_2       ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA Klebsiella_pneumoniae_3       ACGCGUUAAAUCGACCGCCUGGGGAGUACGGCCGCAAGGUUAAA                               ********* * ********************************  
Full sequence alignment of the V3-V5 regions of five 16S rRNA sequences from the organisms: 
Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella 
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Appendix 4 
 
Tables listing the top 50 OTUs for sequencing data derived from: 
1) Faecal samples from all NEC (Bell Stage 1, 2 and 3) and control infants 
2) Faecal samples from all control infants 
3) Faecal samples from all NEC infants (Bell Stage 1, 2 and 3) 
4) Gut tissue specimens/intestinal luminal contents 
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Rank OTU label as designated by QIIME % of reads OTU descriptor used in thesis 
1 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Klebsiella; s__Klebsiella_pneumoniae 49.50 Klebsiella 
2 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Escherichia-shigella; s__Escherichia_coli 11.62 Escherichia 
3 p__Firmicutes; c__Bacilli; o__Bacillales; f__Staphylococcaceae; g__Staphylococcus 11.45 Staphylococcus (1) 
4 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Enterococcaceae; g__Enterococcus 6.99 Enterococcus 
5 p__Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; g__Bifidobacterium; s__Uncultured_bacterium 4.72 Bifidobacterium 
6 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Incertae_sedis; s__Clostridium_perfringens_cpe_str._f4969 3.62 Clostridium (1) 
7 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__Uncultured_bacterium 2.30 Veillonella 
8 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__Clostridium_butyricum 1.26 Clostridium (2) 
9 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus 1.01 Streptococcus (1) 
10 p__Actinobacteria; c__Actinobacteria; o__Propionibacteriales; f__Propionibacteriaceae; g__Propionibacterium; s__Propionibacterium_avidum 0.72 Propionibacterium 
11 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__Streptococcus_agalactiae 0.68 Streptococcus (2) 
12 p__Proteobacteria; c__Gammaproteobacteria; o__Pseudomonadales; f__Moraxellaceae; g__Acinetobacter; s__Acinetobacter_baumannii 0.64 Acinetobacter 
13 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__Uncultured_streptococcus_sp. 0.60   
14 p__Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; g__Haemophilus; s__Uncultured_bacterium 0.56 Haemophilus 
15 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Proteus; s__Proteus_mirabilis 0.41 Proteus 
16 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__Uncultured_bacterium 0.41 Bacteroides 
17 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Anaerococcus; s__Anaerococcus_vaginalis_atcc_51170 0.36 Anaerococcus 
18 p__Proteobacteria; c__Gammaproteobacteria; o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__Pseudomonas_aeruginosa 0.33   
19 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__Uncultured_organism 0.27   
20 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Incertae_sedis; s__Uncultured_organism 0.25 Incertae sedis (1) 
21 p__Proteobacteria; c__Betaproteobacteria; o__Burkholderiales; f__Burkholderiaceae; g__Ralstonia; s__Uncultured_bacterium 0.19 Ralstonia 
22 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides 0.19   
23 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Peptostreptococcaceae; g__Peptostreptococcus; s__Uncultured_bacterium 0.15   
24 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Finegoldia; s__Uncultured_bacterium 0.13   
25 p__Proteobacteria; c__Gammaproteobacteria; o__Xanthomonadales; f__Xanthomonadaceae; g__Stenotrophomonas 0.12   
26 p__Actinobacteria; c__Actinobacteria; o__Corynebacteriales; f__Corynebacteriaceae; g__Corynebacterium 0.11   
27 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Peptostreptococcaceae; g__Incertae_sedis 0.11 Incertae sedis (2) 
28 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__Uncultured_bacterium 0.11   
29 p__Proteobacteria; c__Betaproteobacteria; o__Burkholderiales; f__Oxalobacteraceae; g__Undibacterium 0.10   
30 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__Uncultured_bacterium 0.10   
31 p__Actinobacteria; c__Actinobacteria; o__Corynebacteriales; f__Corynebacteriaceae; g__Corynebacterium 0.10   
32 p__Proteobacteria; c__Alphaproteobacteria; o__Rhizobiales; f__Bradyrhizobiaceae; g__Bradyrhizobium 0.08   
33 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Prevotellaceae; g__Prevotella 0.06   
34 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Lactobacillaceae; g__Lactobacillus; s__Uncultured_compost_bacterium 0.06   
35 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium 0.06 Clostridium (3) 
36 p__Actinobacteria; c__Actinobacteria; o__Actinomycetales; f__Actinomycetaceae; g__Actinomyces 0.05   
37 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Peptoniphilus; s__Uncultured_bacterium 0.05   
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38 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia 0.05   
39 p__Firmicutes; c__Bacilli; o__Bacillales; f__Staphylococcaceae; g__Staphylococcus 0.05   
40 p__Fusobacteria; c__Fusobacteria; o__Fusobacteriales; f__Fusobacteriaceae; g__Fusobacterium; s__Uncultured_bacterium 0.04   
41 p__Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; g__Haemophilus 0.04   
42 p__Actinobacteria; c__Actinobacteria; o__Micrococcales; f__Dermabacteraceae; g__Dermabacter; s__Uncultured_bacterium 0.04   
43 p__Actinobacteria; c__Actinobacteria; o__Micrococcales; f__Brevibacteriaceae; g__Brevibacterium 0.03   
44 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Porphyromonadaceae; g__Parabacteroides; s__Parabacteroides_distasonis 0.02   
45 p__Proteobacteria; c__Gammaproteobacteria; o__Pseudomonadales; f__Moraxellaceae; g__Uncultured; s__Photorhabdus_luminescens 0.02   
46 p__Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; g__Haemophilus 0.02   
47 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Negativicoccus; s__Negativicoccus_succinicivorans 0.02   
48 p__Firmicutes; c__Clostridia; o__Clostridiales 0.01   
49 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Anaerococcus; s__Uncultured_bacterium 0.01   
50 p__Actinobacteria; c__Actinobacteria; o__Actinomycetales; f__Actinomycetaceae; g__Actinomyces 0.01    
OTU table listing top 50 OTUs (accounting for 99.84% of sequencing reads) derived from faecal 
samples from control and NEC infants. 
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Rank OTU label as designated by QIIME % of reads OTU descriptor used in thesis 
1 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Klebsiella; s__Klebsiella_pneumoniae 47.96 Klebsiella 
2 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Escherichia-shigella; s__Escherichia_coli 11.70 Escherichia 
3 p__Firmicutes; c__Bacilli; o__Bacillales; f__Staphylococcaceae; g__Staphylococcus 10.54 Staphylococcus (1) 
4 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Enterococcaceae; g__Enterococcus 7.27 Enterococcus  
5 p__Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; g__Bifidobacterium; s__Uncultured_bacterium 6.37 Bifidobacterium 
6 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Incertae_sedis; s__Clostridium_perfringens_cpe_str._f4969 3.77 Clostridium (1) 
7 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__Uncultured_bacterium 2.44 Veillonella 
8 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__Clostridium_butyricum 2.09 Clostridium (2) 
9 p__Proteobacteria; c__Gammaproteobacteria; o__Pseudomonadales; f__Moraxellaceae; g__Acinetobacter; s__Acinetobacter_baumannii 1.01 Acinetobacter 
10 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__Uncultured_bacterium 0.67 Bacteroides 
11 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__Uncultured_streptococcus_sp. 0.66   
12 p__Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; g__Haemophilus; s__Uncultured_bacterium 0.54 Haemophilus 
13 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__Streptococcus_agalactiae 0.46 Streptococcus (2) 
14 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Incertae_sedis; s__Uncultured_organism 0.42 Incertae sedis (1) 
15 p__Actinobacteria; c__Actinobacteria; o__Propionibacteriales; f__Propionibacteriaceae; g__Propionibacterium; s__Propionibacterium_avidum 0.39 Propionibacterium 
16 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Proteus; s__Proteus_mirabilis 0.37 Proteus 
17 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides 0.31   
18 p__Proteobacteria; c__Betaproteobacteria; o__Burkholderiales; f__Burkholderiaceae; g__Ralstonia; s__Uncultured_bacterium 0.31 Ralstonia 
19 p__Proteobacteria; c__Gammaproteobacteria; o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__Pseudomonas_aeruginosa 0.30   
20 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__Uncultured_organism 0.20   
21 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Finegoldia; s__Uncultured_bacterium 0.20   
22 p__Actinobacteria; c__Actinobacteria; o__Corynebacteriales; f__Corynebacteriaceae; g__Corynebacterium 0.17   
23 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__Uncultured_bacterium 0.17   
24 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Peptostreptococcaceae; g__Incertae_sedis 0.16 Incertae sedis (2) 
25 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Peptostreptococcaceae; g__Peptostreptococcus; s__Uncultured_bacterium 0.14   
26 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus 0.14 Streptococcus (1) 
27 p__Actinobacteria; c__Actinobacteria; o__Corynebacteriales; f__Corynebacteriaceae; g__Corynebacterium 0.11   
28 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Prevotellaceae; g__Prevotella 0.10   
29 p__Proteobacteria; c__Betaproteobacteria; o__Burkholderiales; f__Oxalobacteraceae; g__Undibacterium 0.10   
30 p__Actinobacteria; c__Actinobacteria; o__Actinomycetales; f__Actinomycetaceae; g__Actinomyces 0.09   
31 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Peptoniphilus; s__Uncultured_bacterium 0.09   
32 p__Proteobacteria; c__Alphaproteobacteria; o__Rhizobiales; f__Bradyrhizobiaceae; g__Bradyrhizobium 0.09   
33 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia 0.09   
34 p__Firmicutes; c__Bacilli; o__Bacillales; f__Staphylococcaceae; g__Staphylococcus 0.06   
35 p__Actinobacteria; c__Actinobacteria; o__Micrococcales; f__Brevibacteriaceae; g__Brevibacterium 0.06   
36 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium 0.05 Clostridium (3) 
37 p__Actinobacteria; c__Actinobacteria; o__Micrococcales; f__Dermabacteraceae; g__Dermabacter; s__Uncultured_bacterium 0.05   
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38 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Anaerococcus; s__Anaerococcus_vaginalis_atcc_51170 0.04 Anaerococcus 
39 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Porphyromonadaceae; g__Parabacteroides; s__Parabacteroides_distasonis 0.04   
40 p__Fusobacteria; c__Fusobacteria; o__Fusobacteriales; f__Fusobacteriaceae; g__Fusobacterium; s__Uncultured_bacterium 0.02   
41 p__Proteobacteria; c__Gammaproteobacteria; o__Pseudomonadales; f__Moraxellaceae; g__Uncultured; s__Photorhabdus_luminescens 0.02   
42 p__Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; g__Haemophilus 0.02   
43 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Negativicoccus; s__Negativicoccus_succinicivorans 0.02   
44 p__Firmicutes; c__Clostridia; o__Clostridiales 0.02   
45 p__Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; g__Haemophilus 0.02   
46 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__Uncultured_bacterium 0.02   
47 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Lactobacillaceae; g__Lactobacillus 0.01   
48 p__Proteobacteria; c__Gammaproteobacteria; o__Xanthomonadales; f__Xanthomonadaceae; g__Stenotrophomonas 0.01   
49 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Porphyromonadaceae; g__Parabacteroides 0.01   
50 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Anaerococcus; s__Uncultured_anaerococcus_sp. 0.01   
51 p__Fusobacteria; c__Fusobacteria; o__Fusobacteriales; f__Leptotrichiaceae; g__Sneathia; s__Uncultured_bacterium 0.01    
OTU table listing top 50 OTUs (accounting for 99.88% of sequencing reads) derived from faecal 
samples collected from control infants.  
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Rank OTU label as designated by QIIME % of reads OTU descriptor used in thesis 
1 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Klebsiella; s__Klebsiella_pneumoniae 56.71 Klebsiella 
2 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Escherichia-shigella; s__Escherichia_coli 10.81 Escherichia 
3 p__Firmicutes; c__Bacilli; o__Bacillales; f__Staphylococcaceae; g__Staphylococcus 7.80 Stahylococcus (1) 
4 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Enterococcaceae; g__Enterococcus 7.39 Enterococcus 
5 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Incertae_sedis; s__Clostridium_perfringens_cpe_str._f4969 3.09 Clostridium (1) 
6 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus 2.61 Streptococcus (1) 
7 p__Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; g__Bifidobacterium; s__Uncultured_bacterium 2.49 Bifidobacterium 
8 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__Uncultured_bacterium 2.36 Veillonella 
9 p__Actinobacteria; c__Actinobacteria; o__Propionibacteriales; f__Propionibacteriaceae; g__Propionibacterium; s__Propionibacterium_avidum 1.11 Propionibacterium 
10 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Anaerococcus; s__Anaerococcus_vaginalis_atcc_51170 0.95 Anaerococcus 
11 p__Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; g__Haemophilus; s__Uncultured_bacterium 0.59 Haemophilus 
12 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__Uncultured_streptococcus_sp. 0.56 
13 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Proteus; s__Proteus_mirabilis 0.53 Proteus 
14 p__Proteobacteria; c__Gammaproteobacteria; o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__Pseudomonas_aeruginosa 0.43 
15 p__Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__Uncultured_organism 0.43 Bacteroides 
16 p__Proteobacteria; c__Gammaproteobacteria; o__Xanthomonadales; f__Xanthomonadaceae; g__Stenotrophomonas 0.33 
17 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__Uncultured_bacterium 0.27 
18 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__Streptococcus_agalactiae 0.25 Streptococcus (2) 
19 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Peptostreptococcaceae; g__Peptostreptococcus; s__Uncultured_bacterium 0.19 
20 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Lactobacillaceae; g__Lactobacillus; s__Uncultured_compost_bacterium 0.17 
21 p__Proteobacteria; c__Betaproteobacteria; o__Burkholderiales; f__Oxalobacteraceae; g__Undibacterium 0.11 
22 p__Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; g__Haemophilus 0.09 Haemophilus 
23 p__Proteobacteria; c__Alphaproteobacteria; o__Rhizobiales; f__Bradyrhizobiaceae; g__Bradyrhizobium 0.09 
24 p__Fusobacteria; c__Fusobacteria; o__Fusobacteriales; f__Fusobacteriaceae; g__Fusobacterium; s__Uncultured_bacterium 0.09 
25 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium 0.07 Clostridium (3) 
26 p__Firmicutes; c__Bacilli; o__Bacillales; f__Staphylococcaceae; g__Staphylococcus 0.04 
27 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Peptostreptococcaceae; g__Incertae_sedis 0.04 Incertae sedis (1) 
28 p__Proteobacteria; c__Gammaproteobacteria; o__Pseudomonadales; f__Moraxellaceae; g__Acinetobacter; s__Acinetobacter_baumannii 0.03 Acinetobacter 
29 p__Actinobacteria; c__Actinobacteria; o__Corynebacteriales; f__Corynebacteriaceae; g__Corynebacterium 0.03 
30 p__Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; g__Haemophilus 0.03 
31 p__Actinobacteria; c__Actinobacteria; o__Actinomycetales; f__Actinomycetaceae; g__Actinomyces 0.03 
32 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Finegoldia; s__Uncultured_bacterium 0.02 
33 p__Actinobacteria; c__Actinobacteria; o__Micrococcales; f__Dermabacteraceae; g__Dermabacter; s__Uncultured_bacterium 0.02 
34 p__Actinobacteria; c__Actinobacteria; o__Corynebacteriales; f__Corynebacteriaceae; g__Corynebacterium 0.02 
35 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Family_xi_incertae_sedis; g__Anaerococcus; s__Uncultured_bacterium 0.02 
36 p__Actinobacteria; c__Actinobacteria; o__Actinomycetales; f__Actinomycetaceae; g__Varibaculum 0.02 
37 p__Proteobacteria; c__Betaproteobacteria; o__Burkholderiales; f__Alcaligenaceae; 0.02 
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g__Achromobacter; s__Achromobacter_xylosoxidans 
38 p__Proteobacteria; c__Betaproteobacteria; o__Burkholderiales; f__Burkholderiaceae; g__Ralstonia; s__Uncultured_bacterium 0.02 Ralstonia 
39 p__Proteobacteria; c__Gammaproteobacteria; o__Pseudomonadales; f__Moraxellaceae; g__Uncultured; s__Photorhabdus_luminescens 0.02 
40 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Negativicoccus; s__Negativicoccus_succinicivorans 0.01 
41 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae 0.01 
42 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__Uncultured_bacterium 0.01 
43 p__Actinobacteria; c__Actinobacteria; o__Corynebacteriales; f__Corynebacteriaceae; g__Corynebacterium; s__Corynebacterium_aurimucosum 0.01 
44 p__Actinobacteria; c__Actinobacteria; o__Corynebacteriales; f__Nocardiaceae; g__Rhodococcus; s__Rhodococcus_erythropolis 0.01 
45 p__Proteobacteria; c__Gammaproteobacteria 0.01 
46 p__Proteobacteria; c__Alphaproteobacteria; o__Rhizobiales; f__Brucellaceae; g__Ochrobactrum; s__Uncultured_bacterium 0.01 
47 p__Actinobacteria; c__Actinobacteria; o__Corynebacteriales; f__Corynebacteriaceae; g__Corynebacterium; s__Uncultured_corynebacterium_sp. 0.01 
48 p__Actinobacteria; c__Coriobacteriia; o__Coriobacteriales; f__Coriobacteriaceae; g__Eggerthella; s__Uncultured_bacterium 0.01 
49 p__Firmicutes; c__Bacilli 0.01 
50 p__Firmicutes; c__Bacilli; o__Bacillales; f__Bacillaceae; g__Bacillus; s__Bacillus_cereus 0.00  
OTU table listing top 50 OTUs (accounting for 99.95% of sequencing reads) derived from faecal 
samples collected from infants with NEC (Bell Stage 1, 2 and 3).  
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Rank OTU label as designated by QIIME % of reads OTU descriptor used in thesis 
1 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Klebsiella; s__Klebsiella_pneumoniae 66.24 Klebsiella 
2 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__Escherichia-shigella; s__Escherichia_coli 32.51 Escherichia 
3 p__Proteobacteria; c__Alphaproteobacteria; o__Rhizobiales; f__Bradyrhizobiaceae; g__Bradyrhizobium 0.74   
4 p__Firmicutes; c__Bacilli; o__Bacillales; f__Staphylococcaceae; g__Staphylococcus 0.31 Staphylococcus (1) 
5 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Incertae_sedis; s__Clostridium_perfringens_cpe_str._f4969 0.06 Clostridium (1) 
6 p__Proteobacteria; c__Betaproteobacteria; o__Burkholderiales; f__Burkholderiaceae; g__Ralstonia; s__Uncultured_bacterium 0.05 Ralstonia 
7 p__Firmicutes; c__Bacilli; o__Lactobacillales; f__Enterococcaceae; g__Enterococcus 0.03 Enterococcus 
8 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Incertae_sedis; s__Uncultured_organism 0.03 Incertae sedis (1) 
9 p__Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__Uncultured_bacterium 0.01 Veillonella 
10 p__Proteobacteria; c__Alphaproteobacteria; o__Rhizobiales; f__Brucellaceae; g__Ochrobactrum; s__Uncultured_bacterium 0.01   
11 p__Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae 0.01    
OTU table listing all the OTUs (100% of sequencing reads) derived from gut tissue/intestinal lumen 
contents from NEC infants. 
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Appendix 5 
 
NeoM as a resource 
 
What has become apparent at the end of the study is that NeoM is an incredible resource – with over 
10,000 samples archived and rich clinical metadata, many questions can be asked and answered. With 
the fine interval sampling, it is possible to look in detail at the influence of variables such as feeds, 
antibiotic use, and the environment on the faecal microbiota (see figure below). The database has been 
designed to hold both pseudonymised clinical data and associated sequencing data enabling data 
mining to be carried out. 
 
Microbial community of longitudinal faecal samples from a premature infant. The number of 
days of continuous antibiotic use and important clinical details such as NEC and bloodstream 
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infection diagnosis, and type of feeds are also displayed. Figure constructed and reproduced with 
permission by Dr. Alex Shaw. 
 
Late-onset bloodstream infection and the gastrointestinal microbiota 
30 infants in the NeoM cohort were identified who developed late-onset bloodstream infection (>72 
hours after birth). Weekly faecal samples from birth until the point of diagnosis were selected from 
these infants together with faecal samples from matched controls. DNA was extracted from these 
samples and the faecal microbiota characterised using 16S rRNA gene sequencing in order to identify 
microbial signatures anticipating disease onset. 
 
In the week prior to diagnosis, infants who went on to develop late-onset bloodstream infection had 
higher proportions of facultative anaerobes/aerobes in their faeces compared to controls. Interestingly, 
infants who developed Staphylococcal sepsis had a high abundance of a Staphylococcal OTU in their 
faecal microbiota, and those who developed Enterobacteriaceal sepsis had a high proportion of 
Enterobacteriaceae in their faeces. Together with the high concordance of antibiogram results that 
matched between the bloodstream isolate and the faecal isolate, this indicates that the GI tract is a 
potential reservoir for organisms that can cause late-onset bloodstream infection. The full publication 
can be found in Appendix 6.  
 
 
Long-term development of the gastrointestinal microbiota  
Ethical permission (REC number: 13/LO/0693) has been obtained to re-approach the parents of the 
NeoM study and to ask for a faecal sample from their child now that they are 2-3 years old. So far 
over 230 verbal consents have been obtained and approximately 150 faecal samples collected. 
Information on the infants’ current health status, medical history since discharge from the NICU, 
pro/pre-biotic use, feeding/diet and specific information on atopic manifestations is also being 
collected. 
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The possible long-term effects of prematurity/NICU environment on the faecal microbiota is 
particularly interesting. To address this, characterisation of the faecal microbiota (using 16S rRNA 
gene sequencing) of the participants of the NeoM study in early childhood is underway and will be 
compared to the results to that of similarly aged children who were born at term and recruited in the 
DORMICe study (a parallel study also run by our group). Each participant of the NeoM study was 
matched to one in the DORMICe study such that the mode of delivery and antibiotic use are the same. 
Faecal samples at multiple time points (where possible) were selected: birth, six weeks and two years, 
allowing the trajectory of the faecal microbiota to be compared, and to determine at what point (if 
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Appendix 6 
 
 Publications arising from work carried out during my PhD: 
 
o Sim K, Cox MJ, Wopereis H, et al. Improved detection of bifidobacteria with 
optimised 16S rRNA-gene based pyrosequencing. PloS one 2012; 7(3): e32543. 
 
o Sim K, Powell E, Shaw AG, McClure Z, Bangham M, Kroll JS. The neonatal 
gastrointestinal microbiota: the foundation of future health? Archives of disease 
in childhood Fetal and neonatal edition 2013; 98(4): F362-4. 
  
o Sim K, Shaw AG, Randell P, et al. Dysbiosis anticipating necrotizing enterocolitis 
in very premature infants. Clinical infectious diseases : an official publication of 
the Infectious Diseases Society of America 2015; 60(3): 389-97. 
 
o Shaw AG, Sim K, Randell P, et al. Late-Onset Bloodstream Infection and 
Perturbed Maturation of the Gastrointestinal Microbiota in Premature Infants. 
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